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Abstract
ImmunoCAP® ISAC and Microtest for multiplex allergen
testing in people with difficult to manage allergic disease:
a systematic review and cost analysis
Marie Westwood,1* Bram Ramaekers,2 Shona Lang,1
Nigel Armstrong,1 Caro Noake,1 Shelley de Kock,1 Manuela Joore,2
Johan Severens3 and Jos Kleijnen4
1Kleijnen Systematic Reviews Ltd, York, UK
2Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University
Medical Centre, Maastricht, The Netherlands
3Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam,
The Netherlands
4School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht,
The Netherlands
*Corresponding author marie@systematic-reviews.com
Background: Allergy is a form of immune-mediated exaggerated sensitivity (hypersensitivity) to a
substance that is either inhaled, swallowed, injected or comes into contact with the skin. Foreign
substances that provoke allergies are called allergens. It has been claimed that multiplex allergen testing
may help in diagnosing the cause of symptoms in patients with an unclear cause of allergy or who are
allergic to more than one substance.
Objectives: To evaluate multiplex allergen testing [devices that can measure the presence of multiple
immunoglobulin E (IgE) antibodies in a patient’s blood at the same time], by assessing (1) clinical
effectiveness (allergy symptoms, incidence of acute exacerbations, mortality, adverse events of testing and
treatment, health-care presentations or admissions, health-related quality of life); (2) effects on treatment
(diet, immunotherapy medications, other potential testing); (3) any additional diagnostic information
provided by multiplex allergen testing; and (4) cost-effectiveness (cost of different assessment strategies).
Methods: Fifteen databases were searched from 2005 to April 2015, including MEDLINE (via OvidSp),
MEDLINE In-Process Citations, MEDLINE Daily Update, PubMed (National Library of Medicine), EMBASE,
Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials
(CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA)
database, Science Citation Index (SCI), Conference Proceedings Citation Index-Science (CPCI-S), BIOSIS
Previews, Latin American and Caribbean Health Sciences Literature (LILACS), National Institute for Health
Research (NIHR) HTA programme, and the US Food and Drug Administration (FDA); supplementary
searches of conference proceedings and trials registries were performed. Review methods followed
published guidance from the Cochrane Collaboration and the Centre for Reviews and Dissemination,
University of York, UK. The methodological quality of included studies was assessed using appropriate
published tools or a review-specific tool designed by the project team. Studies were summarised in a
narrative synthesis. Owing to a lack of data on the clinical effectiveness of multiplex allergen testing, no
long-term cost-effectiveness model was developed. A conceptual model structure was developed and cost
analyses were performed to examine the short-term costs of various possible diagnostic pathways.
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Results: Fifteen studies were included in the review. The very limited available data indicated that the
addition of multiplex allergen testing [ImmunoCAP® Immuno Solid-phase Allergen Chip (ISAC), Thermo
Fisher Scientific/Phadia AB, Uppsala, Sweden] to standard diagnostic work-up can change the clinicians’
views on the diagnosis, management and treatment of patients. There was some indication that the use of
ImmunoCAP ISAC testing may be useful to guide decisions on the discontinuation of restrictive diets,
the content of allergen-specific immunotherapy (SIT) prescriptions, and whether or not patients should
receive SIT. However, none of the studies that we identified reported any information on clinical outcomes
subsequent to changes in treatment or management. There was some evidence that ImmunoCAP ISAC
may be useful for discriminating allergens that are structurally similar and are recognised by the same IgE
antibody (cross-immunoreactive). No data were available for Microtest (Microtest Matrices Ltd, London, UK).
Detailed cost analyses suggested that multiplex allergen testing would have to result in a substantial
reduction of the proportions of patients receiving single IgE testing and oral food challenge tests in order to
be cost-saving in the short term.
Conclusions: No recommendations for service provision can be made based on the analyses included in
this report. It is suggested that a consensus-based protocol for the use of multiplex allergen testing be
developed. The clinical effectiveness and cost-effectiveness of the proposed protocol should then be
assessed by comparing long-term clinical and quality of life outcomes and resource use in patients
managed using the protocol with those managed using a standard diagnostic pathway.
Study registration: This study is registered as PROSPERO CRD42015019739.
Funding: This project was a Diagnostic Assessment Report commissioned by the NIHR HTA programme on
behalf of the National Institute for Health and Care Excellence.
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Glossary
Allergen A substance that causes an allergic reaction.
Antibody A large Y-shaped protein, also known as an immunoglobulin, which is used by the immune
system to identify pathogens.
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs for additional health gain.
Cross-immunoreactive An antibody which can interact or bind with more than one antigen.
Cross-sensitisation The process of producing a specific IgE antibody from one of several
homologous allergens.
False negative Incorrect negative test result – number of diseased persons with a negative test result.
False positive Incorrect positive test result – number of non-diseased persons with a positive test result.
Homologous allergens Allergen molecules with very similar molecular structures.
Immunoglobulin E A type of antibody that is found in mammals and which mediates allergic responses.
Immunoreactive Interaction between an allergen and an antibody.
Index test The test whose performance is being evaluated.
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Opportunity costs The cost of forgone outcomes that could have been achieved through
alternative investments.
Publication bias Bias arising from the preferential publication of studies with statistically significant results.
Quality-adjusted life-year A measure of health gain, used in economic evaluations, in which survival
duration is weighted or adjusted by the patient’s quality of life during the survival period.
Quality of life An individual’s emotional, social and physical well-being and their ability to perform the
ordinary tasks of living.
Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and
specificity which result from varying the diagnostic threshold.
Reference standard The best currently available method for diagnosing the target condition. The index
test is compared against this to allow calculation of estimates of accuracy.
Sensitisation The process of producing a specific immunoglobulin E antibody from exposure to a
specific allergen.
Sensitivity Proportion of people with the target disorder who have a positive test result.
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Specificity Proportion of people without the target disorder who have a negative test result.
True negative Correct negative test result – number of non-diseased persons with a negative test result.
True positive Correct positive test result – number of diseased persons with a positive test result.
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Plain English summary
A llergy is a form of exaggerated sensitivity (hypersensitivity) to a substance that is either inhaled,swallowed, injected or comes into contact with the skin, involving the immune system. Substances
that provoke allergies are called allergens (e.g. pollens, house dust mite, fungal spores, insect sting,
animal hair, foods and chemicals found at home and work).
Most allergic reactions happen when chemicals in the body called immunoglobulin E (IgE) antibodies bind
to an allergen and are then taken up by specialist cells in the immune system. The body responds by
triggering allergy symptoms (e.g. rash or skin irritation, wheezing, watering eyes, nose irritation or stomach
upset). In extreme cases, a severe allergic reaction (anaphylaxis) can result in difficulties in breathing and
circulation, and can even cause death.
This project aimed to evaluate devices that can measure levels of many different IgE antibodies in a
patient’s blood at the same time (multiplex allergen testing). It has been claimed that these devices may
help in diagnosing the cause of symptoms in patients with an unclear cause of allergy or who are allergic
to more than one substance.
We found a small number of studies which indicated that multiplex allergen testing can change the
clinicians’ views on the cause of allergy symptoms and treatment options. However, none of the studies
reported information on what happened to patients’ allergy symptoms after changes to treatment.
Therefore, we do not yet know how using multiplex allergen testing might affect people’s experience of
allergic disease.
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Scientific summary
Background
Multiplex allergen tests are molecular diagnostic tests, in the form of a glass slide, which can
simultaneously test for the presence of multiple antibodies in blood samples (up to 51 allergen sources).
Multiplex allergen testing is likely to be used in secondary care settings or specialist tertiary care centres, as
an addition to allergen challenge testing and in addition to, or in place of, single immunoglobulin E (IgE)
antibody testing. Multiplex tests may be useful for investigating people with difficult to manage allergic
disease: people who are allergic to two or more allergens and/or have allergies to unknown sources. In the
UK it is estimated that 10 million patients have two or more allergies.
Objectives
The overall aim of this project was to summarise the evidence available to inform estimates of the clinical
effectiveness and cost-effectiveness of adding multiplex allergen testing to the investigation of people with
difficult to manage allergic disease, in secondary or tertiary UK care settings. We defined the following
research objectives to address this aim:
1. To assess the effects on clinical outcomes (e.g. allergy symptoms, incidence of acute exacerbations) of
adding multiplex allergen testing to the investigation of people with difficult to manage allergic disease.
2. To assess the effects on treatment (e.g. restriction diets, immunotherapy, number of allergen challenge
tests required) of adding multiplex allergen testing to the investigation of people with difficult to
manage allergic disease.
3. To assess the accuracy of multiplex allergen testing in predicting clinical reactivity and to investigate
whether or not multiplex allergen testing can provide diagnostic information additional to that provided
by current standard care in the UK [clinical history, skin prick tests (SPTs), single IgE testing].
4. To assess the cost-effectiveness of adding multiplex allergen testing to the investigation of people
difficult to manage allergic disease in secondary or tertiary care settings.
Methods
Assessment of clinical effectiveness
Fifteen databases, including MEDLINE (via OvidSp), MEDLINE In-Process Citations, MEDLINE Daily Update,
PubMed (National Library of Medicine), EMBASE, Cochrane Database of Systematic Reviews (CDSR), Cochrane
Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health
Technology Assessment (HTA) database, Science Citation Index (SCI), Conference Proceedings Citation
Index-Science (CPCI-S), BIOSIS Previews, Latin American and Caribbean Health Sciences Literature (LILACS),
National Institute for Health Research (NIHR) HTA programme, and the US Food and Drug Administration (FDA),
were searched from 2005 to April 2015 for terms relating to ImmunoCAP®, Microtest (Microtest Matrices Ltd,
London, UK) or allergy microarray tests. Additional searching was performed for grey literature, three trial
registries and seven conference proceedings. Risk of bias was assessed using QUADAS-2, The Critical Appraisal
Skills Programme (CASP) cohort risk-of-bias tool, or a review-specific tool designed by the authors, as
appropriate. Search results were screened for relevance independently by two reviewers. Studies were included
if they were of adults or children with allergy who received a multiplex allergen test [ImmunoCAP® Immuno
Solid-phase Allergen Chip (ISAC) Thermo Fisher Scientific/Phadia AB, Uppsala, Sweden, or Microtest] in
comparison with standard pathways of care. Full text inclusion assessment, data extraction and quality
assessment were conducted by one reviewer and checked by a second. Results were summarised narratively.
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Assessment of cost-effectiveness
MEDLINE, MEDLINE In-Process and Daily Update, EMBASE, EconLit, IDEAS via Research Papers in
Economics and NHS Economic Evaluation Database were searched for full cost-effectiveness analysis of
multiplex allergen testing from 2005 to May 2015. Included studies are appraised using a quality checklist
based on Drummond (Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods For
The Economic Evaluation Of Health Care Programmes. 3rd edn. Oxford: Oxford University Press; 2005).
Owing to a lack of data on the clinical effectiveness of multiplex allergen testing, no long-term
cost-effectiveness model was developed. A conceptual model structure was developed, literature on utility
scores was reviewed, and cost analyses were performed to examine the short-term costs of various
possible diagnostic pathways.
Results
Clinical effectiveness
A total of 8619 records were identified from searching and screened for inclusion. Fifteen studies were
included in the review. No studies were identified of people with difficult to manage allergic disease in the
UK. All studies evaluated versions of ImmunoCAP ISAC: none was identified for Microtest. ImmunoCAP
ISAC 112 is the most recent version of the ImmunoCAP ISAC array (the number refers to the number
of tests per array). None of the included studies was classified as having a low risk of bias.
No studies were identified which investigated clinical outcomes.
Two studies (n= 97) investigated the use of ImmunoCAP ISAC to guide decisions on the discontinuation of
restrictive diets in children with food allergies. Both studies reported that the results from ImmunoCAP
ISAC were used to reintroduce foods, but details were unclear.
Two studies (n= 373) assessed clinicians’ views on whether or not ImmunoCAP ISAC provided information
useful in the management of patients. Clinicians judged that ImmunoCAP ISAC 103 provided new
information useful in the management of the patient in 91–95% of cases. Added value was defined as the
ability to discriminate allergens that were cross-immunoreactive rather than those that were responsible for
sensitisation, or the ability to impact upon accuracy of diagnosis or allergen-specific immunotherapy (SIT)
prescription that was not possible using standard diagnostic work-up.
Two studies (n= 459) investigated the effect on SIT prescriptions of adding ImmunoCAP ISAC testing to
the standard diagnostic work-up of people with respiratory allergy. Clinicians judged that for 27–54%
of patients changes were made to SIT prescriptions after ImmunoCAP ISAC 103 or ImmunoCAP ISAC
96 testing.
Two studies (n= 428) investigated the effect on diagnostic classification of adding ImmunoCAP ISAC 103
testing to the standard diagnostic work-up of people with allergic disease. In one study of idiopathic
anaphylaxis, the addition of ImmunoCAP ISAC 103 led to the identification of new sensitisations with
strong associations with anaphylaxis in 20% of participants, and in 32% additional sensitisations were
identified which were not associated with anaphylaxis. A second study found that the addition of
ImmunoCAP ISAC 103 testing resulted in increases in the numbers of people classified as ‘polysensitised
with suspected cross-reactivity’ and the number of people diagnosed with both inhalant and food allergies,
as well as facilitating a diagnosis for eight previously unclassifiable patients.
One study (n= 9) assessed the relationship between change in IgE levels (measured by ImmunoCAP)
before and after a 3-year course of SIT, and the clinicians’ evaluation of the benefit of SIT. The median
specific IgE levels decreased and this change correlated with clinical benefit of SIT. Single tests for specific
IgE measurements did not show a decrease.
SCIENTIFIC SUMMARY
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Eight studies investigated diagnostic accuracy; none was conducted in people with difficult to manage
allergic disease. ImmunoCAP ISAC 112 was not investigated; however, ImmunoCAP ISAC 103, 89, 50 out
of 51 were investigated. The diagnostic performance of ImmunoCAP ISAC in comparison with either single
IgE or SPT varied considerably between studies, according to the allergens investigated and the way in
which ISAC testing was applied. In general, individual components of ImmunoCAP ISAC tended to have
high specificity, but low sensitivity, relative to whole-allergen single IgE tests or SPTs for the prediction of
allergic response. The studies did not provide any information on the specificity of the whole ImmunoCAP
ISAC panel.
Assessment of cost-effectiveness
Four economic analyses and 14 health-related quality of life studies were included in the literature review.
The systematic review component of this assessment found no data on the clinical consequences of adding
multiplex allergen testing to current clinical practice; therefore, a long-term economic model to inform
health policy decision-making was not possible. Therefore, the assessment aimed to inform research
decisions and support future model-based economic evaluations.
All cost-effectiveness studies showed an increased effectiveness when using ImmunoCAP ISAC and the
majority showed cost savings when using ImmunoCAP ISAC. The methods and assumptions used were
largely unclear and the credibility of the assessments was questionable; therefore, these findings should be
interpreted with extreme caution.
The evidence on utility values for allergic conditions in the UK population was limited.
Test costs for ImmunoCAP ISAC and Microtest were estimated to be £219.51 and £156.85, respectively.
For SPT, single IgE and the food challenge test these were £62.29, £136.37 and £570.00, respectively.
A speculative analysis indicated that multiplex allergen testing would have to result in a substantial
reduction of the proportions of patients receiving single IgE testing and food challenge tests in order to be
cost-saving in the short term. Analyses to compare the effect of replacing single IgE with multiplex testing
were difficult to perform because of lack of information regarding where the multiplex test would sit in the
care pathway.
Conclusions
No recommendations for service provision can be made based on the analyses included in this report. The
clinical effectiveness and cost-effectiveness of using multiplex allergen testing in the investigation of people
with difficult to manage allergic disease have yet to be adequately investigated. It is suggested that a
consensus-based protocol for the use of multiplex allergen testing be developed. The clinical effectiveness
and cost-effectiveness of the proposed protocol should then be assessed by comparing long-term clinical
and quality of life outcomes and resource use in patients managed using the protocol with those managed
using a standard diagnostic pathway.
Study registration
This study is registered as PROSPERO CRD42015019739.
Funding
This project was a Diagnostic Assessment Report commissioned by the NIHR HTA programme on behalf of
the National Institute for Health and Care Excellence.
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Chapter 1 Objective
The overall aim of this project was to summarise the evidence available to inform estimates of the clinicaleffectiveness and cost-effectiveness of adding multiplex allergen testing to the investigation of people
with difficult to manage allergic disease, in secondary or tertiary care settings. Multiplex allergen testing
may replace some single immunoglobulin E (IgE) testing, but, where the multiplex testing panel does not
include all of the suspected allergens, additional single specific IgE (sIgE) tests may be needed.
We defined the following research objectives to address this aim:
l To assess the effects on clinical outcomes [e.g. allergy symptoms, incidence of acute exacerbations,
mortality, adverse events (AEs) of testing and treatment, health-care presentations or admissions,
health-related quality of life (HRQoL)] of adding multiplex allergen testing to the investigation of people
with difficult to manage allergic disease.
l To assess the effects on treatment (e.g. restriction diets, immunotherapy, use of other medications such
as corticosteroids, number of allergen challenge tests required) of adding multiplex allergen testing to
the investigation of people with difficult to manage allergic disease.
l To assess the accuracy of multiplex allergen testing in predicting clinical reactivity (response to allergen
challenge testing or response to immunotherapy) and to investigate whether or not multiplex allergen
testing can provide diagnostic information additional to that provided by current standard care in the
UK (clinical history, skin prick tests) and single IgE testing or a combination of these approaches).
l To assess the cost-effectiveness of adding multiplex allergen testing to the investigation of people with
difficult to manage allergic disease in secondary or tertiary care settings.
l This report contains reference to confidential information provided as part of the National Institute for
Health and Care Excellence (NICE) appraisal process. This information has been removed from the
report and the results, discussions and conclusions of the report do not include the confidential
information. These sections are clearly marked in the report.
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Chapter 2 Background and definition of the
decision problem(s)
Population
The indication for this assessment is to evaluate the clinical effectiveness and cost-effectiveness of using
multiplex allergen testing [ImmunoCAP® Immuno-Solid phase Allergy Chip (ISAC) (Thermo Fisher Scientific/
Phadia AB, Uppsala, Sweden) or Microtest (Microtest Matrices Ltd, London, UK)] as an adjunct to current
clinical investigations in people with allergy that is difficult to manage (defined as people who are allergic
to two or more allergens and/or have allergies to unknown sources).
Multiplex allergen testing is likely to be used in secondary care settings or specialist tertiary care centres,
as an addition to allergen challenge testing and in addition to, or in place of, some sIgE antibody testing.
Multiplex allergen testing may replace some IgE testing, but where the multiplex testing panel does not
include all of the suspected allergens, additional sIgE tests may be needed.
Allergy is a term used to describe immune-mediated hypersensitivity to external stimuli (allergens).
Immune-mediated hypersensitivity reactions are divided into two categories: IgE-mediated reactions and
non-IgE-mediated reactions. IgE antibodies are normally present in very small amounts in the body, but
levels are raised in allergic disease. IgE-mediated immune reactions, also called type 1 hypersensitivity
reactions, are typically rapid in onset and can involve extreme acute symptoms as in anaphylaxis or
prolonged symptoms (e.g. urticaria or eczema). In an IgE-mediated reaction IgE binds to allergen molecules,
which are then taken up by receptors on the surface cells of the immune system, causing the release of
biologically active agents and consequent response: vasodilation (widening of blood vessels); increased
capillary permeability; mucus hypersecretion; smooth muscle contraction; and tissue inflammation.
Non-IgE-mediated reactions are less well understood and are mediated by other components of the
immune system. They are typically delayed in onset, and occur 4–28 hours after exposure.
This assessment will focus on IgE-mediated hypersensitivity.
Sensitisation describes the process at the start of the immune response. Exposure to an allergen [e.g.
house dust mite (HDM) or pollen] initiates a complex set of cellular events within the human body, leading
to the production of a specific IgE antibody to a specific allergen. At this point there is no clinical reaction
(rash, sneezing). Upon re-exposure, the allergen can bind to the specific antibody that orchestrates the
immune system to initiate a more aggressive and rapid response, resulting in an inflammatory response
with clinical symptoms. However, many ‘sensitised’ individuals do not experience clinical reactions upon
subsequent exposure to allergen, a situation known as tolerance.
The term polysensitisation usually refers to sensitisation to two or more allergen sources, and the term
paucisensitisation has been used to describe sensitisation to between two and four allergens. Clinical
reactivity can be difficult to diagnose in polysensitised patients because of problems distinguishing between
sensitisation to cross-reactive allergens. Cross-reactivity occurs when the molecular structure/shape of two
different antigens is very similar and the antibody recognises the two different antigens as the same
antigen; for example, an IgE antibody that recognises and causes an allergic reaction to Bet v 1 in birch
pollen can also trigger an allergic response to Cor a1 in hazelnut. In nature there are many molecules with
similar molecular structures/shapes and this translates into the clinic as an obstacle when trying to identify
all potential allergens that might cause an allergic reaction in a given patient. Currently, patients undergo
allergy testing to identify the allergens to which they are sensitive. This is based on skin prick testing or
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identifying the presence of individual antibodies in the bloodstream using single IgE tests. For both
methods, it is difficult to identify multiple cross-reactive allergens for patients who appear to be
polysensitised or have difficult to diagnose allergic disease. It has been claimed that multiplex allergen
testing may provide improved information about the sensitisation profile in polysensitised patients.
This assessment will summarise the available data on information provided by multiplex allergen testing,
which is additional to that obtained from single IgE tests and/or skin prick or allergen challenge tests.
It is difficult to obtain reliable statistics on allergy prevalence in the UK. The charity Allergy UK states, on its
website, that there are an estimated 21 million adults in the UK who have at least one allergy and that an
estimated 10 million of these have two or more allergies;1 however, these figures appear to be taken from a
2010 report on allergy and allergy remedies from the market research company Mintel. Data from the
QRESEARCH project, a database containing the psuedoanonymised health records of over 13 million
people, from 950 UK general practices,2 can provide some information on the prevalence of allergy
symptoms and diagnoses seen in primary care and on changing patterns over time. At the end of 2005,
QRESEARCH data indicated that approximately one in nine people had a recorded diagnosis of ‘any allergic
disease’ (including asthma, hay fever, eczema, anaphylaxis or peanut allergy); this figure represented a
27.7% increase over a 4-year period.3 Increases in the incidence of eczema and allergic rhinitis were
reported for the same time period; the age- and sex-standardised incidence of eczema was 9.58 per 1000
patient-years in 2001, rising to 13.58 per 1000 patient-years in 2005,4 with the corresponding figures for
allergic rhinitis being 5.57 per 1000 patient-years and 7.41 per 1000 patient-years, respectively.5
QRESEARCH data also indicate that the incidence of multiple allergic disorders is increasing. The age- and
sex-standardised incidence of multiple allergic disorders was 4.72 per 1000 patient-years in 2001, rising to
6.28 per 1000 patient-years in 2005.6 Alongside data on increasing incidence of allergic disease,
QRESEARCH reports also record increases in the number of allergy-related prescriptions and general
practice consultations, which are indicative of an increasing burden upon the UK NHS.4–6 There are no
QRESEARCH publications that specifically report on food allergy. NICE Clinical Guideline 1167 (food allergy
in children and young people) reports an estimated prevalence for self-reported food allergy of between
3% and 35% for individual foods. However, the guideline also notes that only 25–40% of self-reported
food allergy is confirmed by oral food challenge (OFC) testing.7
Allergic disease can present as a severe, life-threatening reaction (anaphylaxis). The National Institute of
Allergy and Infectious Disease and the Food Allergy and Anaphylaxis Network have recommended that
anaphylaxis be defined as ‘a serious allergic reaction that is rapid in onset and may cause death’ and is
likely to be the diagnosis when there is involvement of skin or mucosal tissue (e.g. hives, angioedema)
and airway compromise (wheezing, dyspnoea) and/or reduced blood pressure or associated symptoms
(hypotonia, syncope), along with a temporal relationship (minutes to several hours) to a potential causative
agent.8 There are limited data on the incidence of anaphylaxis in the UK. Hospital Episode Statistics record
‘allergy (including anaphylaxis)’ as the primary diagnosis associated with Accident and Emergency
attendance for around 70,000 cases (approximately 0.4% of all reports) in both 2013 and 2014; however,
no separate statistics are recorded for anaphylaxis.9 A 2010 study,10 based on the Health Improvement
Network database, estimated the UK incidence of anaphylaxis at 21.3 [95% confidence interval (CI) 17.6
to 25.4] per 100,000 patient-years. This study included 382 cases of anaphylaxis and the causes were
listed as drug (27%); food (24%); insect (12%); latex (0.8%); idiopathic (27%); and no information
(10%).10 NICE Clinical Guideline 13411,12 (anaphylaxis assessment) reports an estimate of 20 UK deaths per
year from anaphylaxis from a study conducted in 2000. A study published in 2015,13 which analysed data
from 1992 to 2012, shows that mortality has not risen, despite an increase in hospitalisations.
Where data are available, this assessment will focus on studies conducted in the people with allergy that is
difficult to manage. If data are lacking for this population, studies conducted in patients with specific
allergic disease (e.g. peanut allergy) will not be excluded and all potential clinical applications of multiplex
allergen testing will be considered.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM(S)
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Intervention technologies
ImmunoCAP Immuno-Solid phase Allergy Chip
The ImmunoCAP ISAC is a miniaturised immunoassay platform (multiple allergen components immobilised
on a slide) that is intended to assess the presence of multiple antibodies in a single blood test. IgE
antibodies from the patient’s blood sample bind to the immobilised allergen components on the slide,
and allergen-bound IgE antibodies are then detected using fluorescence-labelled anti-IgE antibodies.
Slides are read using a separate microarray scanner and image analysis software. Using these technologies
may provide more detailed information about individual sensitisation profiles than single IgE testing.
ImmunoCAP ISAC is intended for use in complex allergy cases, such as those with inconsistent case
histories/unsatisfactory response to treatment, those who are polysensitised and patients with idiopathic
anaphylaxis. These are people with severe or unclear allergic disease who test positive to a range of
allergens but in whom the true cause of symptoms can be difficult to identify. It is claimed that using the
ImmunoCAP ISAC test could improve health outcomes by improving allergy management, more
appropriately targeting specific immunotherapy, and reducing the number of investigative diagnostic tests.
These improvements could also lead to potential savings to the NHS from reducing the number of tests
and avoiding the use of unnecessary immunotherapy.
ImmunoCAP ISAC 112 is a molecular diagnostic test that can simultaneously test for IgE antibodies to
112 components from 51 allergen sources. The ISAC is a miniaturised immunoassay platform that uses a
single sample (30 μl) of serum, plasma or capillary blood to test for IgE antibodies to multiple allergens.
ImmunoCAP ISAC is a two-step assay. IgE antibodies from the patient sample bind to immobilised allergen
components spotted in triplets on polymer-coated slides. Each slide contains four microarrays, giving
results for four samples per slide. The results are measured using a biochip scanner [confocal laser
scanning devices, in particular the CapitalBio LuxScan 10k microarray scanner (Capitalbio, San Diego, CA,
USA), are recommended] and evaluated using proprietary software produced by the same company,
Phadia Microarray Image Analysis software (MIA) (Phadia AB, Uppsala, Sweden). ImmunoCAP ISAC is a
semi-quantitative test and results are reported in International Standard Units (ISUs), giving indications of
specific IgE antibody levels; the operating range is 0.3–100 ISU for IgE (ISU-E). This range approximately
corresponds to a concentration range of 0.3–100 kilo international units of allergen-specific-antibody per
unit volume of sample (kUA/l) of IgE (1 kUA/l is equal to 2.4 ng/ml). The assay takes a total of 4 hours,
including sample processing and incubation time.
Microtest
The Microtest Instrument is a CE (Conformité Européenne)-marked automated immunoassay platform
that uses microarrays to simultaneously test for 26 allergen components. It is designed for processing
and reading protein microarrays of allergens printed in the biochips. The Microtest instrument can
simultaneously process up to five Microtest biochips, each containing a different serum sample, in each
run. The process is fully automated. When the test is completed, the Microtest Instrument uses a
fluorimeter to read the microarrays and the results are semi-quantitative, reported on an allergy risk scale
of 0–4. The user can print or export the reports as appropriate. Microtest is intended for use in any patient
(infants, children and adults) presenting with allergy symptoms.
Table 1 summarises the key characteristics of the multiplex allergen tests ImmunoCAP ISAC and Microtest,
compared with comparator tests that are currently used in the standard diagnostic work-up of patients
with difficult to manage allergic disease.
There are a number of poorly understood factors that influence whether or not clinical symptoms manifest
at a certain IgE level, including inhibitory allergen-specific antibodies of non-IgE subclass. Furthermore,
other factors, for example age, patient population, concomitant exposure to other allergens, other clinical
conditions such as infections, etc., can also affect the degree of symptoms which may occur following
allergen exposure. Thus it is not possible to establish general cut-off values valid for all patients at all times.
However, when combined with clinical history, the results of multiplex allergen testing may aid the clinician
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in the diagnosis of allergy. Multiplex allergen testing should always be used in conjunction with
allergy-focused clinical history and may be used in addition to, or in place of, single IgE antibody tests
and/or skin prick testing.
Comparator
The comparator for this assessment will be current standard care, which should always include
allergy-focused clinical history and can additionally involve tests of IgE antibody status (single IgE antibody
testing), tests of clinical reactivity such as skin prick testing or allergen challenge testing, or a combination
of these approaches.
Single immunoglobulin E testing
Allergen-specific IgE antibody assays are designed to detect and quantify circulating IgE antibodies to one
allergen. The choice of which antibodies to test for is based on the clinical history of the patient, and
several single IgE tests and/or a stepwise strategy which tests for the most likely causative agents first may
be required.
The single IgE test process involves incubation of a blood sample with specific IgE antibodies. Allergen-specific
IgE in the patient’s sample binds to the allergen, and unbound antibodies and excess sample are then
removed by washing. Anti-IgE antibody, labelled to enable detection (e.g. fluorescently labelled anti-IgE
antibody), is then added. The amount of bound allergen-specific IgE is calculated via a standard calibration
curve, which is linked to the World Health Organization (WHO) IgE standard and reported in arbitrary mass
units (kUA/l).
Higher levels of IgE are considered to be associated with allergy, but the amount of IgE is not predictive of
the severity of reaction. Not all patients with a positive specific IgE test will have clinically manifest allergic
reaction when exposed to that allergen. Unlike IgE antibody testing, skin prick tests (SPTs) and allergen
challenge tests can provide direct information about clinical reactivity to a given allergen.
Skin prick testing
Skin prick testing is a method used to assist in the diagnosis of IgE-mediated allergic disease in patients
with rhinoconjunctivitis, asthma, urticaria, anaphylaxis, atopic eczema or gastrointestinal symptoms that
are suspected (based on clinical history) to be caused by type 1 (immediate) allergic reaction. It provides
evidence for sensitisation in the form of reaction to allergenic stimulus.
The test involves putting a drop of liquid allergen onto the skin, followed by a gentle pin prick through the
drop. SPT interpretation utilises the presence and degree of skin reactivity as a marker for sensitisation.
When relevant allergens are introduced into the skin, an IgE-mediated immune response occurs. This
produces a ‘weal and flare’ response, which can be quantified. Many different allergens can be tested
simultaneously because the resultant reaction to a specific allergen is localised to the immediate area of
the SPT.
One potential advantage of SPTs compared with in vitro measurement of IgE antibodies is that the test can
be interpreted within 15–20 minutes after the reagent is applied to the skin, and therefore results can
potentially be given to the patient in the same consultation. SPT results provide evidence of IgE in
skin-resident mast cells which may, but does not always, correlate with clinical reactivity. SPTs can also be
utilised to test less common allergens, (e.g. medications, and fresh fruits and vegetables) where no specific
IgE antibody assays are available. As with any test, the results of SPTs must be interpreted in the context of
medical history, clinical symptoms and, where appropriate, other test results. It has been suggested that
skin prick testing is an inexpensive option. However, whilst the test materials may be relatively inexpensive,
any estimation of costs should consider the staff time needed to perform these tests in an appropriate and
safe health-care setting.
DOI: 10.3310/hta20670 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 67
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
Skin prick testing has the following limitations:
l Skin reactivity might be affected by previous ingestion of antihistamines or other drugs.
l Children may not tolerate multiple skin needle pricks.
l Prior or coexisting dermatological conditions, such as eczema, may preclude the performance of
skin tests.
l The potency of antigen extracts needs to be maintained.
l Systemic reactions, although very rare, may occur.
l SPTs alone are not sufficient as a confirmatory test.
Allergen challenge testing
Oral food challenges or inhalant challenges are indicated where there is a discrepancy between clinical
history and other test results, and can be useful in establishing the identity of specific triggers. The most
rigorous method for allergen challenge tests is double blinded and placebo controlled, thus requiring two
separate visits. Therefore, single (patient)-blind and open challenges are more frequently performed
because only one visit is required. An open challenge describes a challenge in which the patient can
recognise the target trigger and there is no attempt at blinding; this is the least time-intensive type of
challenge test, but may produce less reliable results as there is the potential for the result to be influenced
by either the patient’s anxiety about a particular trigger and/or the health-care professional’s expectations.
The general methodology of any challenge test is to administer the trigger in gradually increasing doses in
a medical setting. Allergen challenge tests should be performed in a setting that is fully equipped for
emergency treatment if an episode of anaphylaxis occurs.
Care pathway
There are a number of National Institute for Health and Care Excellence (NICE) guidelines that consider
elements of the diagnosis, management and treatment of allergy.7,11,14,15
Diagnosis
Clinical guidelines consistently emphasise the importance of obtaining a clinical history and asking specific,
allergy-focused questions.7,15,16 NICE Clinical Guideline 1167 (food allergy in children and young people)
states that this can be done by general practitioners or other primary health-care professionals with the
appropriate competencies. According to the guidelines, the following should be included when taking a
clinical history:
l Any personal history of atopic disease (asthma, eczema or allergic rhinitis).
l Any individual and family history of atopic disease (such as asthma, eczema or allergic rhinitis) or food
allergy in parents or siblings.
l Details of any foods that are avoided and the reasons why.
l An assessment of presenting symptoms and other symptoms that may be associated with food allergy,
including questions about:
¢ the age of the child or young person when symptoms first started
¢ speed of onset of symptoms following food contact
¢ duration of symptoms
¢ severity of reaction
¢ frequency of occurrence
¢ setting of reaction (e.g. at school or home)
¢ reproducibility of symptoms on repeated exposure
¢ what food and how much exposure to it causes a reaction.
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l Cultural and religious factors that affect the foods they eat.
l Who has raised the concern and suspects the food allergy.
l What the suspected allergen is.
l The child or young person’s feeding history, including the age at which they were weaned and
whether they were breastfed or formula fed – if the child is currently being breastfed, consider the
mother’s diet.
l Details of any previous treatment, including medication, for the presenting symptoms and the response
to this.
l Any response to the elimination and reintroduction of foods.
The NICE Clinical Guideline 5715 (atopic eczema in children) recommends that health-care professionals
should seek to identify potential trigger factors during clinical assessment including:
l irritants
l skin infections
l contact allergens
l food allergens
l inhalant allergens.
The Royal College of Paediatrics and Child Health also provides advice on allergy-focused questions to be
used when taking a clinical history. An initial screening set of questions is recommended to identify
patients, in community settings, for whom a more detailed allergy history may need to be taken. If allergy
is suspected, further questions are grouped into six areas:
l general history questions asking about general health, current medications, previous allergy testing,
lifestyle and general home conditions
l general allergy history questions
l food-related questions
l respiratory-related questions
l ear-, nose- and throat-related questions
l skin-related questions.
If IgE-mediated allergy is suspected, based on the results of allergy-focused clinical history, NICE Clinical
Guideline 1167 (food allergy in children and young people) recommends that the child or young person
should be offered a SPT and/or blood tests for specific IgE antibodies to the suspected foods and likely
co-allergens. It further recommends that these tests should be undertaken only by health-care
professionals with the appropriate competencies to select, perform and interpret them, and should be
undertaken only where there are facilities to deal with an anaphylactic reaction.7 The guideline also states
that the patient should be given information on when, where and how an OFC or food reintroduction
procedure may be undertaken. However, these tests should not be performed in primary care.7
Management
The management of allergy is dependent upon type and severity and many allergies can be managed and
treated in primary care settings. More severe allergies and more complex patients may require additional
management and referral on to specialist services.
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The NICE Clinical Guideline 1167 (food allergy in children and young people) recommends referral to
secondary or specialist care when the child or young person has:
l faltering growth in combination with one or more gastrointestinal symptoms
l not responded to a single-allergen elimination diet
l had one or more acute systemic reactions
l had one or more severe delayed reactions
l confirmed IgE-mediated food allergy and concurrent asthma
l significant atopic eczema where multiple or cross-reactive food allergies are suspected by the parent
or carer.
l Or there is:
¢ persisting parental suspicion of food allergy (especially in children or young people with difficult or
perplexing symptoms) despite a lack of supporting history
¢ strong clinical suspicion of IgE-mediated food allergy but allergy test results are negative
¢ clinical suspicion of multiple food allergies.
The NICE Clinical Guideline 57 (atopic eczema in children) and NICE Quality Standard 44 (atopic eczema in
children)14,15 both recommend that children with a suspected food allergy should be referred for specialist
investigation and management by a paediatric allergist or paediatric dermatologist.
With respect to management following a severe acute episode, NICE Clinical Guideline 13411 (anaphylaxis
assessment) recommends that prior to discharge a health-care professional with the appropriate skills and
competencies should offer the following:
l information about anaphylaxis, including the signs and symptoms of an anaphylactic reaction
l information about the risk of a biphasic reaction
l information on what to do if an anaphylactic reaction occurs (use the adrenaline injector and call
emergency services)
l a demonstration of the correct use of the adrenaline injector and when to use it
l advice about how to avoid the suspected trigger (if known)
l information about the need for referral to a specialist allergy service and the referral process
l information about patient support groups.
Treatment
Mild allergies can be treated using over-the-counter medications, such as antihistamines, and simple
avoidance of the identified allergen(s).
The NICE Clinical Guideline 1167 (food allergy in children and young people) recommends that, once an
allergy is suspected, based on clinical history, information should be provided to the patient about:
l type of allergy suspected
l risk of severe allergic reaction
l potential impact of the suspected allergy on other health-care issues, including vaccination.
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If a food elimination diet is advised information should be provided on:
l what foods and drinks to avoid
l how to interpret food labels
l alternative sources of nutrition to ensure adequate nutritional intake
l the safety and limitations of an elimination diet
l the proposed duration of the elimination diet
l when, where and how an OFC or food reintroduction procedure may be undertaken.
The NICE Clinical Guideline 5715 (atopic eczema in children) recommends that health-care professionals
should use a stepped approach for managing atopic eczema in children and should tailor the treatment
step to the severity of the atopic eczema. Emollients should form the basis of atopic eczema management
and should always be used, even when the atopic eczema is clear. Management can then be stepped up
or down, according to the severity of symptoms, with the addition of the other treatments such as
mild-potency topical corticosteroids (for mild eczema), moderate-potency topical corticosteroids
(for moderate eczema), tacrolimus, bandages (for moderate or severe eczema), and potent topical
corticosteroids, phototherapy and systemic therapy (for severe eczema only). Very potent topical
corticosteroids should not be used without specialist dermatological advice.
In selected patients allergen immunotherapy may be appropriate. It involves the repeated administration,
either subcutaneously or sublingually, of allergen extracts. The potential outcomes of immunotherapy are:
l reducing allergy symptoms on subsequent allergen exposure
l improving quality of life (QoL)
l inducing long-term tolerance.
Immunotherapy is time-consuming and expensive, and there is a risk of a severe allergic reaction or
anaphylaxis during administration. According to the British Society for Allergy & Clinical Immunology
guidelines,17 the main indications for immunotherapy in the UK are:
l IgE-mediated seasonal pollen-induced rhinitis, if symptoms have not responded adequately to
optimal pharmacotherapy
l systemic reactions caused by hymenoptera venom allergy
l selected patients with animal dander or HDM allergy in whom rigorous allergen avoidance and
reasonable pharmacotherapy fail to control symptoms.
The selection, initiation and monitoring of all patients for immunotherapy should be supervised by
specialists in allergy. Immunotherapy should be administered only by physicians and nurses with specialist
knowledge of allergy and specific immunotherapy. Immunotherapy is an attractive option for the
treatment of food allergies, as its goal is to induce tolerance in the person. With desensitisation,
the treated person manifests a decreased response to the allergen.17
Regarding treatment following severe acute episodes, NICE Clinical Guideline 13411 (anaphylaxis
assessment) recommends that after emergency treatment for suspected anaphylaxis patients should be
offered an appropriate adrenaline injector as an interim measure before the specialist allergy service
appointment. An adrenaline autoinjector is a medical device for injecting a measured dose or doses of
epinephrine (adrenaline), by means of autoinjector technology. It is most often used for the treatment of
anaphylaxis. Most individuals with a severe IgE-mediated food allergy are advised to carry an autoinjector
in case of accidental exposure. There are many barriers to the successful use of an autoinjector, including
the ability to recognise the symptoms of anaphylaxis, the availability and understanding of how to use the
autoinjector, and anxiety associated with its use.
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Patient issues and preferences
Allergic reactions can have a daily impact on the QoL of the individual, and can affect their ability to
participate in everyday and social activities, perform work-related duties, undertake examinations and
pursue their career of choice. The effect of allergies is described in two reports produced by Allergy UK.
The Stolen Lives survey found that for 28.4% of respondents allergies had a serious effect on how they
planned important life events, and for 26% their allergy severely affected their everyday life.18 The report
The Disturbing Impact of Skin Allergy and Sensitivity in the UK report19 states that 78% of respondents
suffered from reactions to their skin allergy all year round, and for 62% their condition had stopped them
from going out socially and carrying out day-to-day activities.
Where food allergy is diagnosed, implementing special diets for children can also be difficult for families to
manage, particularly where there are multiple dietary requirements in one family. A 201020 review on the
psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families
reported that non-allergic siblings often adopted the restricted diet that the allergic child followed. The
same review20 highlighted the effect of allergy on the QoL of patients and caregivers. It reported that
allergy heightened patients’ and caregivers’ anxiety because of the need for constant vigilance, particularly
in new situations. It also showed that parents tended to be overprotective of children with allergy,
particularly those who have had anaphylaxis. There can also be anxiety for a parent or caregiver associated
with administering an adrenaline injection.20
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Chapter 3 Assessment of clinical effectiveness
A systematic review was conducted to summarise the evidence on the clinical effectiveness andcost-effectiveness of ImmunoCAP ISAC and Microtest for multiplex allergen testing in people with
allergic disease. Systematic review methods followed the principles outlined in the Centre for Reviews and
Dissemination (CRD) guidance for undertaking reviews in health care21 and the NICE Diagnostic
Assessment Programme Manual.22
Systematic review methods
Search strategy
Development of search strategies followed the recommendations of the CRD guidance for undertaking
reviews in health care.21 Strategies were based on the technologies of interest.
Candidate search terms were identified from target references, browsing database thesauri (e.g. MEDLINE
MeSH and EMBASE Emtree) and from existing reviews identified during the initial scoping searches. These
scoping searches were used to generate test sets of target references, which informed text mining analysis
of high-frequency subject indexing terms using EndNote X7 reference management software (Thomson
Reuters, CA, USA). Strategy development involved an iterative approach testing candidate text and
indexing terms across a sample of bibliographic databases, aiming to reach a satisfactory balance of
sensitivity and specificity. Search strategies were developed specifically for each database.
The following databases were searched for relevant studies from 2005 to April 2015:
l MEDLINE (via OvidSP): 1946–week 2 April 2015
l MEDLINE In-Process Citations (via OvidSP): up to 15 April 2015
l MEDLINE Daily Update (via OvidSP): up to 15 April 2015
l PubMed [National Library of Medicine (NLM)] (internet) up to 22 April 2015*
l EMBASE (via OvidSP): 1974–14 April 2015
l Cochrane Database of Systematic Reviews (CDSR) (via Wiley): 2015/April/Iss4
l Cochrane Central Register of Controlled Trials (CENTRAL) (via Wiley): Cochrane Library 2015/March/Iss3
l Database of Abstracts of Reviews of Effects (DARE) (via Wiley): Cochrane Library 2015/January/Iss1
l Health Technology Assessment database (HTA) (via Wiley): Cochrane Library 2015/January/Iss1
l Science Citation Index (SCI) (via Web of Science): 1970–21 April 2015
l Conference Proceedings Citation Index – Science (CPCI-S) (Web of Science): 1990–21 April 2015
l BIOSIS Previews (via Web of Science): 1956–21 April 2015
l Literature in the Health Sciences in Latin America and the Caribbean (LILACS) (internet;
http://lilacs.bvsalud.org/en/): 1982–22 April 2015
l National Institute for Health Research (NIHR) Health Technology Assessment programme (internet;
www.hta.ac.uk/): up to 23 April 2015
l US Food and Drug Administration (FDA) (internet; www.fda.gov): up to 23 April 2015.
*An additional companion PubMed search was undertaken in tandem with MEDLINE via OvidSP; this
approach aims to detect the latest ‘ahead of print’ and ‘online first’ electronic content promoted by many
leading journals.
A supplementary search was undertaken on the following resource to identify grey literature:
l OpenGrey (internet; www.opengrey.eu): up to 22 April 2015
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Completed and ongoing trials were identified by searches of the following resources:
l National Institutes of Health (NIH) ClinicalTrials.gov (internet; www.clinicaltrials.gov/): up to
22 April 2015
l WHO International Clinical Trials Registry Platform (ICTRP) (internet; www.who.int/ictrp/en/): up to
22 April 2015
l International Standard Randomised Controlled Trial Number (ISRCTN) Registry (internet; www.isrctn.com):
up to 22 April 2015.
The following key conference proceedings, were identified in consultation with clinical experts, and were
screened for the last 5 years where available:
l American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
l European Academy of Allergy and Clinical Immunology (EAACI)
l British Society for Allergy & Clinical Immunology (BSACI)
l Food Allergy and Anaphylaxis Meeting (FAAM)
l International Symposium on Molecular Allergology (ISMA)
l American Academy of Dermatology (AAD) Meeting
l British Association of Dermatologists (BAD).
No restrictions on language or publication status were applied. Searches took into account generic and
other product names for the intervention. See Appendix 1 for all search strategies. The main EMBASE
strategy for each search was independently peer reviewed by a second Information Specialist, using the
Canadian Agency for Drugs and Technologies in Health (CADTH) Peer Review checklist.23 Identified
references were downloaded in EndNote X7 software for further assessment and handling. References in
retrieved articles were checked for additional studies.
Inclusion and exclusion criteria
Population
Adults and children with difficult to manage allergic disease who are being assessed in secondary or
tertiary care settings. Owing to the paucity of available data, studies conducted in populations not
specified as polysensitised or having difficult to manage allergic disease were also included. All
presentations of allergic disease (respiratory, skin, gastrointestinal, anaphylaxis) were eligible for inclusion.
Difficult to mange disease was defined as people who are allergic to two or more allergens and/or have
allergies to unknown sources.
Intervention/index test
Multiplex allergen testing:
l ImmunoCAP ISAC 112 and previous generations of ImmunoCAP ISAC (Thermo Fisher Scientific/
Phadia AB)
l Microtest (Microtest Matrices).
Comparator
The comparator for this assessment was current standard care, which included allergy-focused clinical
history, alternative tests of IgE antibody status (single IgE antibody testing), tests of clinical reactivity
(such as skin prick testing or allergen challenge testing) or a combination of these approaches.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Outcomes
l Clinical outcomes (e.g. allergy symptoms, incidence of acute exacerbations, mortality, AEs of testing
and treatment, health-care presentations or admissions, HRQoL, patient anxiety/preferences).
l Change to management, that is, change to treatment or treatment plan (e.g. restriction diets,
immunotherapies, use of other medications such as corticosteroids, number of allergen challenge
tests required).
l Additional diagnostic information – accuracy (sensitivity and specificity) for the prediction of clinical
reactivity, as defined by SPTs, allergen challenge tests or response to immunotherapy, plus numbers of
participants for whom multiplex allergen testing provided additional information (e.g. allergens
component-specific information, cross-reactivities, information on multiple sensitisation), diagnostic
yield (number of participants with a definitive diagnosis).
Study design
There were no restrictions on study design. Randomised controlled trials (RCTs), controlled clinical trials,
other comparative studies (e.g. ‘before-and-after’ studies) and diagnostic test accuracy studies were eligible
for inclusion. Observational study designs were eligible for inclusion only if they reported measures of
additional diagnostic information provided by multiplex allergen testing; studies that assessed only
concordance between multiplex allergen testing and single IgE antibody testing or other tests were
not included.
Protocol change The protocol stated that diagnostic accuracy studies would be included only if they
reported both the accuracy (sensitivity and specificity) of multiplex allergen testing for the prediction of
clinical reactivity, as defined by SPTs, allergen challenge tests or response to immunotherapy, and the
numbers and details of participants for whom multiplex allergen testing provided additional information.
No studies of this type were identified. The inclusion criteria were expanded to allow studies that reported
direct comparisons of diagnostic accuracy between single IgE testing and multiplex allergen testing, using
SPTs or allergen challenge tests as the reference standard. These studies do not address the primary aim of
the project, ‘to assess the clinical effectiveness and cost-effectiveness of adding multiplex allergen testing
to the investigation of people with difficult to manage allergic disease in secondary or tertiary care
settings’, because they provide no information on any additional benefit conferred by the use of multiplex
testing. Studies of this type were included with the aim of providing some indication of the performance
of multiplex allergen testing, compared with current single IgE antibody testing practice, for predicting
clinical response. Data of this type may inform the question of whether or not multiplex testing might,
in some circumstances, replace single IgE testing as well as helping to guide possible future
research recommendations.
Inclusion screening and data extraction
Two reviewers (MW and SL) independently screened the titles and abstracts of all reports identified by
searches and any discrepancies were discussed and resolved by consensus. Full copies of all studies
deemed potentially relevant were obtained and the same two reviewers independently assessed these for
inclusion; any disagreements were resolved by consensus. Details of studies excluded at the full paper
screening stage are presented in Appendix 3.
The principal investigators of completed trials (identified through searches of clinical trials registries) that
appeared to meet our inclusion criteria but for which no publication could be identified were contacted
and asked to provide publication details or unpublished data.
Data were extracted on the following: study details (including study design, country and funding); stated
objective of the study; inclusion and exclusion criteria; participant characteristics (age, gender, primary
presentation and previous allergy-related history); details of the multiplex allergen testing method used;
details of the tests included in the standard care comparator (e.g. SPT, OFC, single IgE); details of the
reference standard test (diagnostic accuracy studies only); outcome measures (included change to
DOI: 10.3310/hta20670 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 67
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
treatment or treatment plan, e.g. restriction diets, immunotherapies), change to diagnosis or number of
participants with a definitive diagnosis, and comparative accuracy (sensitivity and specificity) of multiplex
allergen testing and single IgE for the prediction of clinical reactivity, as defined by SPTs, allergen challenge
tests. Data were extracted by one reviewer, using a piloted, standard data extraction form, and checked by
a second (MW and SL); any disagreements were resolved by consensus. Full data extraction tables are
provided in Appendix 2.
Quality assessment
We planned to use the Cochrane risk-of-bias tool to assess the methodological quality of RCTs;24 however,
no RCTs or non-RCTs were identified. The methodological quality of studies providing comparative
accuracy data was assessed using QUADAS-2.25 Observational studies that used a ‘before-and-after’
type of study design to assess the effects of adding information from multiplex allergen testing to the
standard diagnostic work-up in the same group of participants were assessed using a review-specific tool
designed by the authors (MW, SL and NA). This tool has been designed to focus on elements of study
design that we considered relevant to this specific study type, and is based upon the structure of the
QUADAS-2 tool. The Critical Appraisal Skills Programme (CASP) cohort risk-of-bias tool was used to assess
other observational studies.26 A narrative description of the potential limitations of any other included
studies is provided. The results of the quality assessment have been used for descriptive purposes to
provide an evaluation of the overall quality of the included studies and to provide a transparent method of
recommendation for design of any future studies. Quality assessment was undertaken by one reviewer
and checked by a second reviewer (MW and SL) and any disagreements were resolved by consensus.
The applicability of studies to current UK practice was also considered and a narrative description of
potential applicability issues is provided. The results of the risk-of-bias assessments are summarised and
presented in tables and graphs in the results of the systematic review (see Study quality) and are presented
in full, by study, in Appendix 4.
Methods of analysis/synthesis
We planned to use a bivariate/hierarchical summary receiver operating characteristic random-effects model
to generate summary estimates and a summary receiver operating characteristic (SROC) curve for test
accuracy data,27–29 and a DerSimonian and Laird random-effects model to generate summary estimates of
treatment effects. However, because the review identified a small number of studies with between-study
variations in participant characteristics (allergy history), multiplex allergen testing methods, allergens tested
for, standard care comparators, and outcomes assessed, we did not consider meta-analyses to be
appropriate and have provided a structured narrative synthesis. The results of studies included in this
review are summarised by outcome type (clinical, change to management and diagnostic accuracy) and are
further stratified by allergen type (food and aeroallergens). The results of individual studies are summarised
in text and tables. The results of studies providing comparative accuracy data are also illustrated in receiver
operating characteristic (ROC) space plots.
Results of the assessment of clinical effectiveness assessment
The searches of bibliographic databases and conference abstracts identified 8619 references. After initial
screening of titles and abstracts, 169 were considered to be potentially relevant and ordered for full paper
screening; of these, 20 were included in the review30–49 and one50 could not be obtained. All potentially
relevant studies cited in documents supplied by the test manufacturers had already been identified by
bibliographic database searches. Additional data, relating to the study by Hermansson et al.,33,34 were
obtained through contact with the authors. Figure 1 shows the flow of studies through the review process,
and Appendix 3 provides details, with reasons for exclusions, of all publications excluded at the full paper
screening stage.
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Records identified through database searching
(n = 12,137)
• MEDLINE, n = 1955
• Medline in-process and daily update, n = 237
• EMBASE, n = 5244
• PubMed, n = 375
• CENTRAL, n = 104
• DARE, n = 0
• CDSR, n = 41
• HTA, n = 0
• SCI and CPCI-S, n = 2626
• BIOSIS, n = 1282
• LILACS, n = 156
• NIHR HTA programme, n = 0
• FDA, n = 44
• OpenGrey, n = 15
• ClinicalTrials.gov, n = 40
• ISRCTN, n = 4
• WHO ICTRP, n = 14
Conference searching
(n = 349)
• AAAAI, n = 58
• EAACI, n = 260
• BSACI, n = 14
• FAAM, n = 11
• ISMA, n = 5
• AAD, n = 0
• BAD, n = 0
Additional records identified through 
other sources
• Information from manufacturers, n = 0
• Contacting author, n = 1
Records after duplicates removed
(n = 8619)
Id
en
ti
fi
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ti
o
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
u
d
ed
Records screened
(n = 8619)
Records excluded
(n = 8450)
Full-text articles assessed
for eligibility
(n = 169)
Studies included in 
qualitative synthesis
n = 15
(20 publications)
Additional unpublished 
data were obtained
for one study
Full-text articles excluded
(n = 130)
Full-text articles identified
as duplicates
(n = 18)
Unobtainable articles
(n = 1)
FIGURE 1 Flow of studies through the review process.
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Overview of included studies
Based on the searches and inclusion screening described above (see Search strategy and Inclusion and
exclusion criteria, above), 20 publications,30–49 of 15 studies, were included in the review; the results
section of this report cites studies using the primary publication and, where this is different, the publication
in which the referenced data were reported.
Two of the included studies39,40 were conducted in the UK and, where reported, the remaining studies
were conducted in other European countries; one study47 did not report location. Of the 15 included
studies, four were funded by,38,46 or received reagents and consumables39 or testing services45 from, the
manufacturer. Five studies were publicly funded32,42–44,49 and six studies33,36,37,40,41,47 did not report funding
sources. Full details of funding are reported in the baseline study details tables (see Appendix 2,
Tables A–C).
All of the included studies evaluated versions of ImmunoCAP ISAC; one study33 evaluated ImmunoCAP
ISAC 112, five studies37–39,42,43 evaluated ImmunoCAP ISAC 103, four studies32,44,45,49 evaluated other
versions of ImmunoCAP ISAC and five studies36,40,41,46,47 did not specify the version used. We did not
identify any studies of Microtest which met the inclusion criteria for this review.
We did not identify any studies that reported clinical outcomes (i.e. allergy symptoms, incidence of acute
exacerbations, mortality, AEs of testing and treatment, health-care presentations or admissions, HRQoL,
patient anxiety/preferences).
Five studies32,33,37,38,40 assessed the effects on patient management of adding ImmunoCAP ISAC to the
standard diagnostic work-up (SPT/single IgE); two studies33,40 reported data on discontinuation or potential
discontinuation of food avoidance diets, two studies32,38 assessed changes to immunotherapy prescriptions,
and one study37 reported information on clinicians’ judgement of the utility of ImmunoCAP ISAC results in
informing patient management. One study33 assesed ImmunoCAP ISAC 112, two studies37,38 assessed
ImmunoCAP ISAC 103, one study32 assessed ImmunoCAP ISAC 96 and the remaining study40 did not
specify the version used. None of the five studies32,33,37,38,40 reported the inclusion of patients with difficult
to manage allergic disease; one study40 reported inclusion criteria which may have been consistent with
this classification (moderate to severe eczema and multiple food allergies); however, this study40 was
reported only as a conference abstract and hence provided very limited details of participants. One study40
was conducted in the UK, two studies32,37 were conducted in Spain, and one study was conducted in each
of Finland33 and Italy.38
Two studies38,39 assessed the effects on clinical diagnosis of adding ImmunoCAP ISAC 103 to the standard
diagnostic work-up: one study39 reported data on new sensitisations identified in patients with idiopathic
anaphylaxis and assessed their clinical relevance and the other study38 reported changes to the diagnostic
classification made by clinicians following access to ImmunoCAP ISAC results and was conducted in
patients with allergic rhinitis, with or without concomitant food allergy. One additional study36 assessed the
relationship between change in IgE levels, measured by ImmunoCAP single IgE and an unspecified version
of ImmunoCAP ISAC before and after a 3-year course of allergen-specific immunotherapy (SIT), and the
clinicians’ evaluation of the benefit of SIT. None of these studies reported test accuracy data. One study39
was conducted in the UK, one study38 was conducted in Italy and one study36 did not report location.
Eight studies41–47,49 compared the diagnostic accuracy of ImmunoCAP ISAC to that of alternative
investigations (single IgE testing or SPT) to predict clinical reactivity as defined by SPT or OFC testing
(the reference standard). Six studies41,42,44,46,47,49 investigated people with food allergies and two studies43,45
investigated people with allergic rhinitis/respiratory symptoms. None of the eight studies41–47,49 reported the
inclusion of patients with difficult to diagnose and manage allergic disease, or described inclusion criteria
that could be considered consistent with this classification (e.g. polysensitised patients). One study41
included patients with birch allergy, one study42 included patients with suspected egg allergy, two
studies44,49 included patients with suspected cow’s milk and/or hen’s egg allergy, one study46 included
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patients with cow’s milk allergy, one study47 included patients with hazelnut allergy, one study45 included
patients with symptoms of allergic rhinitis and one study43 included patients with pollen allergy. None of
the studies was conducted in the UK, seven studies41–46,49 were European and one study47 was unreported.
Two studies investigated ISAC 103,42,43 one study44 investigated ISAC 89, one study49 investigated ISAC 59
and one study45 investigated ISAC 50, whereas three studies41,46,47 used unspecified ISAC.
Full details of the characteristics of study participants, study inclusion and exclusion criteria, and
intervention and comparator or reference standard are reported in the data extraction tables presented in
Appendix 2 (see Tables A–E).
Excluded studies
One hundred and forty-eight full-text articles were retrieved: 18 were identified as duplicates and 130
were subsequently excluded. In all but two cases,51,52 these studies reported no relevant outcomes.
Further details of the 131 excluded full papers and the reasons for exclusion can be found in Appendix 4.
One study50 could not be obtained.
Study quality
Studies of changes to management, treatment or diagnosis
Seven studies investigated changes to treatment or management outcomes.32–34,36–40 One very small cohort
study,36 with nine participants, assessed the relationship between change in IgE levels (measured by
ImmunoCAP single IgE and an unspecified version of ImmunoCAP ISAC before and after a 3-year course
of SIT) and the clinicians’ evaluation of the benefit of SIT. The methodological quality of this study36
was assessed using the CASP cohort tool. The remaining studies used a ‘diagnostic before-and-after’ type
study design, which compared clinicians’ views and decisions on management, treatment or diagnosis
in a single group of patients, before and after access to the results of multiplex allergen testing. The
methodological quality of these studies was assessed using a tool designed specifically for this review,
which was based on the structure of QUADAS-2. Risk of bias and concerns regarding applicability are
summarised in Tables 2 and 3 and Figure 2; full assessments for each study are provided in Appendix 4.
The ‘diagnostic before-and-after studies’ were generally poorly reported, resulting in a high number of
‘unclear’ ratings, with all studies rated as ‘unclear’ risk of bias on at least one domain; four of the studies
were published as conference abstracts only.33,34,36,37,40 Two studies33,38 were rated as ‘high’ risk of bias.
One study33 was rated as ‘high’ risk of bias for patient selection; participants were selected from a
database of children who were receiving special diets in school catering, and reasons for exclusion
TABLE 2 Risk of bias for included diagnostic studies (change to management or treatment): review-specific
QUADAS-2
Study
Risk of bias Applicability concerns
Patient
selection
Index
test Comparator
Flow and
timing Patient
Index
test
Reference
standard
Heaps 201439 ? + + + + + +
Hermansson 201433,34 – ? ? ? ? + ?
Noimark 201240 ? ? ? + + + +
Luengo 201037 ? ? ? ? ? + +
Passalacqua 201338 ? + + – – + ?
Sastre 201232 ? + + + – + ?
■– , high risk; ■+ , low risk; ■? , unclear risk.
DOI: 10.3310/hta20670 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 67
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
TA
B
LE
3
R
is
k
o
f
b
ia
s
fo
r
in
cl
u
d
ed
d
ia
g
n
o
st
ic
st
u
d
ie
s
(c
h
an
g
e
to
m
an
ag
em
en
t
o
r
tr
ea
tm
en
t)
:
C
A
SP
co
h
o
rt
St
u
d
y
A
.A
re
th
e
re
su
lt
s
o
f
th
e
st
u
d
y
va
lid
?
B
.W
h
at
ar
e
th
e
re
su
lt
s?
C
.W
ill
th
e
re
su
lt
s
h
el
p
lo
ca
lly
?
1.
D
id
th
e
st
ud
y
ad
dr
es
s
a
cl
ea
rly
fo
cu
se
d
is
su
e?
2.
W
as
th
e
co
ho
rt
re
cr
ui
te
d
in
an
ac
ce
pt
ab
le
w
ay
?
3.
W
as
th
e
ex
po
su
re
ac
cu
ra
te
ly
m
ea
su
re
d
to
m
in
im
is
e
bi
as
?
4.
W
as
th
e
ou
tc
om
e
ac
cu
ra
te
ly
m
ea
su
re
d
to
m
in
im
is
e
bi
as
?
5.
(a
)
H
av
e
th
e
au
th
or
s
id
en
tif
ie
d
al
l
im
po
rt
an
t
co
nf
ou
nd
in
g
fa
ct
or
s?
(b
)
H
av
e
th
ey
ta
ke
n
ac
co
un
t
of
th
e
co
nf
ou
nd
in
g
fa
ct
or
s
in
th
e
de
si
gn
an
d/
or
an
al
ys
is
?
6.
(a
)
W
as
th
e
fo
llo
w
-u
p
of
su
bj
ec
ts
co
m
pl
et
e
en
ou
gh
?
(b
)
W
as
th
e
fo
llo
w
-u
p
of
su
bj
ec
ts
lo
ng
en
ou
gh
?
7.
W
ha
t
ar
e
th
e
re
su
lts
of
th
is
st
ud
y?
8.
H
ow
pr
ec
is
e
ar
e
th
e
re
su
lts
?
9.
D
o
yo
u
be
lie
ve
th
e
re
su
lts
?
10
.
C
an
th
e
re
su
lts
be
ap
pl
ie
d
to
th
e
lo
ca
l
po
pu
la
tio
n?
11
.
D
o
th
e
re
su
lts
of
th
is
st
ud
y
fit
w
ith
ot
he
r
av
ai
la
bl
e
ev
id
en
ce
?
12
.
W
ha
t
ar
e
th
e
im
pl
ic
at
io
ns
of
th
is
st
ud
y
fo
r
pr
ac
tic
e?
G
ay
-C
ro
si
er
20
10
36
+
?
?
?
?
–
?
+
+
?
?
?
?
?
■–
,
hi
gh
ris
k;
■+
,
lo
w
ris
k;
■ ?
,
un
cl
ea
r
ris
k.
0
20
40
60
80
10
0
Pa
ti
en
t 
se
le
ct
io
n
In
d
ex
 t
es
t
R
ef
er
en
ce
 s
ta
n
d
ar
d
Fl
o
w
 a
n
d
 t
im
in
g
Pr
o
p
o
rt
io
n
 o
f 
st
u
d
ie
s 
w
it
h
 lo
w
, h
ig
h
 o
r 
u
n
cl
ea
r
ri
sk
 o
f 
b
ia
s 
(%
)
Domain
0
20
40
60
80
10
0
Pr
o
p
o
rt
io
n
 o
f 
st
u
d
ie
s 
w
it
h
 lo
w
, h
ig
h
 o
r 
u
n
cl
ea
r
co
n
ce
rn
s 
re
g
ar
d
in
g
 a
p
p
lic
ab
ili
ty
 (
%
)
Lo
w
H
ig
h
U
n
cl
ea
r
FI
G
U
R
E
2
R
is
k
o
f
b
ia
s
ac
ro
ss
in
cl
u
d
ed
‘d
ia
g
n
o
st
ic
b
ef
o
re
-a
n
d
-a
ft
er
’
st
u
d
ie
s
(c
h
an
g
e
to
m
an
ag
em
en
t
o
r
tr
ea
tm
en
t)
.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
included ‘no longer allergic’ (according to self-report or nurse interview) and unwillingness to participate
because of, for example, fear of needles, lack of trust in tests and multiple previous testing. The second
study38 was rated as ‘high’ risk of bias for flow and timing because the standard care comparator differed
between participants; all participants received SPT, and single IgE testing was used ‘as required.’ Although
this is likely to be representative of standard practice, it remains a potential source of bias when estimating
test performance.
Although this review included patients with any allergy, the primary objective was to assess the clinical
effectiveness of multiplex allergen testing in people with complex or difficult to manage allergies, in UK
health-care settings. Studies that did not specify that they included participants with difficult to manage
allergic disease, or describe inclusion criteria which could be considered consistent with this classification
(e.g. polysensitised patients), were therefore rated as having ‘high’ concerns regarding applicability. Studies
that were conducted in non-UK settings and which assessed allergens considered unlikely to be relevant to
UK populations (e.g. aeroallergens associated with Mediterranean countries) were also rated as having
‘high’ concerns regarding applicability. Two studies39,40 were rated as having ‘low’ concerns regarding
participant applicability, and in two studies33,37 insufficient reporting details prevented a judgement and
therefore they were rated ‘unclear’. The remaining two studies32,38 were rated as having ‘high’ concerns
regarding participant applicability: for both this was because the patients were not from the UK and in one
study38 patients did not have difficult to manage disease.
The small observational study36 that was assessed using the CASP cohort tool for risk of bias was reported
only as conference abstract; therefore, risk of bias was largely unclear owing to lack of study details.
Studies of diagnostic accuracy
Eight studies41–47,49 compared the diagnostic accuracy of ImmunoCAP ISAC to that of alternative
investigations (single IgE testing or SPT) to predict clinical reactivity as defined by SPT or OFC testing
(the reference standard). The methodological quality of these studies was assessed using the QUADAS-2
tool (summarised in Table 4 and Figure 3). The full QUADAS-2 assessments for each study are provided
in Appendix 4.
TABLE 4 QUADAS-2 assessments for included diagnostic accuracy studies
Study
Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Albarini 201347 ? ? + ? – ? +
Alessandri 201242 ? – ? – – + +
Cabrera–Freitag 201143 – – + ? – + +
De Swert 201241 – – + – – + +
D’Urbano 201044 – – ? + – + +
Ott 200849 ? – ? ? – + +
Sokolova 200946 – ? + ? – + +
Wöhrl 200645 – – + ? – + +
■– , high risk; ■+ , low risk; ■? , unclear risk.
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The comparative accuracy studies were generally poorly reported; seven42–47,49 of the eight studies were
rated as ‘unclear’ risk of bias on at least one QUADAS-2 domain. One study47 was reported only as a
conference abstract.
Seven studies41–46,49 were rated as ‘high’ risk of bias on at least one domain. The main potential sources of
bias were in relation to participant selection and application of the index test. Five studies41,43–46 were rated
as ‘high’ risk of bias for participant selection because they used a diagnostic case–control design, a design
likely to produce inflated estimates of test performance, or applied inappropriate exclusion criteria (patients
with eczema,44 high levels of single IgE45 or complex allergy43). Five studies41,43–46 were rated as ‘high’ risk of
bias for the index test. In all cases this was because diagnostic thresholds were not prespecified, but were
optimised using ROC analyses in the same population that was used to assess test performance, an
approach that is likely to result in inflated estimates of test performance. Two of these studies41,42 were
also rated as ‘high’ risk of bias for flow and timing, because not all the participants were included in the
analysis41 or because not all participants received the same reference standard.42
As was the case for studies of change to management, treatment or diagnosis, studies that did not specify
that they included participants with difficult to manage allergic disease or describe inclusion criteria that
could be considered consistent with this classification (e.g. polysensitised patients) were therefore rated as
having ‘high’ concerns regarding applicability, and studies that were conducted in non-UK settings and
which assessed allergens considered unlikely to be relevant to UK populations (e.g. aeroallergens
associated with Mediterranean countries) were also rated as having ‘high’ concerns regarding applicability.
All eight comparative accuracy studies41–47,49 were rated as having ‘high’ concerns regarding participant
applicability because they did not include people with difficult to manage allergic disease, and three of
these studies41,43,45 also focused on allergens that were considered unlikely to be fully applicable to the UK.
Effects on management, treatment and diagnostic classification of adding
multiplex allergen testing to the diagnostic work-up of people with difficult
to manage allergic disease
Study details
Six studies32,33,37–40 assessed the effects of adding multiplex allergen testing to the standard diagnostic
work-up (SPT/single IgE) on the management, treatment or diagnosis of patients. One study assessed
ImmunoCAP ISAC 112,33 three studies assessed ImmunoCAP ISAC 103,37–39 one study assessed
ImmunoCAP ISAC 9632 and the remaining study used an unspecified version of ImmunoCAP ISAC.40
All six studies32,33,37–40 used a ‘diagnostic before-and-after’ type study design to assess the effects of adding
ImmunoCAP ISAC results to the information available to clinicians on their judgements regarding the
management, treatment or diagnosis of a given group of patients.
Change to management or treatment
Two studies investigated the use of ImmunoCAP ISAC to guide decisions on the discontinuation of
restrictive diets in children with food allergies.33,40 Both studies were reported as conference abstracts only
and hence provided only limited study details and results. Hermansson et al.33 used a database to identify
199 school children in Härkätie, Finland, receiving special diets in school catering; (confidential information
has been removed) (e-mail from Johannes Savolainen, University of Turku, Finland, to Shona Lang,
23 June 2015, personal communication). (Confidential information has been removed) (Johannes
Savolainen, personal communication). The Hermansson study33 did not report any information on clinical
outcomes following changes to dietary management. Noimark and Harnik40 investigated 12 children
selected from patients attending an East London allergy clinic (no details of the selection criteria were
reported). Participants were investigated using SPT and/or single IgE, and an unspecified version of
ImmunoCAP ISAC. The authors reported that ISAC enabled potential food reintroductions (peanut n= 4,
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soy n= 2, wheat n= 4), additional to that indicated by single IgE alone; the numbers of potential
reintroductions based on standard diagnostic work-up (SPT and/or single IgE) were not reported. No details
were reported of which single IgE/SPTs were conducted or which ISAC components were assessed.
Noimark and Harnik40 did not report the number of food reintroductions that occurred following testing or
clinical outcomes of any changes to dietary management.
Two studies37,38 assessed the views of clinicians on whether or not ImmunoCAP ISAC testing provided
information useful in the management of patients. Luengo et al.37 performed ImmunoCAP ISAC 103 testing
in 55 well-characterised, polysensitised patients (as assessed by SPTs and single IgE tests) with various
allergies; no details were reported of which ISAC components were assessed or how these were interpreted.
Participating clinicians judged that ImmunoCAP ISAC 103 provided new information useful in the
management of the patient in 50 (91%) cases.37 The added value was in the ability of ImmunoCAP ISAC to
differentiate between protein homologues and hence to aid in the discrimination of allergens that were
cross-immunoreactive rather than those that were responsible for sensitisation. In 34 (62%) cases the
clinicians considered that it would have been useful to perform ImmunoCAP ISAC 103 testing before SPT,
as several protein homologues can be investigated at once using ImmunoCAP ISAC.37 Passalacqua et al.38
investigated 318 consecutive polysensitised (at least two positive SPTs) patients with respiratory allergy in six
allergy units in Italy. Participants were initially investigated using clinical history, SPT and single IgE testing
(including mites, grass, olive, Parietaria, birch, cypress, ragweed, mugwort, cat and dog dander, Alternaria
and Aspergillus) and were assessed using ImmunoCAP ISAC 103 (no details reported of components
assessed or interpretation, but cross-immunoreactive allergens were considered); treating clinicians were
required to review their diagnosis/treatment based on the ImmunoCAP ISAC 103 results and provide a
judgement of the value of any additional information provided.38 New information was classified as
‘remarkable’ if it could not be obtained using standard diagnostic work-up and could impact upon accuracy
of diagnosis or SIT prescription; new information related to patient management was classified as
‘remarkable’ in 299 (95%) cases and ‘to some extent’ (not defined) in 232 (73%) cases.38
Two studies32,38 investigated the effect on SIT prescriptions of adding ImmunoCAP ISAC testing to the
standard diagnostic work-up of people with respiratory allergy. Passalacqua et al.38 (described above)
reported that a SIT prescription was made for 85 new patients, following testing with ImmunoCAP ISAC
103, who would not have received SIT based on standard diagnostic work-up (SPT/single IgE) alone. In
addition, the existing SIT prescription was changed in a further three patients, following ImmunoCAP ISAC
103 testing.38 Sastre et al.32 investigated 141 people with respiratory allergy (with or without concomitant
food allergy) in one allergy outpatient clinic in Spain. SIT indications were initially assessed based on
clinical history and SPT (Olea e, Platanus a, Cupressus a, grass mix, Cynodon d, Phragmites c, Artemisia v,
Salsola k and Plantago I), blind to the results of ImmunoCAP 96 testing (Ole e1, Cup s1, Cry j1, Pla a1,
Pla a2, Phl p1, Phl p5, Phl p4, Phl p6, rPhl p11, Phl p12, Cyn d1, Sal k1, Aln g1, Bet v1, Cor a1.0101,
Amb a1, Art v1, Art v3 and Par j2).32 Clinicians then reassessed SIT indications based on all diagnostic
information, including ImmunoCAP ISAC 96 results.32 Disagreements on the SIT prescription based on
standard diagnostic work-up and that based on all information, including ImmunoCAP ISAC, occurred for
79 (54%) study participants; details are reported in Table 5.32 Neither study reported details of which SIT
prescriptions were actually used, or any subsequent clinical outcomes.
Change to diagnostic classification
Two studies investigated the effect on diagnostic classification of adding ImmunoCAP ISAC 103 testing to
the standard diagnostic work-up of people with allergic disease.38,39 Heaps et al.39 investigated 110 patients,
from five UK specialist allergy centres, who had a diagnosis of idiopathic anaphylaxis [based on clinical
assessment, SPT, single IgE testing and mast cell tryptase (MCT)]. Study participants were reassessed using
ImmunoCAP ISAC 103 and clinicians were asked to score the additional information provided. Information
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provided by ImmunoCAP ISAC 103 was given the highest score (new heat- and digestion-stable sensitisations
found, which were thought to have a strong association with anaphylaxis) for 22 (20%) of participants;
however, large numbers of sensitisations that were not thought to be associated with anaphylaxis were also
identified (see Table 6 for full details).39 In addition, for a further 35 (32%) of participants the information
provided by ImmunoCAP ISAC was deemed to have identified only additional sensitisations which were
not thought to be associated with anaphylaxis.39 Passalacqua et al.38 (described above; see Change to
management or treatment) reported clinicians’ ratings of the value of additional diagnostic information
provided by ImmunoCAP ISAC 103 (see Table 6). In addition, this study38 reported detailed information on
changes to diagnostic category using five classifications (see Table 6); the addition of ImmunoCAP ISAC
103 testing resulted in increases in the numbers of people classified as ‘poly sensitised with suspected
cross-reactivity’ and the number of people diagnosed with both inhalant and food allergies, as well
as facilitating a diagnosis for eight previously unclassifiable patients.38 Full details are provided in Table 6.
Other
We identified one additional study36 that assessed the relationship between change in IgE levels measured
by ImmunoCAP single IgE and change in IgE levels measured by an unspecified version of ImmunoCAP
ISAC before and after a 3-year course of SIT, and the clinicians’ evaluation of the benefit of SIT. This
study36 included only nine participants who received a total of 31 courses of SIT (no details of diagnosis
were reported). The median specific IgE levels, measured by ISAC, decreased from 5.6 ISU/ml at the
beginning of SIT to 0.01 ISU/ml at the end of SIT, and this change correlated with clinical benefit of SIT
(evaluated by clinicians) (Spearman’s r= 0.46; p= 0.02).36 Conversely, allergen-specific single IgE
measurements did not show a decrease from the beginning to the end of SIT.36
Summary
The results of studies in this section provide some indication that the addition of ImmunoCAP ISAC to
standard diagnostic work-up can change clinicians’ views on the diagnosis, management and treatment of
patients. There was some indication that the use of ImmunoCAP ISAC testing may guide decisions on the
discontinuation of restrictive diets, the content of SIT prescriptions, and whether or not patients should
receive SIT. However, importantly, none of the studies that we identified reported any information on
clinical outcomes subsequent to changes in treatment or management based on ImmunoCAP ISAC. Three
studies report the usefulness of ImmunoCAP ISAC for discriminating allergens that are structurally similar
and are recognised by the same IgE antibody (cross-immunoreactive); this discrimination appears to be
particularly useful for identifying the cause of food allergies. The UK-based study on the use of
ImmunoCAP ISAC to investigate idiopathic anaphylaxis indicated that the addition of ImmunoCAP ISAC to
standard diagnostic work-up may identify a potentially causative agent in previously undiagnosed patients.
However, it should be noted that the addition of ImmunoCAP ISAC also resulted in the identification of
large numbers of sensitisations that were not considered to be associated with the anaphylaxis, that is,
large numbers of clinically false-positive test results or sensitisations associated with other allergic
conditions such as rhinitis.
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Diagnostic accuracy of ImmunoCAP Immuno Solid-phase Allergen Chip,
compared with other testing options, for the prediction of allergic response
Study details
Six studies41,42,44,46,47,49 were identified which compared the accuracy of ImmunoCAP ISAC to existing
diagnostic tests (SPT or single IgE tests) in people with food allergies; two studies43,45 were identified of
people with allergies to aeroallergens. None of the studies looked at ISAC 112, two investigated ISAC
103,42,43 one investigated ISAC 89,44 two investigated ISAC 50/5145,49 and three investigated unknown
ISAC versions.41,46,47 The results of the comparative diagnostic accuracy studies are summarised in Table 7.
Diagnosis of food allergy
De Swert et al.41 investigated soy flour allergy. The diagnostic accuracy of an unknown ISAC version to
measure the soy flour component rGly m4 was compared with the single IgE test for the same component
and to a SPT for soy flour. Cut-off values were reported separately for each test and OFC testing was used
as the reference standard. ISAC had the highest sensitivity, 86% (95% CI 42% to 100%), but the lowest
specificity, 80% (95% CI 28% to 100%). The single IgE test and SPT had similar sensitivity (75%) and
specificity (100%).
Alessandri et al.42 investigated allergy to boiled or raw egg. The diagnostic accuracy of ISAC 103, when
used to measure three individual egg components (Gal d1 or Gal d2 or Gal d3), was compared with the
accuracy of single IgE tests (egg yolk or egg white) and compared with the accuracy of SPTs (egg white
extract or raw egg white or boiled egg white or egg yolk extract or raw egg yolk or boiled egg yolk).
Cut-off values were reported separately for each test and OFC testing was used as the reference standard.
SPT had the highest sensitivity for prediction of allergic response to raw egg white, 88% (95% CI 71.8%
to 96.6%), whereas Gal d3 measured using ISAC 103 had the highest specificity, 100% (95% CI 90% to
100%). Results for raw egg were similar to those for boiled egg. In general, single IgE performed similarly
to SPT (both measured whole extracts), whereas ISAC 103 gave much more variable results for the
three different components measured. No measure of the overall diagnostic performance of ISAC 103
(all components combined) was reported.
Two studies44,49 investigated allergy to cow’s milk and hen’s egg. D’Urbano et al.44 compared the accuracy of
ISAC 89, used to measure two individual components (Gal d1 or Bos d8), to the accuracy of single IgE tests
(egg white or cow’s milk). Cut-off values were reported separately for each test and OFC testing was used as
the reference standard. Specificity was consistent (96%) for both ISAC 89 components and for cow’s milk
and egg white single IgE. Sensitivity values were higher for ISAC 89 components (78% for Bos d8 and 73%
for Gal d1) than for the corresponding whole-allergen single IgE tests (41% for cow’s milk and 27% for egg
white). When whole-allergen single IgE tests and ISAC 89 were used in series (i.e. ISAC 89 results were
considered only in single IgE-negative participants), the combined sensitivity was greater than that for single
IgE alone (84% compared with 41% for cow’s milk allergy, and 73% compared with 27% for hen’s egg
allergy); specificity was 92% in both cases. Ott et al.49 compared the accuracy of ISAC 51, used to measure
eight individual components (α-casein, β-casein, κ-casein, Bos d4, Bos d5, Gal d1, Gal d2, Gal d4), with the
accuracy of single IgE tests (hen’s egg or cow’s milk extract) and to the accuracy of SPTs (native hen’s egg or
native cow’s milk). Cut-off values were reported separately for each test and OFC testing was used as the
reference standard. The results were very variable between tests. SPT had the highest sensitivity for cow’s
milk allergy, 93.6% (95% CI 78.5% to 99%). The ISAC 51 components all had low sensitivity for cow’s milk
allergy (ranging from 23.9% to 50% for the five components assessed). Conversely, all five ISAC 51
components had high specificity for cow’s milk allergy (ranging from 88.4% to 97.7%), whereas SPT had low
specificity, 48.2% (95% CI 28.7% to 68%). Single IgE testing had the highest sensitivity for hen’s egg allergy,
71.1% (95% CI 55.7% to 83.6%). All three ISAC 51 components had low sensitivity (ranging from 17.8%
to 57.8%) and high specificity for hen’s egg allergy; the individual specificities of the ISAC 51 components
were 100% for Gal d4, 86.7% for Gal d1 and 80% for Gal d2. Single IgE testing and skin prick testing had
comparable specificity (86.7% and 100%, respectively). No measure of the overall diagnostic performance of
ISAC 51 (all relevant components combined) was reported for either cow’s milk or hen’s egg allergy.
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Sokolova et al.46 investigated milk allergy. The diagnostic accuracy of an unknown ISAC version, used to
measure nine individual components (Bos d 4, Bos d 6, Bos d 7, Bos d 8, casein α-S1, casein β and casein κ,
Bos d lactoferrin, Bos d 5.0101), was compared with the accuracy of single IgE tests for four allergens (whole
milk, α-lactoalbumin, ββ-lactoglobulin and casein). For both methods, a positive result was defined as positive
for at least one component or whole allergen; the cut-off values used to define positivity for individual
components and allergens were not reported. OFC testing was used as the reference standard. Both combined
ISAC testing and combined single IgE testing had 100% sensitivity; however, ISAC testing had much higher
specificity, 91.7% (95% CI 73% to 99%), than the single IgE testing, 37.5% (95% CI 18.8% to 59.4%).
Albarini et al.47 investigated hazelnut allergy. The diagnostic accuracy of an unknown ISAC version, used to
measure four individual components (Cor.a.1.1010, Cor.a.1.0401, Cor.a.8, Cor.a.9), was compared to the
accuracy of single IgE tests (hazelnut) and to SPT. Cut-off values were not reported for the ISAC test. OFC
testing was used as the reference standard. Both the SPT and the single IgE test had 100% sensitivity,
whereas the ISAC components generally had low sensitivity (ranging from 6.3% to 56.3%). However, the
ISAC components had higher specificity (ranging from 73.7% to 100%) than either single IgE (21.1%) or
skin prick testing (52.6%).
Diagnosis of aeroallergy
Wöhrl 200645 investigated five different aeroallergens (HDM, cat dander, birch pollen, grass pollen and
mugwort pollen). The diagnostic accuracy of ISAC 50, used to measure the presence of one or more
aeroallergens (up to five), was compared with the accuracy of single IgE tests of whole allergens. Where
multiple ISAC components were assessed, a positive result was defined as positive for at least one
component. The cut-off points for each test were not reported. Skin prick testing was used as the
reference standard. The specificity of ISAC 50 was high for all aeroallergens investigated, regardless of
whether a single component or multiple components were assessed (range 89.9–98.1%), and, with the
exception of mugwort pollen, was comparable to the specificity estimate for the corresponding whole
allergen single IgE test for all aeroallergens investigated (see Table 7). The sensitivity of ISAC 50 was lower
than that of single IgE tests for HDM, cat and mugwort pollen. The sensitivities and specificities of the
individual components ISAC 50 components were not reported.
Cabrera-Freitag et al.43 investigated two different pollens (grass pollen or Phleum pratense and cypress
pollen or C. arizonica). Two cut-off points (manufacturers’ recommended and ROC optimised) were
reported per test and SPT was used as the reference standard. The diagnostic accuracy of ISAC 103, when
used to measure the eight components for grass pollen (rPhl p1, rPhl p2, nPhl p4, rPhl p5, rPhl p6, rPhl p7,
rPhl p11, rPhl p12), was compared with the accuracy of a single IgE test to measure P. pratense; a positive
result was defined as positive for at least one component. The sensitivity and specificity for ISAC 103 and
single IgE were similar, irrespective of the cut-off point used. Sensitivity and specificity estimates for
individual grass pollen ISAC 103 components were not reported. In addition, the accuracy of ISAC 103
was used to measure the presence of a one component for cypress pollen (nCup a1) in comparison with
the accuracy of single IgE tests to measure C. arizonica. The sensitivity estimates for the two tests were
equal at both cut-off points (91.7%); however, specificity was higher for ISAC 103 at both cut-off points
(91.3% and 95.6%) than for the single IgE test (range 80.4–89.1%).
Summary
The diagnostic performance of ImmunoCAP ISAC in comparison with other tests (single IgE and SPT) varied
considerably between studies, according to the allergens investigated and the way in which ISAC testing was
applied. In general, individual ISAC components tended to have high specificity, but low sensitivity, relative to
whole-allergen single IgE tests or SPT for the prediction of allergic response. The relatively low sensitivities of
individual ISAC components are likely to be indicative of the proportions of patients in whom each component
is associated with the observed allergic response. Conversely, a high specificity is indicative of a strong
association between ISAC positivity for the individual component and an allergic response to whole allergen.
However, when ISAC was used to measure the same component as single IgE testing or to measure multiple
components (homologous proteins), with a positive test defined as any component positive, it appeared that
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equivalent sensitivities could be achieved without corresponding loss of specificity. The ability of ImmunoCAP
ISAC to discriminate between allergens that are structurally similar and are recognised by the same IgE antibody
(cross-immunoreactive) may represent clinically useful additional information (see Effects on management,
treatment and diagnostic classification of adding multiplex allergen testing to the diagnostic work-up of people
with difficult to manage allergic disease, above). Therefore, if the focused use of groups of ISAC components
can achieve equivalent sensitivity and specificity to that of single IgE testing, ISAC testing may be preferred.
The results of the only study to investigate serial testing suggested that use of ImmunoCAP ISAC after
single IgE testing only in participants who were negative on single IgE could increase sensitivity relative to
single IgE alone without any loss in specificity. None of the comparative diagnostic accuracy studies
included in this review was conducted in people with difficult to manage allergic disease, and all studies
investigated the diagnostic performance of a limited range of ISAC components of a specified allergen.
These studies are therefore unable to provide any information on the specificity of the whole ISAC panel
when used to investigate people with difficult to manage allergic disease, that is, the extent to which the
multiplex allergen testing may produce ‘false-positive’ results by detecting sensitisations that are not
clinically relevant. This indicates the importance of using confirmatory tests after the array and that the
current array cannot wholly replace OFC or SPT as a diagnostic procedure.
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Chapter 4 Assessment of cost-effectiveness
This chapter explores the cost-effectiveness of multiplex allergen testing compared with current clinicalassessment in patients referred for specialist allergy investigation in secondary or tertiary care settings.
More specifically, the following research question will be addressed:
l What is the cost-effectiveness of adding multiplex allergen testing to the investigation of people with
difficult to manage IgE-mediated allergic disease in secondary or tertiary care settings?
Review of economic analyses of multiplex allergen testing
Search strategy
Searches were undertaken to locate relevant economic evaluations on adults and children undergoing
specialist allergy investigation in secondary or tertiary care settings.
The following databases were searched for relevant studies from 2005 to May 2015:
l NHS Economic Evaluation Database (NHS EED) (via Wiley): 2005–Issue 2 of 2015/May/Iss2
l IDEAS via Research Papers in Economics (REPEC) (internet; http://repec.org/): 2005–26 May 2015
l EconLIT (via EBSCOhost): 2005–21 May 2015
l EMBASE (via OvidSP): 1974–21 May 2015
l MEDLINE (via OvidSP): 1946–May Week 3 2015
l MEDLINE In-Process and Daily Update (via OvidSP): up to 20 May 2015.
Inclusion criteria
Studies reporting outcomes of a full cost-effectiveness analysis, with (at least) one of the comparators
including multiplex allergen testing, were eligible for inclusion.
Quality assessment
Included studies are appraised using a quality checklist based on that of Drummond et al.53
Results
The literature search identified 311 records from bibliographic database searches and supplementary
searching (e.g. reference/citation checking, additional database searches including the database search for
the assessment of clinical effectiveness). After removing duplicates, and title and abstract screening, 15
records were considered to be potentially relevant; after full-text screening four studies (nine publications,
all abstracts) were considered eligible for inclusion (Figure 4). All four included studies are authored by
Hermansson (as either first or second author), an employee of Thermo Fisher Scientific. Three studies,
reported in six publications,33,34,54–57 considered multiplex allergen testing for children with suspected food
allergy (specifically peanut allergy in two studies) and one study, reported in three publications,58–60
considered multiplex allergen testing for patients sensitised to pollen. These studies are described in more
detail below and summarised in Table 8. The results of the quality assessment are shown in Table 9.
Hermansson 2014
Hermansson et al.33,34 considered the cost-effectiveness of ImmunoCAP ISAC in addition to a standard
diagnostic work-up compared with standard diagnostic work-up without ImmunoCAP ISAC for Finnish
school children with a restricted diet as a result of suspected food allergy (community setting). The analysis
was informed by 24 children from a larger database (including a total of 2317 school children). The results
indicated an unnecessary restricted diet for 63% of the children, resulting in a cost per avoided
unnecessary diet of €480 for ImmunoCAP ISAC.
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Titles and abstracts identified and
screened for potential relevance
• Bibliographic database search, n = 309
• Supplementary searching, n = 2
Potentially relevant publications
obtained for full-text screening 
(n = 15)
Total number of studies 
included in the review
[n = 4 studies (9 publications)]
Excluded duplicates
(n = 65)
Excluded at title and 
abstract screening
(n = 231)
Excluded at full-paper
screening
(n = 6a)
FIGURE 4 Flow chart (review of economic analyses). a, Reasons for exclusion: did not report outcomes of a full
cost-effectiveness analysis (n= 6).
TABLE 8 Summary of included economic evaluations (all abstracts)
Hermansson 201433,34
Hermansson 2013,54
201255,56 Glaumann 201357
Mascialino 2013,58,59
Hermansson 201260
Population Finnish suspected
food-allergic school
children
Children with suspected
peanut allergy
Children with
suspected peanut
allergy
Spanish patients with allergic
rhinoconjunctivitis and/or
asthma sensitised to pollen
from a complex pollen area
Setting Primary care Primary care Primary care NR
Time horizon NR 5 years 5 years 9 years
Objective To evaluate the health-
economic benefit of
ImmunoCAP ISAC
To demonstrate that MA
for peanut allergy at the
general practitioner level
could increase QALYs
and have a considerable
economic impact
To compare different
diagnostic methods:
MA, SPT, OFC and
DBPCFC for children
with a suspected
peanut allergy and to
evaluate the patients’
QoL and the
economic impact for
the health-care
system in Sweden
To analyse the
cost-effectiveness of MA
for SIT indication and QoL
Source of
effectiveness
information
Database from Primary
Care Unit (n= 24
children agreed to
participate)
Literature Literature Database of 141 patients with
allergic rhinoconjunctivitis and/or
asthma sensitised to pollen from
a complex pollen area32
Comparators Traditional diagnostic
algorithm with and
without ImmunoCAP
ISAC added
Different diagnostic
approaches including
DBPCFC, SPT and/or MA
Different diagnostic
approaches including
DBPCFC, OC, SPT
and/or MA
SPT and MA vs. SPT
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TABLE 8 Summary of included economic evaluations (all abstracts) (continued )
Hermansson 201433,34
Hermansson 2013,54
201255,56 Glaumann 201357
Mascialino 2013,58,59
Hermansson 201260
Costs items NR General practitioner visit,
specialist visitor, tests,
allergic reaction,
allergy treatment
(including EpiPen and
antihistamine), indirect
costs (for sensitivity
analysis)
Doctor visits, tests,
allergic reaction,
allergy treatment
(including EpiPen and
antihistamine),
indirect costs (for
sensitivity analysis)
General practitioner visit,
nurse visit, specialist visitor,
emergency visit, tests, SIT,
symptomatic treatment,
indirect costs
Main measure
of benefit
Unnecessary diets QALYs QALYs QALYs
Assumptions NR NR NR Patients would get 6 years of
‘sustained effect’ (i.e. remain
healthy) after 3 years of SIT
Perspective NR Health care Health care NR
Discount rate NR NR NR NR
Uncertainty
around cost-
effectiveness
ratio expressed
No No No No
Sensitivity
analysis
No No No No
Monetary
outcomes
€ SEK (Sweden), USD
(USA), RMB (China)
SEK (Sweden) €
Outcomes per
comparator
QALYs: NR
Other outcomes:
adding ImmunoCAP
ISAC could identify
63% of the patients
as having an
unnecessary diet
(this was 70% on
the posters)
Costs: NR
MA vs. DBPCFC vs. SPT:
QALYs: 3.97 vs. 2.54 vs.
3.86
Costs:
l Sweden: 70,051 SEK
vs. 77,840 SEK vs.
130,306 SEK
l USA: 27,023 USD vs.
27,892 USD vs.
45,010 USD
l China: 8963 RMB vs.
25,982 RMB vs.
41,437 RMB
The results presented on
the posters differed but
the order of the cost
and effects of the
comparators remained
the same, except for
China on one poster,
where DBPCFC became
most expensive while MA
remained least expensive.
Moreover, on another
poster MA became most
expensive for Korea and
second most expensive
for Japan (DBPCFC was
least expensive)
MA vs. DBPCFC vs.
OC vs. SPT:
QALYs: 4.34 vs. 3.22
vs. 2.23 vs. 3.66
Costs: 11,267 SEK vs.
24,278 SEK vs.
33,031 SEK vs.
44,851 SEK
The results presented
on the poster differed
but the order of the
cost and effects of
the comparators
remained the same
MA reduces SIT by at least 20%
SPT and MA vs. SPT:
QALY: 7.03 vs. 6.88
Costs: €2538 vs. €2608
The costs for SPT and MA
presented on the poster were
slightly higher (€2583)
Moreover, the results presented
on the presentation slides
differed but the order of the
cost and effects of the
comparators remained the same
continued
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TABLE 8 Summary of included economic evaluations (all abstracts) (continued )
Hermansson 201433,34
Hermansson 2013,54
201255,56 Glaumann 201357
Mascialino 2013,58,59
Hermansson 201260
Summary of
incremental
analysis
Adding ImmunoCAP
ISAC resulted in a
cost per avoided
unnecessary diet of
€480 (€15 was
reported on the
poster)
MA is both more
effective and less
expensive than
alternative diagnostic
strategies
MA is both more
effective and less
expensive than
alternative diagnostic
strategies
SPT and MA combined is both
more effective and less
expensive than SPT only
DBPCFC, double-blind placebo-controlled food challenge; MA, molecular allergology; NA, not applicable; NR, not reported;
OC, open oral food challenge; RMB, Chinese renminbi; SEK, Swedish krona; SIT, specific immunotherapy; USD, US dollar.
TABLE 9 Study quality checklist for included studies
Hermansson
201433,34
Hermansson
2013,54 201255,56
Glaumann
201357
Mascialino
2013,58,59
Hermansson
201260
Study design
The research question is stated ✗ ✗ ✗ ✗
The economic importance of the research question
is stated
✗ ✗ ✗ ✗
The viewpoint(s) of the analysis are clearly stated
and justified
✗ ✗ ✗ ✗
The rationale for choosing alternative programmes
or interventions compared is stated
✗ ✗ ✗ ✗
The alternatives being compared are clearly
described
✗ ✗ ✗ ✗
The form of economic evaluation used is stated ✗ ✓ ✓ ✓
The choice of form of economic evaluation is
justified in relation to the questions addressed
✗ ✗ ✗ ✗
Data collection
The source(s) of effectiveness estimates used are
stated
✓ ✗ ✗ ✓
Details of the design and results of effectiveness
study are given (if based on a single study)
✗ ✗ ✗ ✗
Details of the methods of synthesis or meta-analysis
of estimates are given (if based on a synthesis of a
number of effectiveness studies)
NAa ✗ ✗ NAa
The primary outcome measure(s) for the economic
evaluation are clearly stated
✗ ✗ ✗ ✗
Methods to value benefits are stated NA ✗ ✗ ✗
Details of the subjects from whom valuations were
obtained were given
NA ✗ ✗ ✗
Productivity changes (if included) are reported
separately
✗ ✗ ✗ ✗
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TABLE 9 Study quality checklist for included studies (continued )
Hermansson
201433,34
Hermansson
2013,54 201255,56
Glaumann
201357
Mascialino
2013,58,59
Hermansson
201260
The relevance of productivity changes to the study
question is discussed
✗ ✗ ✗ ✗
Quantities of resource use are reported separately
from their unit costs
✗ ✗ ✗ ✗
Methods for the estimation of quantities and unit
costs are described
✗ ✗ ✗ ✗
Currency and price data are recorded ✗ ✗ ✗ ✗
Details of currency of price adjustments for inflation
or currency conversion are given
✗ ✗ ✗ ✗
Details of any model used are given NAa ✗ ✗ ✗
The choice of model used and the key parameters
on which it is based are justified
NAa ✗ ✗ ✗
Analysis and interpretation of results
Time horizon of costs and benefits is stated NAa ✓ ✓ ✓
The discount rate(s) is stated ✗ ✗ ✗ ✗
The choice of discount rate(s) is justified ✗ ✗ ✗ ✗
An explanation is given if costs and benefits are not
discounted
✗ ✗ ✗ ✗
Details of statistical tests and CIs are given for
stochastic data
NA NA NA NA
The approach to sensitivity analysis is given NA NA NA NA
The choice of variables for sensitivity analysis is
justified
NA NA NA NA
The ranges over which the variables are varied are
justified
NA NA NA NA
Relevant alternatives are compared ✓ ✓ ✓ ✓
Incremental analysis is reported ✓ ✗ ✗ ✗
Major outcomes are presented in a disaggregated
as well as aggregated form
✗ ✗ ✗ ✗
The answer to the study question is given ✗ ✗ ✗ ✗
Conclusions follow from the data reported ✗b ✓ ✓ ✓
Conclusions are accompanied by the appropriate
caveats
✗ ✗ ✗ ✗
QALY, quality-adjusted life-year; NA, not applicable; ✗, no; ✓, yes.
a This assessment is likely to be directly based on trial data, hence this item is probably not applicable.
b It is unclear why this ICER is considered cost-effective.
Note that the quality assessment was based on the published abstracts only.
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Hermansson 2013 and Hermansson 2012
Another study by Hermansson et al.54–56 examined the cost-effectiveness of ImmunoCAP ISAC compared
with double-blind placebo-controlled food challenge (DBPCFC) and skin prick testing for children with
suspected peanut allergy. For this purpose, a Markov model was constructed with a 5-year time horizon.
Health states included non-allergic and allergic, and mild and severe allergic reactions were modelled as
events. The costs were considered for Sweden, the USA and China. The results indicated that ImmunoCAP
ISAC is least expensive, whereas SPT is most expensive, in all three countries. Moreover, ImmunoCAP ISAC
was also found to be most effective, leading to 3.97 quality-adjusted life-years (QALYs), whereas the
DBPCFC strategy is least effective (2.54 QALYs). Consequently, ImmunoCAP ISAC dominated both the SPT
and DBPCFC strategies.
Glaumann 2013
Glaumann et al.57 examined the cost-effectiveness of ImmunoCAP ISAC compared with DBPCFC, open
OFC and SPT for children with suspected peanut allergy in Sweden. A Markov model with a 5-year time
horizon was constructed for this purpose. Health states included non-allergic and allergic, and mild and
severe allergic reactions were modelled as events. The results indicated that ImmunoCAP ISAC is least
expensive, whereas SPT is most expensive. Furthermore, ImmunoCAP ISAC was also found to be most
effective, leading to 4.34 QALYs, whereas the OFC strategy was considered least effective (2.23 QALYs).
Consequently, ImmunoCAP ISAC dominated all three alternative strategies.
Mascialino 2013 and Hermansson 2012
Mascialino et al.58,59 and Hermansson et al.60 examined the cost-effectiveness of ImmunoCAP ISAC with SPT
compared with SPT only for Spanish patients sensitised to pollen in a complex pollen area. The analysis was
based on a Markov model with a 9-year time horizon and the assumption that patients on specific
immunotherapy (SIT) continue this treatment for 3 years and remain healthy for the subsequent 6 years or
discontinue SIT and move to symptom management treatment until year 9. The analysis was informed
by a data set of 141 patients with allergic rhinoconjunctivitis and/or asthma sensitised to pollen.32 The results
indicated that the addition of ImmunoCAP ISAC to SPT reduces SIT prescriptions and hence results in cost
savings compared with SPT only (€2538 vs. €2608). ImmunoCAP ISAC with SPT was also found to be more
effective (7.03 QALYs) than SPT only (6.88 QALYs); hence ImmunoCAP ISAC with SPT dominated SPT only.
Quality assessment and summary of studies in the cost-effectiveness review
All four studies33,34,54–60 reported benefits associated with adding ImmunoCAP ISAC to the diagnostic
work-up (increased effectiveness), and three out of four studies also showed cost savings when using
ImmunoCAP ISAC. However, as all included studies were reported only as conference abstracts, the methods
and assumptions used were largely unclear; this severely hampered the assessment of the validity of the
results. It was often unclear precisely which diagnostic strategies were examined. The lack of information
about these studies is illustrated in Table 9 (study quality checklist for included papers). Besides this
transparency issue, the credibility of the sources used in these studies may be questionable. Fundamental
inputs of the model were based on expert opinion, inaccessible references, or no references were provided
(information was still lacking after full retrieving of copies of the posters and a presentation supplied by the
authors). For example, the numbers of true positives, false positives, false negatives and true negatives for
ImmunoCAP ISAC appeared to be based on expert opinion in most cases.33,34,54–57,59,60 In addition, two
assessments from this group54–57 focused on the same population, both using a Markov model with a 5-year
time horizon, but the reported QALYs and outcomes differed substantially (see Table 8). In conclusion, the
available economic assessments indicate that the addition of ImmunoCAP ISAC will increase effectiveness
and can be cost-saving. However, given the lack of detail on how these results were produced and the use
of expert opinion for key inputs, these findings should be interpreted with extreme caution.
Overview of potentially relevant excluded studies
In addition to the included studies described above, one potentially relevant study61 that considered the
incremental costs of multiplex allergen testing was excluded, as it did not report effectiveness outcomes
and, as a result, was not considered to be a full cost-effectiveness analysis. For completeness, the results of
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this study61 (also reported only as a conference abstract) are summarised below (despite efforts in
contacting the authors, the full copy of the poster could not be retrieved).
The study by Rodriguez-Ferran et al.61 considered the costs of SPT, Phadiatop and ImmunoCAP Rapid for
screening respiratory allergy in children in primary care. Their results showed that SPT is least expensive
(€10–15), followed by ImmunoCAP® RAPID (Thermo Fisher Scientific/Phadia AB, Uppsala, Sweden; €30) and
Phadiatop® (Phadia AB, Uppsala, Sweden; €36–67). The authors stated that they believe SPT is cost-effective.
Review of health-related quality of life studies
Search strategy
Searches were undertaken to locate relevant utility studies on adults and children with allergic conditions.
The following databases were searched for relevant studies from database inception date to July 2015:
l MEDLINE (via OvidSP): 1946–June Week 3 2015
l MEDLINE In-Process Citations and Daily Update (via OvidSP): up to 29 June 2015
l EMBASE (via OvidSP): 1974 to 29 June 2015
l Patient-Reported Outcome and Quality Of Life Instruments Database (PROQOLID) (internet;
www.proqolid.org/): up to 1 July 2015
l NHS EED (via Wiley): 2005–Issue 2, April 2015
l Cost-Effectiveness Analysis (CEA) Registry (internet; www.ceareregistry.org): up to 1 July 2015.
Inclusion criteria
Studies were required to include utility values obtained using a preference-based instrument. Also, studies
were limited to a population with an allergic condition associated with food or pollen. This limitation was
applied in order to be pragmatic and focus on allergies for which there was at least some evidence,
albeit limited, from the clinical effectiveness review. Non-English-language studies were excluded.
Results
Searches identified 1300 (1074 after removing duplicates) potentially relevant publications, of which 1028
were excluded at the abstract screening stage. Full texts were obtained for the 46 publications that were
potentially relevant. Thirty-one publications were excluded at the full-text screening stage because no
utility values were reported (n= 29) or the study was not written in English (n= 2). Four of the excluded
publications were reviews. The studies included in these reviews were all present in the search results.
Three additional publications were identified through reference checking of the included studies. The four
studies33,34,54–59 identified in the review of economic analyses of multiplex allergen testing were also
identified in this review, but excluded because no original utility data were provided. Seventeen
publications were included,62–77 describing 14 studies (Figure 5).
Fourteen studies reporting health-state utilities for allergic conditions were found. Ten studies, reported in
13 publications, used the EuroQol instrument, and reported either the European Quality of Life-5
Dimensions (EQ-5D) utility score62–67 or the visual analogue scale (VAS) score.68–73 One study reported
utilities obtained by the HUI Mark III instrument.74 Three studies used a direct utility elicitation
technique.75–77 The 10 studies reported on 28 populations: 14 studies with rhinitis/rhinosinusitis/
rhinoconjunctivitis/asthma,62–66,68–73,78 11 studies with eczema,67,73,75–77 two studies with food allergy73,74 and
one study with mixed allergies except food allergies.74 Utility values ranged from 0.5000 for patients with
allergic rhinitis receiving allergy vaccination72 to 0.970 for persons with mild eczema.76 Patients who sought
help from a specialised allergy clinic (to receive allergy vaccination) and patients currently exposed to
allergens seemed to have lower utility scores than the other populations. Only two studies reported on the
relationship between the severity of allergic symptoms and utility value75,76 (Table 10).
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Titles and abstracts identified and 
screened for potential relevance
• Bibliographic database search, n = 1226
• Supplementary searching, n = 74
Potentially relevant publications
obtained for full-text screening 
(n = 46)
Additional publications identified 
through reference lists
(n = 3)
Total number of studies 
included in the review
[n = 14 studies (17 publications)]
Excluded duplicates
(n = 226)
Excluded at title and 
abstract screening
(n = 1028)
Excluded at full-paper
screening
(n = 32a)
FIGURE 5 Flow chart (review of HRQoL studies). a, Reasons for exclusion: no utility values (n= 30), non-English (n= 2).
TABLE 10 Health-state utilities and values for allergic conditions
Source Population N Country Instrument
Health-state utility or
value
Mean
SD or
95% CI
Remenschneider
201562
Chronic rhinosinusitis 242 USA EQ-5D 0.8100 0.1300
Pitt 200468 Seasonal allergic
conjunctivitis
310 UK EUROQOL-VAS 0.8169a 0.1489
Poole 2014,63
Canonica 2007,64
Bachert 2007,65
Currie 201463
Seasonal allergic
rhinoconjunctivitis
634 Europe,
including
UK
EQ-5D 0.9380 0.9320 to
0.9430
Smith 200569 Seasonal allergic
rhinoconjunctivitis
200 Spain EUROQOL-VAS 0.8009 0.1524
Wasserfallen 199970 Allergic rhinitis 21 USA EUROQOL-VAS 0.6250b 0.1300
Petersen 201366 Allergic
rhinoconjunctivitis or
asthma
248 Denmark EQ-5D 0.7000b 0.2000
Grass pollen induced 169 0.7000b 0.1800
HDM induced 25 0.6000b 0.3000
Grass and HDM
induced
54 0.7200b 0.1800
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Six studies,63,67–69,73,78 describing 10 populations, compared health-state utility scores for persons with and
without allergic conditions. The largest difference was observed for persons with asthma (–0.0530, EQ-5D)
and eczema [–0.0660, EuroQol Visual Analogue Scale (Euroqol-VAS)]. For the other populations (food and
airway allergies) the differences ranged between –0.0240 and –0.0330 (Table 11).
TABLE 10 Health-state utilities and values for allergic conditions (continued )
Source Population N Country Instrument
Health-state utility or
value
Mean
SD or
95% CI
Egert-Schmidt 2014 71 Rhinitis, conjunctivitis,
asthma
753 Germany EUROQOL-VAS 0.7000c NR
Petersen 201172 Allergic rhinitis
patients receiving
allergy vaccination
366 Denmark EUROQOL-VAS 0.5000 0.2000
Covaciu 201373 Any allergic disease 3137 Sweden EUROQOL-VAS 0.9260 0.0860
Asthma 3220 0.8990 0.0100
Rhinitis 3214 0.9230 0.0860
Food hypersensitivity 3218 Sweden EUROQOL-VAS 0.9220 0.0870
Eczema 3156 Sweden EUROQOL-VAS 0.9220 0.0910
Mittmann 199974 Food allergy 1075 Canada HUI Mark III 0.8500 0.1700
Other allergies 3102 0.8800 0.1500
Moberg 200967 Hand eczema 25247 Sweden EQ-5D 0.7820 0.7720 to
0.7920
Lundberg 199977 Atopic eczema 132 Sweden VAS 0.7300 NR
TTO 0.9300 NR
SG 0.9800 NR
Stephens 200575 Mild atopic eczema in
children
150 UK SG 0.8625 NR
Moderate atopic
eczema in children
0.6900 NR
Severe atopic eczema
in children
0.5900 NR
Friedman 200476 Mild atopic eczema 3539 USA VAS converted to
utilities using 2.4 in
the power function
0.9970 NR
Mild to moderate
atopic eczema
0.9876 NR
Moderate atopic
eczema
0.9571 NR
Moderate to severe
atopic eczema
0.8971 NR
Severe atopic eczema 0.8052 NR
NR, not reported; SD, standard deviation; SG, standard gamble; TTO, time trade-off; VAS, visual analogue scale.
a During pollen season.
b On days with symptoms.
c Median.
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Of the excluded studies, three are worth mentioning because they were conducted in UK
health-care settings:
l Armstrong et al.79 investigated the cost-effectiveness of a specialist allergy service and adrenaline
injectors for those who had suffered anaphylaxis. In this study79 the impact of anaphylactic shock on
QoL was, in absence of utility evidence, assumed by the authors to be equal to zero utility for a
duration of 9 days at maximum.
l Meadows et al.80 investigated immunotherapy in adults and children with seasonal allergic rhinitis.
They used mapping to obtain EQ-5D change scores from changes in scores on the Rhinoconjunctivitis
Quality of Life Questionnaire (RQLQ).81 The RQLQ scale ranges from 0 (best) to 6 (worst). It was
assumed that the top end of the scale maps to the EQ-5D state representing no problems in any of the
five dimensions. The bottom end of the RQLQ scale was mapped to the EQ-5D state representing
maximum problems with usual activities, pain/discomfort and anxiety/depression, but no problems with
mobility or self-care, which were assumed to be unaffected by seasonal allergic rhinitis. This state has a
QoL score of –0.07 on the standard UK tariff. As a result, going from worst to best was a 6-point
reduction in RQLQ and a 1.07-point increase in the EQ-5D score. Each unit decrease (improvement) in
RQLQ was assumed to map to a 0.178-point increase in QoL score (assuming that a unit decrease has
the same value at all points on the scale). The authors state that it could be argued that mapping the
RQLQ to the whole range of three of the five dimensions of the EQ-5D scale could have led to an
overestimation of utility gains, as the bottom score of –0.07 on the EQ-5D (representing a state worse
than death) would not be equivalent to the worst score on the RQLQ.
l Garside et al.82 investigated the effectiveness of treatments for atopic eczema. In the absence of utility
values in the literature they used a UK Utility Panel (n= 15 laypeople) to estimate utilities for three
severity stages of atopic eczema using the standard gamble. They used the Dermatology Life Quality
Index83 to develop scenarios and obtained valuations of these using SG. The median results were 0.985
for mild eczema, 0.875 for moderate eczema and 0.675 for severe eczema.
Methodology
The aim of this assessment was to compare the cost-effectiveness of adding multiplex allergen testing to
current clinical practice with current clinical practice alone for people with difficult to manage IgE-mediated
allergic disease in secondary or tertiary care settings. In this setting, multiplex allergen testing might be used
to inform clinical decisions (e.g. to perform a food challenge and/or to initiate SIT) through aiding allergy
diagnosis, predicting the probability of allergic reactions and/or predicting response to SIT. However, given
the paucity of data on the clinical effectiveness of multiplex allergen testing (see Chapter 3), no long-term
cost-effectiveness model is developed. This is in accordance with the published protocol for this assessment
(PROSPERO registration no. CRD42015019739). More specifically, the lack of data on the clinical
consequences of adding multiplex allergen testing to current clinical practice renders the development of a
long-term economic model unusable to inform health policy decision-making.
Instead of developing a long-term cost-effectiveness model, the following sections aim to inform research
decisions and support future model-based economic evaluations and include the following components:
l relevant cost-effectiveness analyses are identified and reviewed (see Review of economic analyses of
multiplex allergen testing, above)
l available health-state utility studies are identified and reviewed (see Review of health-related quality of
life studies, above)
l the current clinical diagnostic pathway as well as the potential place for multiplex allergen testing are
examined (see Current clinical diagnostic pathways, below)
l a concept model structure is developed (see Model structure, below)
l a survey is performed to retrieve the proportions of patients receiving each test (see Model
parameters, below)
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l test costs were calculated (see Model parameters, below), and
l cost analyses were performed to examine the short-term costs of diagnostic pathways with
ImmunoCAP ISAC vs. with Microtest vs. without either (standard diagnostic pathway)
(see Cost analyses, below).
Current clinical diagnostic pathways
Current clinical diagnostic pathways for patients referred for specialist allergy investigation in secondary or
tertiary care settings may include SPT, single IgE testing and an OFC test where appropriate, combined
with clinical history. SPT is often the first investigation performed in allergy diagnostics.84,85 Based on
consultations with clinical experts, it is assumed that single IgE testing will be performed in cases where
the results of the SPT are not consistent with the clinical history of a patient (e-mail from Roisin Fitzsimons,
Guys and St Thomas’ NHS Foundation Trust, 15 July 2015, personal communication). Inconsistency can
occur if the SPT for the most likely allergen (based on clinical history) is negative or if a SPT is positive for
an allergen that does not seem to explain the symptoms completely. Additionally, an OFC test is usually
performed to confirm or rule out allergy to a specific food-related allergen or allergens.85–87 If SPT is not
considered acceptable/practical (e.g. in children with atopic eczema), single IgE testing might be the
first-line investigation, using confirmatory OFC or SPT as necessary. Moreover, it might be possible to
proceed to OFC based on SPT (and patient history) alone. Figure 6 provides an overview of the possible
diagnostic pathways with and without SPT. It should be noted that it is unclear whether or not this
theoretical diagnostic pathway (based on clinical expertise and literature) is representative of current UK
clinical practice in all secondary or tertiary care settings.
IgE allergy
ruled out
Clinical
history
(a)
Challenge
test
Allergy
diagnosed
No allergy
Allergy
diagnosed
sIgE test
SPT
No allergy
Allergy
diagnosed
Clinical
history
(b)
No allergy
IgE allergy
ruled out
Challenge
test
sIgE test
No allergy
Allergy
diagnosed
Clinical
history
(c)
No allergy
Allergy
diagnosed
Challenge
test
SPT
No allergy
FIGURE 6 Current diagnostic pathways. In these pathways it is assumed that no further testing will be performed if
IgE-mediated allergic response can be ruled out as an explanation for the observed symptoms. In all other cases it
is assumed that further testing will be performed.
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When considering patients with difficult to manage allergic disease who have been referred for assessment
in secondary or tertiary care settings, multiplex allergen testing is likely to occur as a first-line investigation
(assuming that all of the allergens of interest are on the array). Its role would be to identify which allergens
a patient is sensitive to. Any allergens identified would have to be confirmed by SPT or OFC. The potential
advantage of the array is that it can simultaneously test for homologous proteins or cross-sensitive proteins
and therefore can aid the clinician in tailoring which confirmatory tests are required. For example, if the test
is negative for particular proteins this might rule out the need for OFC. It is likely that multiplex allergen
testing would replace single IgE testing, although some single IgE testing might still be required, for
example if the array does not test for all suspected allergens. Figure 7 provides an overview of potential
diagnostic pathways including multiplex allergen testing. In some pathways (see Figure 7a and b) it is
IgE allergy
ruled out
Clinical
history
(a)
Multiplex
allergen test
IgE allergy
ruled out
Challenge
test
Allergy
diagnosed
No allergy
Allergy
diagnosed
sIgE test
SPT
No allergy
Clinical
history
(b)
IgE allergy
ruled out
Multiplex
allergen test
IgE allergy
ruled out
Challenge
test
Allergy
diagnosed
No allergy
sIgE test
No allergy
Clinical
history
(c)
Allergy
diagnosed
Multiplex
allergen test
IgE allergy
ruled out
Challenge
test
Allergy
diagnosed
No allergy
SPT
No allergy
Clinical
history
(d)
IgE allergy
ruled out
Challenge
test
Allergy
diagnosed
No allergy
Multiplex
allergen test
No allergy
FIGURE 7 Potential diagnostic pathways including multiplex allergen testing. In these pathways it is assumed that
no further testing will be performed if IgE-mediated allergic response can be ruled out as an explanation for the
observed symptoms. In all other cases it is assumed that further testing will be performed.
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assumed, based on clinical opinion (e-mail from Paul Turner, Imperial College London and St Mary’s
Hospital, London, 15 July 2015, personal communication), that single IgE testing will always be performed
before multiplex allergen testing (if single IgE testing is applicable). However, this might not always be the
case, as multiplex allergen testing may also be performed instead of single IgE testing (see Figure 7a and d).
The most important point is that multiplex allergen testing would be likely to reduce the number of single
IgE tests, by ruling out particular allergens, thereby reducing the need for OFC.
Model structure
This section describes a model structure that could potentially be used to assess the cost-effectiveness of
multiplex allergen testing compared with current clinical practice for people with difficult to manage
allergic disease in secondary or tertiary care settings. Three comparators would be evaluated in the
economic model:
l ImmunoCAP ISAC testing
l Microtest testing
l current (standard) diagnostic pathway.
The health-economic model would potentially consist of a decision tree and a state-transition (i.e. Markov)
model. The decision tree can be used to model the short-term outcomes, based on test results and the
accompanying treatment decision. These outcomes consist of ‘at risk of allergic reaction (treated)’, ‘not at
risk of allergic reaction (treated)’, ‘at risk of allergic reaction (untreated)’ and ‘not at risk of allergic reaction
(untreated)’. Moreover, potential AEs of testing can be considered in the decision tree. The decision tree is
shown in Figure 8.
The long-term consequences in terms of costs and QALYs can be estimated using a state-transition cohort
model (Figure 9) with a lifetime time horizon. The initial health state in the state-transition model is
determined by the short-term outcome from the decision tree. The following health states are included in
the state-transition model:
l at risk of allergic reaction
l not at risk of allergic reaction/remission
l allergic reaction (experienced during cycle)
l death (either background mortality or death due to an allergic reaction).
Different types and severities of allergic reactions can be included in the model separately. Given the
diversity of allergy reactions, which depend on the type of allergy, separate models would ideally be
developed for separate populations, for example those suspected of having clinical reactivity to an inhaled
versus an ingested allergen.
Model parameters
Decision tree
To inform the decision tree for the diagnostic pathway the following parameters are required:
l proportion of patients who receive a particular test (i.e. SPT, single IgE test, multiplex allergen test
and/or OFC test) as well as the number of SPTs and/or single IgE tests per patient
l accuracy of the diagnostic pathways (i.e. proportion of true positives, false positives, false negatives
and true negatives as a result of the combined diagnostic performance of SPT, single IgE and/or
multiplex testing)
l the treatment decision.
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The proportions of patients receiving a particular test and the number of tests per patient are unclear for
both the standard diagnostic pathway and the diagnostic pathway including multiplex allergen testing.
To alleviate this issue, a survey was sent to clinicians to inform these parameters (see Appendix 6 for the
survey). However, no valid responses were received for multiplex allergen testing; the only respondent who
indicated having any experience with ImmunoCAP ISAC responded that the number of OFC tests used was
too few to comment on. Hence it was not possible to use the survey results in the cost analyses. Moreover,
as described in the systematic review (see Effects on management, treatment and diagnostic classification
of adding multiplex allergen testing to the diagnostic work-up of people with difficult to manage allergic
disease, above), full information on the accuracy of the diagnostic pathways is not available. Finally,
information on how treatment decisions relate to the diagnostic pathways is not available. Although two
studies examined changes in SIT prescriptions32,38 following the addition of multiplex allergen testing results
to standard diagnostic work-up, the results of these studies were not consistent: one study38 described an
increase in SIT prescriptions following multiplex allergen testing, whereas the other study32 described a
decrease in SIT prescriptions following multiplex allergen testing (see Table 5 for more details).
State-transition model
To inform the long-term state-transition model, the following parameters would be required
(all conditional on the test result):
l probability of allergic reactions (might be multiple allergic reactions and population specific)
l probability of remission, and
l probability of dying.
No long-term consequences for multiplex allergen testing were identified in the systematic review
(see Chapter 3, Overview of included studies).
Health-state utilities
The evidence on utility values for allergic conditions in the UK population was limited. For food allergies,
no utility values were found. For seasonal allergic rhinoconjunctivitis, EuroQol VAS scores from Pitt et al.68
or EQ-5D scores from a European study63–65 could be taken. Stephens et al.75 used standard gamble to
obtain utility values for atopic eczema in UK children. Only in the study by Stephens et al.75 were utilities
reported per degree of severity of the allergic conditions (see Tables 10 and 11). Utility values for
complications of allergies, such as anaphylactic shock, could not be found in the literature, apart from the
assumption made by Armstrong et al.79 that the impact of anaphylactic shock on QoL was equal to zero
utility for a duration of 9 days at maximum.
Not at risk of
allergic reaction/remission
Allergic reactiona
(experienced during cycle)
At risk of allergic
reaction
FIGURE 9 Potential state-transition model structure. a, Different types and severities of allergic reactions can be
separately included in the model. †Death.
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Resource use and costs
To estimate the costs of the individual tests, a detailed cost calculation (see Appendix 7) was performed
considering test costs, capital costs (if applicable), service and maintenance costs and personnel costs for
performing and interpreting the tests. The results of the detailed test cost calculation are presented in
Table 12. For ImmunoCAP ISAC and Microtest testing, the minimum and maximum prices were calculated
and subsequently averaged. For ImmunoCAP ISAC testing, the main differences between the minimum
and maximum prices can be attributed to the difference in time (between 5 and 60 minutes) that was
needed to interpret the test results. This also holds true for Microtest testing, although the range was
smaller (between 5 and 10 minutes). Additionally, for Microtest testing it is assumed that the test sample
would be sent to the Microtest DX laboratory, where the test would be performed (companies preferred
and most conservative scenario), whereas for ImmunoCAP ISAC testing it is assumed that the test would
be performed at the service provider laboratory. Hence, for ImmunoCAP ISAC testing capital costs are
included while for Microtest testing it is assumed that these costs would be included in the test costs
(see Appendix 7). Capital costs are annuitised using a cost discount rate of 3.5%.
Additional costs that would be considered in a long-term cost (-effectiveness) analysis may include the
costs of SIT, health-state costs for being at risk of allergic reaction, and health-state costs for having
experienced an allergic reaction. These costs are likely to be very specific for the population to be
considered. Moreover, different types of SIT might be provided within a specific population (see, for
example, the study by Sastre et al.32). Hence the specific type(s) of SIT prescribed and the SIT duration
would be required to calculate these costs (see, for example, the study by Meadows et al.80 for a
calculation of the immunotherapy costs for rhinitis).
Cost analyses
In this section we report on a cost comparison of three diagnostic strategies: with ImmunoCAP ISAC versus
with Microtest versus the standard diagnostic pathway without multiplex allergen testing.
Given that the proportion of patients receiving single IgE and OFC tests in addition to ImmunoCAP ISAC
or Microtest is unclear, the cost analyses are performed using two-way threshold analysis for these
parameters.90 Specifically, in pairwise comparisons of two test strategies, the minimal reduction
(i.e. threshold) in proportions of single IgE and OFC tests is identified that was needed for the most
expensive test strategy to become cheaper than the alternative test strategy, assuming that everything else
remains equal. Here, 100% for both tests was defined as all patients receiving eight single IgE tests on
average and all patients receiving on average one OFC test (see Appendix 7). Therefore, for example, if it
was assumed that the use of multiplex allergen testing would result in no single IgE testing then this
would imply a 100% reduction in single IgE testing compared with the standard diagnostic pathway.
Given that multiplex allergen testing is more costly than single IgE testing, threshold analysis could then
show what percentage reduction in OFC tests would be required to give the multiplex allergen pathway
the same cost as the standard diagnostic pathway. On the other hand, if it was instead assumed that there
TABLE 12 Results of the test cost calculation (see Appendix 7 for more details)
£ per patient tested Sources
SPT 62.28 NICE 2011,86 Curtis88
IgE test 136.37 NICE 2011,86 Curtis88
OFC test 570.00 NICE 2011,86 Department of Health (NHS reference costs 2013–1489)
ImmunoCAP ISAC 219.51 Information submitted to NICE by Thermo Fisher Scientific, Curtis88
Microtest 156.85 Information submitted to NICE by Microtest DX, Curtis88
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was no reduction in single IgE testing by use of multiplex allergen, then this would result in a different
threshold for the percentage reduction in OFC tests required to give the multiplex allergen pathway the
same cost as the standard diagnostic pathway.
As previously stated, in these analyses, it is assumed everything except the number of single IgE tests and
the number of OFC tests remains equal; this includes the assumption that the proportion of patients
receiving any SPT is equal for all test strategies. Although this assumption is debatable, it might be justified
given that SPT is a simple, safe and quick test (providing results within 15–20 minutes) that is often the
first-line investigation in allergy diagnostics. Moreover, one clinician (e-mail from Paul Turner, personal
communication), with experience with ImmunoCAP ISAC testing, indicated that all patients would receive
SPT when using ImmunoCAP ISAC.
Scenario analyses
Several scenario analyses were performed:
1. In the calculation of the base-case costs for ImmunoCAP ISAC it is assumed that the LuxScan 10k
reader would be used only for ImmunoCAP ISAC testing (on average 386 tests per year). However, the
LuxScan 10k reader might be used for other purposes. Therefore, in the first scenario analysis, it is
assumed that the LuxScan 10k reader would be fully occupied for 253 days per year. This reduces the
ImmunoCAP ISAC testing costs to £201.91 per patient tested.
2. The second scenario analysis considered a scenario wherein the Microtest test would be performed at
the service provider laboratory instead of at the Microtest DX laboratory (as assumed in the base-case
analysis). This scenario reduces the costs of Microtest testing to £149.37 per patient tested (see
Appendix 8).
3. The third scenario analysis considered the impact of the number of allergens tested using single IgE
testing (base-case value= eight allergens tested per person).86 The number of allergens was set to 1 and
20, respectively.
4. The final scenario analysis considered a reduced OFC costs of £256.00, excluding the costs of
implementing the food elimination diet.
Threshold analyses
For the situation where ImmunoCAP ISAC or Microtest are used as replacement test(s) for single IgE
testing (rather than as an add-on), a threshold analysis was performed to examine the minimum number
of allergens to be tested with single IgE tests in order for single IgE testing to be equally as expensive as, or
more expensive than multiplex allergen testing, assuming that everything else remains equal. This analysis
was also performed for SPT.
Results of cost analyses
The cost analyses consider the short-term test costs using two-way threshold analyses for the proportion
of single IgE tests and the proportion of OFC tests. The base-case analysis indicated that in order for
ImmunoCAP ISAC and Microtest to be cost-saving compared with the standard diagnostic pathway,
the absolute proportion of OFC tests should be reduced by at least 15 and 4 percentage points,
respectively (e.g. from 50% to 35% or from 50% to 46%, respectively), if there was a 100% reduction in
single IgE tests (i.e. from 100% to 0%). On the other hand, if there is no reduction in the proportion of
single IgE tests (assuming an average of eight per person), the reduction in OFC tests should be at least
39% and 28% for ImmunoCAP ISAC and Microtest, respectively. Moreover, for ImmunoCAP ISAC
compared with Microtest, the proportion of OFC tests for ImmunoCAP ISAC should be reduced by at least
11% if there is no reduction in the proportion of single IgE tests. When assuming no reduction in the
proportion of OFC tests, the proportion of patients receiving an average of eight single IgE tests for
ImmunoCAP ISAC should be reduced by at least 44% (Figure 10).
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Scenario analyses
1. The ImmunoCAP ISAC costs are reduced by £18 when assuming that the LuxScan 10k reader would be
fully occupied. This resulted in a decrease in the proportions for ImmunoCAP ISAC needed to reduce in
order to be cost-saving compared with the standard diagnostic pathway and Microtest (Figure 11).
2. The Microtest costs are reduced by £7 when assuming that the Microtest test would be performed at
the service provider laboratory instead of at the Microtest DX laboratory. This resulted in a decrease in
the proportions for Microtest tests needed to reduce in order to be cost-saving compared with the
standard diagnostic pathway (Figure 12).
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FIGURE 10 Results of two-way threshold analyses (base case). Combinations of percentage reductions in food
challenge and single IgE testing above a line lead to lower costs, and below a line lead to higher costs.
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FIGURE 11 Results of two-way threshold analyses (assuming that the LuxScan 10k reader would be fully occupied).
Combinations of percentage reductions in food challenge and IgE testing above a line lead to lower costs, and
below a line lead to higher costs.
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3. Assuming that the number of allergens tested using single IgE testing is ‘one’ decreases the impact of
reducing the proportion of patients with single IgE tests, while assuming 20 allergens tested increases
the impact of reducing the proportion of patients with single IgE tests (Figures 13 and 14).
4. Finally, decreasing the OFC costs to £256.00 substantially increases the reduction in OFC needed in
order for multiplex allergen testing to be cost-saving (Figure 15).
Threshold analyses
In these analyses, it is assumed that there is no reduction in OFC testing with multiplex testing.
The minimum numbers of allergens tested using single IgE tests were 13 and 10 in order for the standard
pathway to be as expensive as or more expensive than the ImmunoCAP ISAC and Microtest pathways,
respectively. This means that, if multiplex testing replaced single IgE testing, then it would have to replace
at least 13 or 10 tests to be cost-saving. For SPT these numbers were 39 and 27, respectively.
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FIGURE 12 Results of two-way threshold analyses (assuming that the Microtest test would be performed at the
service provider lab). Combinations of percentage reductions in food challenge and IgE testing above a line lead to
lower costs, and below a line lead to higher costs.
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FIGURE 13 Results of two-way threshold analyses (assuming one allergy tested during single IgE test).
Combinations of percentage reductions in food challenge and IgE testing above a line lead to lower costs,
and below a line lead to higher costs.
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FIGURE 14 Results of two-way threshold analyses (assuming 20 allergens tested during single IgE test).
Combinations of percentage reductions in food challenge and IgE testing above a line lead to lower costs,
and below a line lead to higher costs.
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FIGURE 15 Results of two-way threshold analyses (assuming OFC costs of £256.00). Combinations of percentage
reductions in food challenge and IgE testing above a line lead to lower costs, and below a line lead to higher costs.
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Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness
The results of the very limited number of available studies provide some indication that the addition of
multiplex allergen testing (ImmunoCAP ISAC) to standard diagnostic work-up can change clinicians’ views
on the diagnosis, management and treatment of patients; no data were available for Microtest. There was
some indication that the use of ImmunoCAP ISAC testing may guide decisions on the discontinuation of
restrictive diets, the content of SIT prescriptions, and whether or not patients should receive SIT. However,
importantly, none of the studies that we identified reported any information on clinical outcomes
subsequent to changes in treatment or management based on ImmunoCAP ISAC. There was some
evidence that ImmunoCAP ISAC may be useful for discriminating allergens that are structurally similar and
are recognised by the same IgE antibody (cross-immunoreactive), and this may be useful for identifying the
cause of food allergies. A UK-based study on the use of ImmunoCAP ISAC to investigate idiopathic
anaphylaxis indicated that the addition of ImmunoCAP ISAC to standard diagnostic work-up may identify a
potentially causative agent in previously undiagnosed patients.39 However, it should be noted that the
addition of ImmunoCAP ISAC also resulted in the identification of large numbers of sensitisations that
were not considered to be associated with the anaphylaxis (i.e. large numbers of clinically false-positive
test results).
The diagnostic performance of ImmunoCAP ISAC in comparison with other tests (single IgE and SPT) varied
considerably between studies, according to the allergens investigated and the way in which ISAC testing
was applied. In general, individual ISAC components tended to have high specificity, but low sensitivity,
relative to whole-allergen single IgE tests or SPTs for the prediction of allergic response. The relatively low
sensitivities of individual ISAC components are likely to be indicative of the proportions of patients in
whom each component is associated with the observed allergic response. Conversely, a high specificity is
indicative of a strong association between ISAC positivity for the individual component and an allergic
response to whole allergen. When ISAC was used to measure the same component as single IgE testing or
to measure multiple components (homologous proteins) with a positive test defined as any component
positive, it appeared that equivalent sensitivities could be achieved without corresponding loss of
specificity. As noted above, the ability of ImmunoCAP ISAC to discriminate between allergens that are
structurally similar and are recognised by the same IgE antibody (cross-immunoreactive) may represent
clinically useful additional information. Therefore, if the focused use of groups of ISAC components can
achieve equivalent sensitivity and specificity to that of single IgE testing, ISAC testing may be preferred.
The clinical effects of adding multiplex allergen testing to the investigation of people with difficult to
manage allergic disease have yet to be adequately investigated; in particular, the clinical consequences of
changes to diagnosis or treatment, and the frequency and relevance of clinically false-positive sensitisations
has been under investigated.
Cost-effectiveness
The initial aim of this assessment was to compare the cost-effectiveness of multiplex allergen testing
with current clinical practice for people with difficult to manage allergic disease in secondary or tertiary
care settings. However, the lack of data on the clinical consequences of multiplex allergen testing rendered
the development of a long-term economic model uninformative for health policy decision-making.
Therefore, instead of developing a long-term cost-effectiveness model, this assessment aimed to inform
research decisions and support future model-based economic evaluations. For this purpose, relevant
cost-effectiveness analyses and available health-state utility studies were identified and reviewed. Also,
the current clinical diagnostic pathway, as well as the potential place for multiplex allergen testing, were
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examined, and a concept model structure was developed. Finally, a survey was performed to retrieve the
number of patients receiving each test, test costs were calculated and cost analyses were performed to
examine the short-term costs of the test strategies.
All four identified cost-effectiveness studies33,34,54–60 (all abstracts) showed an increased effectiveness when
using ImmunoCAP ISAC and three54–60 out of four studies also showed cost savings when using ImmunoCAP
ISAC. However, the methods and assumptions used in these assessments are largely unclear, severely
hampering the assessment of the validity of the results. In addition, the credibility of these assessments was
questioned as fundamental inputs of their models were based on expert opinion or inaccessible references,
or no references were provided. Therefore, these findings should be interpreted with extreme caution.
The evidence on utility values for allergic conditions in the UK population was limited. For food allergies no
utility values were found, whereas UK utility values were available for seasonal allergic rhinoconjunctivitis
and atopic eczema in children.
Test costs for ImmunoCAP ISAC and Microtest were estimated to be £219.51 and £156.85, respectively. For
SPT, single IgE and the food challenge test these were £62.29, £136.37 and £570.00, respectively. Detailed
cost analyses were performed to estimate the short-term cost of diagnostic pathways with and without
multiplex allergen testing. As the place of multiplex allergen testing in the diagnostic pathway and the
proportions of patients receiving a particular test are unclear, and the survey did not provide the required
results, different scenario and threshold analyses were performed. The results of these analyses depend on
precisely the effect of multiplex testing on the need for single IgE, SPT and OFC testing. For example, if
multiplex testing replaced single IgE testing (assuming eight tests per person) then a 15% or 4% reduction in
OFC would be required for ImmunoCAP ISAC and Microtest, respectively, to be cost-saving. However, if there
was no reduction in OFC testing, then the number of single IgE tests or SPTs per patient that needed replacing
would have to be at least 39% or 28% for ImmunoCAP ISAC and Microtest, respectively, to be cost-saving.
Strengths and limitations of assessment
Clinical effectiveness
Extensive literature searches were conducted in an attempt to maximise retrieval of relevant studies.
These included electronic searches of a variety of bibliographic databases, as well as screening of clinical
trials registers and conference abstracts to identify unpublished studies. Despite this, we were unable to
identify any studies that reported clinical outcomes and available data were generally very sparse.
The possibility of publication bias cannot be ruled out. Owing to the small number of included studies and
between-study clinical heterogeneity, we were unable to perform any meta-analyses or to undertake a
formal assessment of publication bias. However, our search strategy included a variety of routes to identify
unpublished studies and resulted in the inclusion of a number of conference abstracts.
Clear inclusion criteria were specified in the registered protocol for this review (PROSPERO registration no.
CRD42015019739). One change was made to the published protocol, expanding the inclusion criteria to
allow inclusion of studies that reported direct comparisons of diagnostic accuracy between single IgE testing
and multiplex allergen testing, using SPTs or allergen challenge tests as the reference standard, but did not
report details of any participants for whom multiplex allergen testing provided additional information
(details provided in Chapter 3; see Inclusion and exclusion criteria). These studies were included with the aim
of providing some indication of the performance of multiplex allergen testing, compared with current
single IgE antibody testing practice, for predicting clinical response; studies that reported only the accuracy
of multiplex allergen testing, without a comparison to current testing practice, were therefore not included.
In addition, we have provided specific reasons for exclusion for all of the studies that were considered
potentially relevant at initial citation screening and were subsequently excluded on assessment of the full
publication (see Appendix 3). The eligibility of studies for inclusion is therefore transparent.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
The review process followed recommended methods to minimise the potential for error and/or bias;21
studies were independently screened for inclusion by two reviewers, and data extraction and quality
assessment were done by one reviewer and checked by a second (MW and SL). Any disagreements were
resolved by consensus.
Studies included in this review were assessed for risk of bias, where possible using published validated
tools [the QUADAS-2 tool25 and CASP cohort risk-of-bias tool (www.casp-uk.net/)]. The review included a
number of observational studies, which used a ‘before-and-after’ type study design to assess the effects of
adding information from multiplex allergen testing to the standard diagnostic work-up in the same group
of participants. We are not aware of any published risk-of-bias tool that is appropriate for the assessment
of this type of study. A review-specific tool was therefore designed by the authors (MW, SL and NA) to
allow the methodological quality of these studies to be systematically assessed and described. This tool
focuses on elements of study design that we considered relevant to this specific study type, and is
based upon the structure of the QUADAS-2 tool. The results of the risk-of-bias assessment are reported,
in full, for all included studies in Appendix 4 and are summarised in Chapter 3 (see Study quality). Studies
were generally of unclear quality due to limitations in reporting, with full publications lacking for many
studies (reported as conference abstracts only). None of the studies included in this review can be
considered to have low risk of bias; all studies were rated as ‘high’ or ‘unclear’ risk of bias on at least one
domain of the relevant tool. The main ‘high’ risk-of-bias areas identified were participant selection
(inappropriate exclusions) and application of testing procedures (variation in testing procedures between
study participants and within-study optimisation of the diagnostic threshold).
An important potential advantage of ImmunoCAP ISAC and other multicomponent arrays is their ability to
differentiate between allergens that have similar structures; these homologous allergens maybe recognised
by the same antibody (cross-reactivity) or homologous allergens may cause the same allergic response
(cross-sensitisation). For example, a blood sample that shows immunoreactivity to Bet v1 may indicate that
a patient is sensitised to birch pollen or they may be sensitised to one of many protein homologues
(proteins of similar molecular structure to Bet v1), or they may be sensitised to both. Bet v1 is a PR10
protein that has several homologues or protein family members. On the ISAC 112 chip there are nine Bet
v1 homologues: rCor a1.0401 (hazelnut), rGly m4 (soybean), rAra h8 (peanut), rAct d8 (kiwi), rApi g1
(celery), rMal d1 (apple), rPru p1 (peach), rAln g1 (alder) and rCor a1.0101 (hazel). Therefore, ISAC 112
has the potential to discriminate between immunoreactivity to Bet v1 and nine homologues, a process that
would take much longer by single allergen (single IgE) testing. According to the ImmunoCAP ISAC 112
technical brochure91 there are seven other protein families represented on the chip; therefore, its potential
to provide information regarding cross-immunoreactivity of homologous proteins is apparent. However,
data showing the effects of providing additional information of this type were very limited. It is important
to note that ISAC multiplex testing on its own can differentiate between the immunoreactivity of a given
allergen and a homologue only if that homologue is present on the array chip. Several reports raised the
fact that not all useful components were present on the array.37,39,40 These reports were carried out on
earlier versions of ISAC and some of the suggested components now appear on ISAC 112. Further
research maybe needed to target specific conditions and interpretation of data should always bear in mind
what components are not on the array as well as what components are on the array.
Predominantly, the accuracy studies included in this review compared the performance of whole allergens
(single IgE) to the ability of allergen components (ImmunoCAP ISAC) to detect specific IgE. Although both
are aiming to identify the presence of specific antibodies in a patient serum sample, this is more likely to
occur if using the whole allergen than part of the allergen. Classically, the interaction between an antibody
and an antigen (allergen) occurs through very specific binding sites on both molecules. Therefore, the
selected allergen component(s) may or may not contain this binding site. Furthermore, multiple antibodies
may have been produced to one allergen each using different binding sites. The use of whole allergens is
likely to give very different results to using a component and this may explain some of the discrepancies
seen between the accuracy studies.
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Overall, only one of the diagnostic studies compared like with like. Only one study compared the ability of
the same component (rGLy m4) to detect specific antibodies using single IgE testing and ImmunoCAP
ISAC. Interestingly, the two methods reported different sensitivities and specificities, indicating that they
perform differently. This was not unexpected as the performance of the single IgE test will be maximised
to give the best result for the single allergen of interest, whereas ImmunoCAP ISAC is developed to give
the best results for a range of allergens. Therefore, the effect of non-specific binding within these two
systems on diagnostic accuracy is unknown.
Studies often included patients with a clinical history of an immediate reaction to an allergen, indicating
that these patients were likely to have had an IgE-mediated event, and excluded patients with delayed
reactions possibly caused by mechanisms other than IgE. This must be borne in mind when evaluating the
clinical performance of tests based on single IgE measurement, in that the research populations may be
unrepresentative of those for whom the test would be used in practice. Nevertheless, it is expected that
these tests will be used only on patients who are strongly suspected of an IgE-mediated reaction.
Finally, the studies included in this systematic review may have limited applicability to the specified
population of interest (people with complex or difficult to manage allergies who are being assessed in UK
secondary or tertiary health-care settings). Studies that did not specify that they included participants with
difficult to manage allergic disease, or described inclusion criteria that could be considered consistent
with this classification (e.g. polysensitised patients), were classified as having ‘high’ concerns regarding
applicability. Studies that were conducted in non-UK settings and which assessed allergens considered
unlikely to be relevant to UK populations (e.g. aeroallergens associated with Mediterranean countries)
were also classified as having ‘high’ concerns regarding applicability. Only two39,40 of the studies included
in the review were rated as having ‘low’ concerns with respect to both of these issues. None of the
comparative accuracy studies was conducted in populations likely to be representative of people
with difficult to manage allergic disease and two43,45 of these studies explicitly excluded people with
complex allergies.
The studies identified by our systematic review did not provide sufficient evidence to adequately assess the
clinical effectiveness of adding multiplex allergen testing to the investigation of people with difficult to
manage allergic disease, in secondary or tertiary UK health-care settings. However, we believe that our
comprehensive assessment of the limited available evidence has highlighted key areas in which data are
lacking and provides a useful framework to guide the development of research recommendations.
Cost-effectiveness
This is the first time that a model structure including diagnostic pathways has been attempted to examine
the place of multiplex testing in the UK. Our cost analysis is also the first to assess the short-term costs of
multiplex allergen testing in the UK. For this purpose a detailed cost analysis was performed, and multiple
scenario and threshold analyses were conducted. Extensive literature searches were conducted to provide
an overview of available cost-effectiveness analyses and available health-state utilities. Additional searching
in terms of reference checking and extensive hand searching was performed to maximise retrieval of
relevant studies (including conference abstracts). Clear inclusion criteria were specified for selecting
relevant studies. Relevant papers were summarised and the quality of cost-effectiveness analyses was
assessed. Authors were contacted to provide more details if needed.
The main limitations of this assessment are the lack of information of the place of multiplex testing in the
care pathway and any effectiveness evidence. There is therefore an inability to incorporate long-term
costs and consequences (i.e. life-years and QALYs), particularly long-term outcomes conditional on the
short-term test outcomes. As illustrated by previous assessments for the UK,80,82 it is possible to estimate
long-term outcomes for treatments of allergic conditions (not conditional on a test result). Nevertheless,
these assessments had severe limitations including that they required extensive assumptions (including
mapping of utility values).80
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Uncertainties
Clinical effectiveness
The potential role of multiplex allergen testing in the care pathway of patients with complex allergic
disease remains unclear. As described in the objectives for this assessment, multiplex allergen testing could
be added to existing standard diagnostic work-up or could be used to replace some or all of the single IgE
tests that would otherwise be used in some patients.
In order to adequately assess the effectiveness of multiplex allergen testing as an add-on test, studies
would be required that compare the management of patients based on standard diagnostic work-up to
management based on standard diagnostic work-up with the addition of multiplex allergen testing and
which provide information on subsequent clinical outcomes. Although it might be suggested that RCTs
represent the ‘gold standard’ for this comparison, other study designs may provide relevant information.
In particular, earlier stage, exploratory studies can be important in determining whether RCTs or other
large-scale comparative studies are justified and in informing the design of such studies. The seven
‘diagnostic before-and-after’ studies included in this assessment show participating clinicians changing
various aspects of their judgement about a given group of patients when they have access to the results of
ImmunoCAP ISAC testing. The findings of these studies indicate that multiplex allergen testing may
provide information, additional to that obtained from standard diagnostic work-up, which can affect
clinicians’ decision-making. However, the studies did not clearly report the extent to which the changes in
clinicians’ judgement resulted in implementation of changes to the care of patients. Further, if additional
information provided by multiplex allergen testing results in changes to the care of patients, it is important
to collect information on subsequent clinical outcomes and to compare these outcomes with those seen in
patients whose care has been based on standard diagnostic work-up. Such comparisons are necessary to
assess whether care decisions based on information that included the results of multiplex allergen testing
ultimately result in benefit or detriment to patients, or have no significant effect.
One study indicated that ImmunoCAP ISAC should be used before single IgE testing. This relates to the
ability of the microarray to analyse 56 allergens and provide data to help identify allergens that are
cross-sensitive or those that are cross-immunoreactive. This has been applied to complex food allergy,
for which ImmunoCAP ISAC can help determine to which food allergens a patient is sensitised; in
particular, it is able to determine which homologous allergens give rise to the sensitivity observed in a
single IgE test. When several food allergens are suspected ImmunoCAP ISAC testing can allow the clinician
to quickly determine and reduce the number of confirmatory oral challenges required. In the absence of
information on clinical outcomes, it may therefore be useful to obtain information on how the addition of
multiple allergen testing to the standard diagnostic work-up of people with difficult to manage allergic
disease affects the overall testing burden (e.g. the number of single IgE tests and/or confirmatory challenge
tests used) or other resource-use outcomes (e.g. the number of subsequent consultations with health-care
professionals). We did not identify any studies that reported resource-use outcomes.
This assessment also includes eight studies that report information on the accuracy of various components
and combinations of components on the ImmunoCAP ISAC chip compared with the accuracy of other
testing options (single IgE or SPT) to predict allergic response (as defined by SPT or OFC). Studies of this
type can determine whether multiplex allergen testing provides similar diagnostic information to that
provided by single IgE or other testing options, when used in the same group of patients; comparable
performance may be considered indicative of the potential of multiplex allergen testing to replace other
tests without significant adverse diagnostic consequences (missed diagnoses or false positives). However,
none of the comparative accuracy studies identified was conducted in populations with difficult to manage
allergic disease. Studies therefore evaluated the diagnostic performance of single components or small
groups of components on the ImmunoCAP ISAC chip that were relevant to the investigation of specific
allergies (e.g. Gal d1, Gal d2 and Gal d3 for hen’s egg allergy). The focused use of the ImmunoCAP ISAC
chip is likely to result in low numbers of false positives and high specificity estimates (i.e. sensitisations
detected are likely to be associated with observed allergic response). These studies have limited
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applicability to the investigation of people with difficult to manage allergic disease, for whom there is
greater diagnostic uncertainty and for whom it might be expected that all or a greater proportion of the
components of the microchip might be used. If multiplex allergen testing is applied in this way, it might be
expected that greater numbers of false positives would be generated (i.e. more sensitisations that are not
associated with observed allergic response would be identified). Some evidence of this can be seen from
the results of Heaps 2014,39 described in Chapter 3 (see Effects on management, treatment and diagnostic
classification of adding multiplex allergen testing to the diagnostic work-up of people with difficult to
manage allergic disease), which, as well as identifying sensitisations thought to be associated with
anaphylaxis in some patients, identified large numbers of sensitisations that were not considered to be
clinically relevant. In addition, two studies92,93 that did not meet the inclusion criteria of this systematic
review reported data comparing rates of sensitisation to various allergen groups relevant to plant-food
allergy in allergic and tolerant individuals. Both studies were conducted in Spain. The first study included
123 children with food allergy, of whom 55 were classified as peanut allergic and 68 as peanut tolerant
(SPT and single IgE) and used ImmunoCAP ISAC 103 to assess sensitisation to a range of allergenic
components.92 There were no significant differences between peanut-allergic and peanut-tolerant children
in the rates of sensitisation to pathogenesis-related protein family PR-10 allergens (Ara h8, Act d8, Cor a1,
Gly m4, Mal d1, Pru p1), profilins (Bet v2, Ole e2, Hev b8, Mer a1, Phl p12), some lipid transfer proteins
(LTPs) (Par j2, Pru p3), cross-reactive carbohydrate determinant Ana c2, or pollens (Ole e1, Phl p1).92
The second study included 130 children with plant-food allergy and LTP sensitisation and found that
sensitisation to a particular plant-food LTP, as determined by ImmunoCAP ISAC 112, was not always
associated with clinical symptoms of allergy to that plant food: 69% (40/58) and 63% (17/27) of
peach- and walnut-tolerant children were sensitised to Pru p3 and Jug r3, respectively; 60% (21/35) of
children without seed/nut allergy were sensitised to storage proteins.93 The potential of multiplex allergen
testing to detect clinically false-positive sensitisations has not yet been adequately investigated and the
long-term relevance of such sensitisations is unknown. However, the limited available data indicate a need
for care in the application and interpretation of multiplex allergen testing.
Finally, we did not identify any studies of multiplex allergen testing using Microtest that met the inclusion
criteria for this assessment. The manufacturer provided unpublished data on the concordance between test
methods (Microtest, ImmunoCAP single IgE, ImmunoCAP ISAC and SPT). These data are summarised in
Appendix 5, for information only.
Cost-effectiveness
The credibility of available cost-effectiveness studies in the literature can be questioned given the use of
expert opinion for fundamental model inputs. Moreover, (UK) health-state utility values for allergic
conditions are scarce (e.g. utilities for food allergy and for test AEs are lacking). However, the main source
of uncertainty regarding the cost-effectiveness of multiplex allergen testing compared with current clinical
practice for people with difficult to manage allergic disease was the lack of data on long-term clinical
consequences conditional on test results of a diagnostic pathway including multiplex allergen testing.
The place of multiplex allergen testing in the diagnostic pathway and the proportions of patients receiving a
particular test was unclear (for both the current diagnostic pathway and the diagnostic pathway including
multiplex allergen testing). Therefore, speculative two-way threshold analyses were performed in this
assessment to consider the diagnostic pathway costs only. These analyses required assumptions regarding
all key parameters relating to the pathway, including the proportions/numbers per patient of single IgE and
OFC tests and SPT. For example, it does seem likely that multiplex testing, by ruling out some allergens,
might avoid confirmatory testing with OFC or SPT. However, SPT is a simple, safe and quick test (providing
results within 15–20 minutes) and it is often the first-line investigation in allergy. In addition, one clinician
(e-mail from Paul Turner, personal communication), with experience with ImmunoCAP ISAC testing,
indicated that all patients would receive SPT when using ImmunoCAP ISAC. Hence, it might be that
multiplex allergen testing would not reduce the number of SPT. Finally, whether single IgE might be used as
an add-on to multiplex allergen testing or would be replaced by multiplex testing remains uncertain,
particularly given the limited experience with multiplex allergen testing in the UK.
DISCUSSION
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Chapter 6 Conclusions
Implications for service provision
No recommendations for service provision can be made based on the analyses included in this report.
The clinical effectiveness and cost-effectiveness of using multiplex allergen testing in the investigation of
people with difficult to manage allergic disease have yet to be adequately investigated. In particular, the
clinical consequences of changes to diagnosis or treatment and the frequency and relevance of clinically
false-positive sensitisations have been under investigated. From the limited evidence available it appears
that the most likely role of multiplex allergen testing would be to replace some or all single IgE testing.
The ability of multiplex testing to simultaneously identify multiple antibodies in the serum samples,
combined with its ability to identify which homologous allergens are cross-immunoreactive, means that
these tests have the potential to provide a lot of information in a single step. Although confirmatory
testing (SPT or OFC) is still likely to be required, multiplex testing could be used to tailor confirmatory
testing to the individual patient and thus reduce the overall testing burden; no studies were identified that
assessed overall testing burden. It should be noted that all of the evidence identified related to one test
(ImmunoCAP ISAC) and conclusions on the potential utility of multiplex allergen testing may not be
generalisible to other products.
Suggested research priorities
There remains considerable uncertainty about the possible role of multiplex allergen testing in
the investigation of people with difficult to manage allergic disease in the UK. The formulation of a
consensus-based protocol for the use of multiplex allergen testing may represent a useful starting point
for future research. A prospective study would then be needed to investigate the clinical effectiveness of
the proposed protocol. The preferred design would be a RCT comparing diagnostic pathways with and
without multiplex allergen testing. Alternatively, an observational study to compare outcomes in centres
using multiplex allergen testing to those using diagnostic pathways without multiplex allergen testing
may also be a useful approach. Such an approach would, however, require careful consideration of
between-centre differences in patient care pathways (other than the use of multiplex allergen testing).
Outcomes measured could include:
l Short-term outcomes:
¢ diagnostic performance, including discrimination between allergens responsible for allergic
reactions and those that are cross-immunoreactive, and false-positive rate (i.e. the number of
sensitisations identified that are not associated with allergic response) when the full panels of
multiplex allergen testing devices are used in people with difficult to manage allergic disease
¢ treatments or management decisions (including type and duration and the use and extent of
restriction diets)
¢ overall testing burden (i.e. the total number of tests, including multiplex allergen testing,
single IgE testing, SPTs and OFC tests, required to reach a diagnosis and formulate a
treatment/management plan)
¢ any AEs associated with testing.
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l Long-term outcomes:
¢ incidence and severity of allergic reactions
¢ mortality
¢ service use (e.g. repeat presentations with allergy symptoms requiring further investigation
and/or treatment).
If different possible methods of multiplex allergen testing are being considered, then direct head-to-head
comparisons would be needed.
CONCLUSIONS
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Appendix 1 Literature search strategies
Clinical effectiveness searches
EMBASE (via OvidSP): 1974–14 April 2015
Searched: 16 April 2015
1. allergy rapid test/ (334)
2. (ImmunoCAP or Immuno-CAP or Thermo Scientific).af. (2136)
3. ISAC.ti,ab,ot. (497)
4. (Immuno$ adj3 solid$ adj3 phase$ adj3 allerg$ adj3 chip$).af. (49)
5. (compon$ adj3 resolv$ adj3 diagnos$).af. (545)
6. (multi adj3 compon$ adj3 assay$).af. (14)
7. 23$ allerg$.ti,ab,ot,hw. (52)
8. 26$ allerg$.ti,ab,ot,hw. (52)
9. 103$ allerg$.ti,ab,ot,hw. (35)
10. 112$ allerg$.ti,ab,ot,hw. (21)
11. (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test
DX”).af. (807)
12. or/1-11 (3743)
13. exp microarray analysis/ or (microarray$ or micro array$ or nanoarray$).ti,ab,ot,hw. (138,557)
14. (multiplex adj3 (test$ or assay$)).ti,ab,ot,hw. (5972)
15. or/13-14 (144,221)
16. exp hypersensitivity/ or (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$).ti,ab,ot,hw. (572,729)
17. 15 and 16 (2744)
18. 12 or 17 (6131)
19. limit 18 to yr=“2005-Current” (5244)
MEDLINE (via OvidSP): 1946–week 2 April 2015
Searched: 16 April 2015
1. (ImmunoCAP or Immuno-CAP or Thermo Scientific).af. (465)
2. ISAC.ti,ab,ot. (116)
3. (Immuno$ adj3 solid$ adj3 phase$ adj3 allerg$ adj3 chip$).af. (9)
4. (compon$ adj3 resolv$ adj3 diagnos$).af. (223)
5. (multi adj3 compon$ adj3 assay$).af. (11)
6. 23$ allerg$.ti,ab,ot,hw. (33)
7. 26$ allerg$.ti,ab,ot,hw. (34)
8. 103$ allerg$.ti,ab,ot,hw. (9)
9. 112$ allerg$.ti,ab,ot,hw. (5)
10. (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test
DX”).af. (520)
11. or/1-10 (1327)
12. exp Microarray Analysis/ or (microarray$ or micro array$ or nanoarray$).ti,ab,ot,hw. (103,970)
13. (multiplex adj3 (test$ or assay$)).ti,ab,ot,hw. (3489)
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14. or/12-13 (107,253)
15. exp Hypersensitivity/ or (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$).ti,ab,ot,hw. (373,147)
16. 14 and 15 (1420)
17. 11 or 16 (2648)
18. limit 17 to yr=“2005-Current” (1955)
MEDLINE In-Process Citations (via OvidSP): up to 15 April 2015; MEDLINE
Daily Update (via OvidSP): up to 15 April 2015
Searched: 16 April 2015
1. (ImmunoCAP or Immuno-CAP or Thermo Scientific).af. (97)
2. ISAC.ti,ab,ot. (37)
3. (Immuno$ adj3 solid$ adj3 phase$ adj3 allerg$ adj3 chip$).af. (4)
4. (compon$ adj3 resolv$ adj3 diagnos$).af. (31)
5. (multi adj3 compon$ adj3 assay$).af. (0)
6. 23$ allerg$.ti,ab,ot,hw. (2)
7. 26$ allerg$.ti,ab,ot,hw. (2)
8. 103$ allerg$.ti,ab,ot,hw. (2)
9. 112$ allerg$.ti,ab,ot,hw. (1)
10. (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test
DX”).af. (22)
11. or/1-10 (173)
12. exp Microarray Analysis/ or (microarray$ or micro array$ or nanoarray$).ti,ab,ot,hw. (7177)
13. (multiplex adj3 (test$ or assay$)).ti,ab,ot,hw. (423)
14. or/12-13 (7590)
15. exp Hypersensitivity/ or (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$).ti,ab,ot,hw. (11,416)
16. 14 and 15 (80)
17. 11 or 16 (237)
NLM PubMed (internet): up to 22 April 2015
Searched: 22 April 2015
#6 Search (#4 and #5) (375)
#5 Search ((pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb])) (1,919,020)
#4 Search (#1 or #2 or #3) (2631)
#3 Search ((Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test
DX”)) (528)
#2 Search ISAC (373)
#1 Search (ImmunoCAP or Immuno-CAP or Thermo Scientific) (1776)
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CDSR (via Wiley): 2015/April/Iss4; DARE (via Wiley): 2015/January/Iss1;
CENTRAL (via Wiley): 2015/March/Iss3; HTA database (via Wiley):
2015/January/Iss1
Searched: 16 April 2015
#1 (ImmunoCAP or Immuno-CAP or Thermo Scientific) (48)
#2 ISAC (20)
#3 (Immuno* near/3 solid* adj3 phase* near/3 allerg* near/3 chip*) (0)
#4 (compon* near/3 resolv* near/3 diagnos*) (5)
#5 (multi near/3 compon* near/3 assay*) (0)
#6 23* near/1 allerg* (46)
#7 26* near/1 allerg* (7)
#8 103* near/1 allerg* (2)
#9 112* near/1 allerg* (1)
#10 (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test DX”) (56)
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 (175)
#12 MeSH descriptor: [Microarray Analysis] explode all trees (275)
#13 (microarray* or micro array* or nanoarray*) (575)
#14 (multiplex near/3 (test* or assay*)) (65)
#15 #12 or #13 or #14 (747)
#16 MeSH descriptor: [Hypersensitivity] explode all trees (15,709)
#17 (allerg* or anaphyla* or hypersensiti* or hyper-sensiti* or poly-sensiti* or polysensiti* or
paucisensiti*) (25,363)
#18 #16 or #17 (32,535)
#19 #15 and #18 (39)
#20 #11 or #19 (210)
#21 #20 Publication Year from 2005 to 2015 (147)
l CDSR search retrieved 41 records
l DARE search retrieved 0 records*
l Central search retrieved 104 records
l HTA search retrieved 0 records.
*Please note: Records ceased to be added to the DARE resource on 31 March 2015; this search was for
archival material only.
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Science Citation Index Expanded (Web of Knowledge) 1970–21 April 2015;
CPCI-S (via Web of Knowledge) 1990–21 April 2015
Searched: 23 April 2015
Indexes=SCI-EXPANDED, CPCI-S Timespan=2005–2015
#13 (2626) #12 OR #7
#12 (1312) #11 AND #10
#11 (108,808) TS=(allerg* or anaphyla* or hypersensiti* or hyper-sensiti* or poly-sensiti* or polysensiti*
or paucisensiti*)
#10 (105,467) #9 OR #8
#9 (5844) TS=(multiplex NEAR/3 (test* or assay*))
#8 (100,025) TS=(microarray* or micro array* or nanoarray*)
#7 (1450) #6 OR #5 OR #4 OR #3 OR #2 OR #1
#6 (149) TS=(Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro
Test DX”)
#5 (11) TS=(multi NEAR/3 compon* NEAR/3 assay*)
#4 (368) TS=(compon* NEAR/3 resolv* NEAR/3 diagnos*)
#3 (16) TS=(Immuno* NEAR/3 solid* NEAR/3 phase* NEAR/3 allerg* NEAR/3 chip*)
#2 (454) TS=(ISAC)
#1 (581) TS=(ImmunoCAP or Immuno-CAP or “Thermo Scientific”)
BIOSIS Previews (via Web of Knowledge): 1956–21 April 2015
Searched: 23 April 2015
Indexes=BIOSIS Previews Timespan=2005–2015
#7 (1282) #6 OR #5 OR #4 OR #3 OR #2 OR #1
#6 (81) TS=(Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro
Test DX”)
#5 (9) TS=(multi NEAR/3 compon* NEAR/3 assay*)
#4 (202) TS=(compon* NEAR/3 resolv* NEAR/3 diagnos*)
#3 (22) TS=(Immuno* NEAR/3 solid* NEAR/3 phase* NEAR/3 allerg* NEAR/3 chip*)
#2 (230) TS=(ISAC)
#1 (914) TS=(ImmunoCAP or Immuno-CAP or “Thermo Scientific”)
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LILACS: 1982–22 April 2015
http://regional.bvsalud.org/php/index.php?lang=en
Searched: 22 April 2015
Terms Records
ImmunoCAP or “Immuno-CAP” or “Thermo Scientific” or ISAC or Allerwatch or ComforTen or “MultiTest” or
“true test” or “Microtest DX” or “Micro Test DX”
156
Total 156
NIHR HTA programme (internet): up to 23 April 2015
www.hta.ac.uk/
Searched: 23 April 2015
Browsed with the following terms.
Terms Records
ImmunoCAP 0
Immuno-CAP 0
Thermo Scientific 0
ISAC 0
Allerwatch 0
ComforTen 0
MultiTest 0
True test 0
Microtest DX 0
Micro Test DX 0
Total 0
FDA (internet): up to 23 April 2015
www.fda.gov/
Searched: 23 April 2015
Searched Medical Devices.
Search terms Records
ImmunoCAP OR Immuno-CAP OR Thermo Scientific 15
ISAC 13
Allerwatch OR ComforTen OR MultiTest OR true test OR Microtest DX OR Micro Test DX 16
Total 44
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OpenGrey: up to 22 April 2015
www.opengrey.eu
Searched: 22 April 2015
Search terms Records
ImmunoCAP OR “Immuno-CAP” OR “Thermo Scientific” 3
ISAC 8
Allerwatch OR ComforTen OR “MultiTest” OR “true test” OR “Microtest DX” OR “Micro Test DX” 4
Total 15
ClinicalTrials.gov (internet): up to 22 April 2015
http://clinicaltrials.gov/ct2/search/advanced
Searched: 22 April 2015
Advanced search option – search terms box.
Search terms Records
ImmunoCAP OR Immuno-CAP OR Thermo Scientific 27
ISAC 5
Allerwatch OR ComforTen OR “MultiTest” OR “true test” OR “Microtest DX” OR “Micro Test DX” 8
Total 40
ISRCTN Registry (internet): up to 22 April 2015
www.isrctn.com/
Searched: 22 April 2015
Advanced search – Text Search.
Search terms Records
ImmunoCAP OR “Immuno-CAP” OR “Thermo Scientific” 2
ISAC 1
Allerwatch OR ComforTen OR “MultiTest” OR “true test” OR “Microtest DX” OR “Micro Test DX” 1
Total 4
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WHO ICTRP (internet): up to 22 April 2015
www.who.int/ictrp/en/
Searched: 22 April 2015
Advanced search option.
Title Intervention Records
ImmunoCAP OR Immuno-CAP OR Thermo
Scientific
OR ImmunoCAP OR Immuno-CAP OR Thermo
Scientific
1
ISAC OR ISAC 0
Allerwatch OR ComforTen OR MultiTest OR
true test OR Microtest DX OR Micro Test DX
OR Allerwatch OR ComforTen OR MultiTest OR
true test OR Microtest DX OR Micro Test DX
13
Total 14
Conference searches
AAAAI Annual Meeting
Searched: 19 May 2015
Searched for last 5 years.
Used “search within this issue” option and exported results for articles only:
2015: www.jacionline.org/issue/S0091-6749%2814%29X0003-5
2014: www.jacionline.org/issue/S0091-6749%2813%29X0015-6
2013: www.jacionline.org/issue/S0091-6749%2813%29X0013-2
2012: www.jacionline.org/issue/S0091-6749%2812%29X0002-2
2011: www.jacionline.org/issue/S0091-6749%2811%29X0002-7
Search terms 2011 2012 2013 2014 2015
ImmunoCAP ISAC 8 2 8 7 4
Immuno-CAP ISAC 5 6 9 6 3
Microtest DX 0 0 0 0 0
Micro Test DX 0 0 0 0 0
Total 13 8 17 13 7
Total before deduplication 58
Total after deduplication 52
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EAACI
Searched: 19 May 2015
2015: www.professionalabstracts.com/eaaci2015/programme-eaaci2015.pdf
2014: www.sessionplan.com/eaaci2014/
2013: http://onlinelibrary.wiley.com/doi/10.1111/all.2013.68.issue-s97/issuetoc
2012: http://onlinelibrary.wiley.com/doi/10.1111/all.2012.67.issue-s96/issuetoc
2011: http://onlinelibrary.wiley.com/doi/10.1111/all.2011.66.issue-s94/issuetoc
Search terms 2011 2012 2013 Search terms 2014 2015 (June 2015)
ImmunoCAP 78 38 104 ImmunoCAP ISAC 18 NA
Immuno-CAP 6 7 8 Immuno-CAP ISAC 0
Microtest 0 0 Microtest 1
Micro Test 0 0 Micro Test 0
Total 84 45 112 19 NA
Total 260
NA, not applicable.
BSACI
Searched: 19 May 2015
2015: NA – conference had not yet taken place at time of searching
2014: http://onlinelibrary.wiley.com/doi/10.1111/cea.12456/epdf
2013: http://onlinelibrary.wiley.com/doi/10.1111/cea.12197/epdf
2012: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2222.2012.012033.x/epdf
2011: http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2222.2011.03897.x/abstract
Please note: Unable to access 2011 online without payment.
Search terms 2011 2012 2013 2014 2015
ImmunoCAP NA 2 4 7 NA
Immuno-CAP 1 0 0
Microtest 0 0 0
Micro Test 0 0 0
Total 3 4 7
Total 14
NA, not applicable.
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FAAM
Searched: 19 May 2015
Searched for last 5 years.
Used ‘Control F’ to search within saved PDFs.
2015: NA – conference not yet taken place at time of search
2014: www.ctajournal.com/supplements/5/S3
2013: www.ctajournal.com/supplements/3/S3
2012: NA – No record on website of having run in that year
2011: www.ctajournal.com/supplements/1/S1
Search terms 2011 2012 2013 2014 2015
ImmunoCAP ISAC 3 NA 5 3 NA
Immuno-CAP ISAC 0 0 0
Microtest DX 0 0 0
Micro Test DX 0 0 0
Total 3 5 3
Total before deduplication 11
NA, not applicable.
ISMA
Searched: 20 May 2015
Searched for last 5 years.
Used ‘Control F’ to search within saved PDFs.
2015: Sixth conference had not yet taken place at time of search
2014: NA
2013: www.ctajournal.com/supplements/4/S2/all (5th conference)
2012: NA
2011: NA (Fourth conference 2010)
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Search terms 2011 2012 2013 2014 2015
ImmunoCAP ISAC NA NA 5 NA Not yet run
Immuno-CAP ISAC 0
Microtest DX 0
Micro Test DX 0
Total 5
Total 5
NA, not applicable.
AAD Meeting
Searched: 26 May 2015
Searched for last 5 years.
2015: http://onlinedigitalpublishing.com/publication/?m=20143&l=1
2014: http://onlinedigitalpublishing.com/publication/?i=199001
2013: http://onlinedigitalpublishing.com/publication/?i=146375
2012: https://s3.amazonaws.com/aad-meetings/AM12_Program.pdf
2011: www.nxtbook.com/nxtbooks/aad/annualmeeting2011/#/0
Search terms 2011 2012 2013 2014 2015
ImmunoCAP 0 0 0 0 0
Immuno-CAP 0 0 0 0 0
Microtest DX 0 0 0 0 0
Micro Test DX 0 0 0 0 0
Total 0 0 0 0 0
Total before deduplication 0
BAD
Searched: 26 May 2015
Searched for last 5 years.
Used “Search within this issue”.
2015: Conference had not yet taken place at time of search
2014: http://onlinelibrary.wiley.com/doi/10.1111/bjd.2014.171.issue-s1/issuetoc
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2013: http://onlinelibrary.wiley.com/doi/10.1111/bjd.2013.169.issue-s1/issuetoc
2012: http://onlinelibrary.wiley.com/doi/10.1111/bjd.2012.167.issue-s1/issuetoc
2011: http://onlinelibrary.wiley.com/doi/10.1111/bjd.2011.165.issue-s1/issuetoc
Search terms 2011 2012 2013 2014 2015
ImmunoCAP 0 0 0 0
Immuno-CAP 0 0 0 0
Microtest DX 0 0 0 0
Micro Test DX 0 0 0 0
Total 0 0 0 0
Total before deduplication 0
Cost-effectiveness
EMBASE (via OvidSP): 1974–20 May 2015
Searched: 21 May 2015
1. allergy rapid test/ (381)
2. (ImmunoCAP or Immuno-CAP or Thermo Scientific or phadia).af. (2718)
3. ISAC.ti,ab,ot. (517)
4. (Immuno$ adj3 solid$ adj3 phase$ adj3 allerg$ adj3 chip$).af. (50)
5. (compon$ adj3 resolv$ adj3 diagnos$).af. (567)
6. (multi adj3 compon$ adj3 assay$).af. (14)
7. 23$ allerg$.ti,ab,ot,hw. (52)
8. 26$ allerg$.ti,ab,ot,hw. (53)
9. 103$ allerg$.ti,ab,ot,hw. (35)
10. 112$ allerg$.ti,ab,ot,hw. (22)
11. (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test
DX”).af. (810)
12. or/1-11 (4290)
13. exp microarray analysis/ or (microarray$ or micro array$ or nanoarray$).ti,ab,ot,hw. (140,563)
14. (multiplex adj3 (test$ or assay$)).ti,ab,ot,hw. (6050)
15. or/13-14 (146,303)
16. exp hypersensitivity/ or (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$).ti,ab,ot,hw. (578,447)
17. 15 and 16 (2794)
18. 12 or 17 (6704)
19. health-economics/ (34,457)
20. exp economic-evaluation/ (226,212)
21. exp health-care-cost/ (217,693)
22. exp pharmacoeconomics/ (173,447)
23. or/19-22 (506,020)
24. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (670,947)
25. (expenditure$ not energy).ti,ab. (26,222)
26. (value adj2 money).ti,ab. (1530)
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27. budget$.ti,ab. (26,297)
28. or/24-27 (696,870)
29. 23 or 28 (978,855)
30. letter.pt. (887,374)
31. editorial.pt. (477,247)
32. note.pt. (599,443)
33. or/30-32 (1964064)
34. 29 not 33 (886,862)
35. (metabolic adj cost).ti,ab. (989)
36. ((energy or oxygen) adj cost).ti,ab. (3348)
37. ((energy or oxygen) adj expenditure).ti,ab. (22,162)
38. or/35-37 (25,637)
39. 34 not 38 (881,415)
40. 18 and 39 (197)
Economics terms based on Costs filter
Centre for Reviews and Dissemination. Search strategies: NHS EED EMBASE using OvidSP (economics filter)
(internet). York: CRD; 2014 (accessed 2 June 2014).
Available from www.crd.york.ac.uk/crdweb/searchstrategies.asp#nhseedembase
MEDLINE (via OvidSP): 1946–week 3 May 2015
Searched: 21 May 2015
1. (ImmunoCAP or Immuno-CAP or Thermo Scientific).af. (471)
2. ISAC.ti,ab,ot. (116)
3. (Immuno$ adj3 solid$ adj3 phase$ adj3 allerg$ adj3 chip$).af. (9)
4. (compon$ adj3 resolv$ adj3 diagnos$).af. (225)
5. (multi adj3 compon$ adj3 assay$).af. (11)
6. 23$ allerg$.ti,ab,ot,hw. (33)
7. 26$ allerg$.ti,ab,ot,hw. (34)
8. 103$ allerg$.ti,ab,ot,hw. (9)
9. 112$ allerg$.ti,ab,ot,hw. (5)
10. (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test
DX”).af. (520)
11. or/1-10 (1335)
12. exp Microarray Analysis/ or (microarray$ or micro array$ or nanoarray$).ti,ab,ot,hw. (105,216)
13. (multiplex adj3 (test$ or assay$)).ti,ab,ot,hw. (3540)
14. or/12-13 (108,548)
15. exp Hypersensitivity/ or (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$).ti,ab,ot,hw. (375,235)
16. 14 and 15 (1439)
17. 11 or 16 (2675)
18. economics/ (26,620)
19. exp “costs and cost analysis”/ (187,805)
20. economics, dental/ (1859)
21. exp “economics, hospital”/ (20,266)
22. economics, medical/ (8615)
23. economics, nursing/ (3914)
24. economics, pharmaceutical/ (2572)
25. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (445,087)
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26. (expenditure$ not energy).ti,ab. (18,132)
27. (value adj1 money).ti,ab. (24)
28. budget$.ti,ab. (17,825)
29. or/18-28 (571,847)
30. ((energy or oxygen) adj cost).ti,ab. (2735)
31. (metabolic adj cost).ti,ab. (818)
32. ((energy or oxygen) adj expenditure).ti,ab. (16,789)
33. or/30-32 (19,615)
34. 29 not 33 (567,494)
35. letter.pt. (847,644)
36. editorial.pt. (356,900)
37. historical article.pt. (316,205)
38. or/35-37 (1,505,328)
39. 34 not 38 (538,417)
40. 17 and 39 (67)
Costs filter
Centre for Reviews and Dissemination. NHS EED Economics Filter: MEDLINE (via Ovid) monthly search
(internet). York: CRD; 2010 (cited 28 September 2010).
Available from: www.york.ac.uk/inst/crd/intertasc/nhs_eed_strategies.html
MEDLINE In-Process & Other Non-Indexed Citations (via OvidSP): up to
20 May 2015; MEDLINE Daily Update (via OvidSP): up to 20 May 2015
Searched: 21 May 2015
1. (ImmunoCAP or Immuno-CAP or Thermo Scientific).af. (95)
2. ISAC.ti,ab,ot. (39)
3. (Immuno$ adj3 solid$ adj3 phase$ adj3 allerg$ adj3 chip$).af. (4)
4. (compon$ adj3 resolv$ adj3 diagnos$).af. (33)
5. (multi adj3 compon$ adj3 assay$).af. (0)
6. 23$ allerg$.ti,ab,ot,hw. (2)
7. 26$ allerg$.ti,ab,ot,hw. (2)
8. 103$ allerg$.ti,ab,ot,hw. (2)
9. 112$ allerg$.ti,ab,ot,hw. (1)
10. (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test
DX”).af. (24)
11. or/1-10 (176)
12. exp Microarray Analysis/ or (microarray$ or micro array$ or nanoarray$).ti,ab,ot,hw. (7501)
13. (multiplex adj3 (test$ or assay$)).ti,ab,ot,hw. (453)
14. or/12-13 (7944)
15. exp Hypersensitivity/ or (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$).ti,ab,ot,hw. (11,612)
16. 14 and 15 (89)
17. 11 or 16 (248)
18. economics/ (0)
19. exp “costs and cost analysis”/ (128)
20. economics, dental/ (0)
21. exp “economics, hospital”/ (8)
22. economics, medical/ (1)
23. economics, nursing/ (1)
24. economics, pharmaceutical/ (0)
DOI: 10.3310/hta20670 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 67
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101
25. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (60,839)
26. (expenditure$ not energy).ti,ab. (1828)
27. (value adj1 money).ti,ab. (3)
28. budget$.ti,ab. (2518)
29. or/18-28 (63,427)
30. ((energy or oxygen) adj cost).ti,ab. (312)
31. (metabolic adj cost).ti,ab. (101)
32. ((energy or oxygen) adj expenditure).ti,ab. (1452)
33. or/30-32 (1820)
34. 29 not 33 (62,936)
35. letter.pt. (32,097)
36. editorial.pt. (21,356)
37. historical article.pt. (131)
38. or/35-37 (53,569)
39. 34 not 38 (62,298)
40. 17 and 39 (8)
Costs filter
Centre for Reviews and Dissemination. NHS EED Economics Filter: MEDLINE (via Ovid) monthly search
(internet). York: CRD; 2010 (cited 28 September 2010).
Available from www.york.ac.uk/inst/crd/intertasc/nhs_eed_strategies.html
NHS EED (via Wiley): 2015/April/Iss2
Searched: 21 May 2015
#1 (ImmunoCAP or Immuno-CAP or Thermo Scientific) (48)
#2 ISAC (20)
#3 (Immuno* near/3 solid* adj3 phase* near/3 allerg* near/3 chip*) (0)
#4 (compon* near/3 resolv* near/3 diagnos*) (5)
#5 (multi near/3 compon* near/3 assay*) (0)
#6 23* near/1 allerg* (46)
#7 26* near/1 allerg* (7)
#8 103* near/1 allerg* (2)
#9 112* near/1 allerg* (1)
#10 (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test DX”) (56)
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 (175)
#12 MeSH descriptor: [Microarray Analysis] explode all trees 280)
#13 (microarray* or micro array* or nanoarray*) (586)
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#14 (multiplex near/3 (test* or assay*)) (66)
#15 #12 or #13 or #14 (761)
#16 MeSH descriptor: [Hypersensitivity] explode all trees (15,764)
#17 (allerg* or anaphyla* or hypersensiti* or hyper-sensiti* or poly-sensiti* or polysensiti* or
paucisensiti*) (25,504)
#18 #16 or #17 (32,705)
#19 #15 and #18 (39)
#20 #11 or #19 (210)
NHS EED search retrieved 1 record.
*Please note: records ceased to be added to the NHS EED resource on 31 March 2015; this search was for
archival material only.
EconLit (via EBSCOhost): 1886–21 May 2015
Searched: 21 May 2015
S13 S7 OR S12 (18)
S12 S10 AND S11 (0)
S11 TX(allerg* or anaphyla* or hypersensiti* or hyper-sensiti* or poly-sensiti* or polysensiti* or
paucisensiti*) (49)
S10 S8 OR S9 (103)
S9 TX(multiplex N3 (test* or assay*)) (1)
S8 TX(microarray* or micro array* or nanoarray*) (102)
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6 (18)
S6 TX (Allerwatch or ComforTen or “MultiTest” or “true test” or “Microtest DX” or “Micro Test DX”) (13)
S5 TX (multi N3 compon* N3 assay*) (0)
S4 TX (compon* N3 resolv* N3 diagnos*) (0)
S3 TX (Immuno* N3 solid* N3 phase* N3 allerg* N3 chip*) (0)
S2 TX (ISAC) (5)
S1 TX (ImmunoCAP or Immuno-CAP or “Thermo Scientific”) (0)
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Research Papers in Economics (RePEc) (internet): up to 26 May 2015
http://repec.org/
Searched: 26 May 2015
IDEAS search interface
#1 (ImmunoCAP | Immuno-CAP | “Thermo Scientific”) (Results 1)
#2 (Allerwatch | ComforTen | “MultiTest” | “true test” | “Microtest DX” | “Micro Test DX”) (Results 17)
RePEc search retrieved 18 records.
Health-related quality of life/utilities searches
EMBASE (via OvidSP): 1974–29 June 2015
Searched: 30 June 2015
1. (food$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$
or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (27,518)
2. ((Cereal$ or wheat or rye or barley or oat or oats or rice or maize or spelt or buckwheat or soybean
or millet or sorghum or corn or Kamut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (2562)
3. ((Gluten or (glutenin adj3 gliadin) or prolamins) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1408)
4. ((Dairy or milk or yog?urt$ or cream or butter$ or cheese$ or ice cream$ or kefir) adj4 (allerg$ or
sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or
pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (6786)
5. ((Casein or whey or lactose) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (4128)
6. (Egg$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$
or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (2858)
7. ((Peanut$ or arachid or Arachis hypog?ea or groundnut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (3239)
8. ((ground or earth or monkey) adj3 nut$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$
or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$
or paucisensiti$)).ti,ab,ot,hw. (1)
9. (arachis oil adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse
reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,
hw. (0)
10. ((Nut or nuts or hazelnut$ or cashew$ or walnut$ or pecan$ or almond$ or Macadamia$ or pistachio$
or chestnut$ or coconut$ or Candlenut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (1338)
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11. ((Brazil or pine or hickory or betel) adj3 nut$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-
sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or
polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (91)
12. ((Crustacea$ or Mollusc$ or mollusk$ or shellfish or seafood or sea food or Lobster or crab$ or shrimp$
or prawn$ or squid$ or oyster$ or crayfish or cuttlefish or abalone or limpet$ or mussel$ or scallop$
or clam or clams or whelk$ or scampi or octopus or langoustine$ or cockle$ or winkles or krill) adj4
(allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or
anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1046)
13. ((Fish or finfish or sole or mackerel$ or hake or whiting or dab or plaice or Anchov$ or Catfish or Eel$
or Haddock or Halibut or Sardine$ or Scad or Snapper or Tilapia or Trout or shark or swordfish or cod
or tuna or herring$ or flounder or mullet or salmon or kipper$ or caviar or seer or mackerel or tilefish or
Pollock or whitebait or flatfish or john dory or carp) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1799)
14. (Fish adj3 roe adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse
reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,
hw. (7)
15. ((Surimi or sashimi or sushi or cerviche or gravlax) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (2)
16. ((Snail$ or frog$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or
adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).
ti,ab,ot,hw. (221)
17. ((Sulfites or sulphites) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or
adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).
ti,ab,ot,hw. (55)
18. (((sulphiting adj2 agents) or (sulphur adj2 dioxide)) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (13)
19. ((Lentil$ or chickpea$ or pea or peas or garbanzo or bengal gram or chana or channa or leblebi) adj4
(allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or
anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (132)
20. ((poppy or sunflower or cotton or flax) adj3 seed$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (59)
21. ((fruit or fruits or vegetable$ or legume$ or kiwi or melon or banana$ or Carrot$ or apple$ or tomato$
or Apricot$ or pepper$ or Cabbage$ or Celery or Celeriac or Cherry or cherries or Courgette$ or
zucchini or Aubergine$ or Dates or Fig or figs or plum or plums or garlic$ or grape$ or Lettuce$ or
Lychee$ or Mango$ or Peach$ or Pear or pears or Pineapple$ or Pomegranate or Potato$ or Pumpkin$
or Strawberry or strawberries or Turnip$ or Avocado$ or Persimmon) adj4 (allerg$ or sensitivit$ or
hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$
or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (2435)
22. ((Acerola or Aniseed or Camomile or Castor bean$ or Cocoa or linseed or Lupin$ or Lupine or Sesame
or soy$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse
reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,
hw. (1227)
23. ((Condiment$ or spice$ or Mustard$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$, or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (230)
24. or/1-23 (42,706)
25. exp food allergy/ (24,867)
26. exp food allergen/ (4698)
27. or/25-26 (26,399)
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28. 24 or 27 (42,706)
29. exp Food/ (721,540)
30. food additive/ (8744)
31. crab meat/ or crab/ or crayfish/ or lobster/ or shrimp/ or mollusc/ or fish/ or fish meat/ (111,052)
32. or/29-31 (822,648)
33. exp allergen/ (54,384)
34. exp hypersensitivity/ (498,826)
35. anaphylaxis/ (34,246)
36. anaphylactic shock/ (4751)
37. (allerg$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or
pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$).ti,ab,ot,hw. (479,818)
38. or/33-37 (649,918)
39. 32 and 38 (35,162)
40. 28 or 39 (58,974)
41. pollen allergy/ or hay fever/ (14,584)
42. ((Pollen or seasonal) adj3 (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (13,145)
43. (hayfever or hay fever or pollinosis or pollinoses).ti,ab,ot,hw. (11,916)
44. or/41-43 (21,333)
45. rhinitis/ or rhiniti$.ti,ab,ot,hw. (47,359)
46. (season$ or spring or summer or pollen$ or grass$ or birch or ragweed or tree$ or weed$ or mugwort
or willow or alder).ti,ab,ot,hw. (397,576)
47. 45 and 46 (9392)
48. 44 or 47 (24,956)
49. 40 or 48 (79,964)
50. quality adjusted life year/ or quality of life index/ (16,036)
51. Short Form 12/ or Short Form 20/ or Short Form 36/ or Short Form 8/ (16,212)
52. “International Classification of Functioning, Disability and Health”/ or “ferrans and powers quality of
life index”/ or “gastrointestinal quality of life index”/ (1859)
53. (sf36 or sf 36 or sf-36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform
thirtysix or shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,
ab,ot. (26,380)
54. (sf6 or sf 6 or sf-6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,
ab,ot. (1612)
55. (sf12 or sf 12 or sf-12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or
short form twelve).ti,ab,ot. (5102)
56. (sf6D or sf 6D or sf-6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or
short form six D).ti,ab,ot. (855)
57. (sf20 or sf 20 or sf-20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty
or short form twenty).ti,ab,ot. (352)
58. (sf8 or sf 8 or sf-8 or short form 8 or shortform 8 or sf eight or sfeight or shortform eight or short
form eight).ti,ab,ot. (492)
59. “health related quality of life”.ti,ab,ot. (34,378)
60. (Quality adjusted life or Quality-adjusted-life).ti,ab,ot. (10,293)
61. “assessment of quality of life”.ti,ab,ot. (1910)
62. (euroqol or euro qol or eq5d or eq 5d).ti,ab,ot. (8735)
63. (hql or hrql or hqol or h qol or hrqol or hr qol).ti,ab,ot. (17,838)
64. (hye or hyes).ti,ab,ot. (98)
65. health$ year$ equivalent$.ti,ab,ot. (39)
66. (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3).ti,ab,ot. (2295)
67. (quality time or qwb or “quality of well being” or “quality of wellbeing” or “index of wellbeing” or
index of well being).ti,ab,ot,hw. (837)
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68. (Disability adjusted life or Disability-adjusted life or health adjusted life or health-adjusted life or “years
of healthy life” or healthy years equivalent or “years of potential life lost” or “years of health life
lost”).ti,ab,ot. (2463)
69. (QALY$ or DALY$ or HALY$ or YHL or HYES or YPLL or YHLL or qald$ or qale$ or qtime$ or AQoL$).
ti,ab,ot. (13,192)
70. (timetradeoff or time tradeoff or time trade-off or time trade off or TTO or Standard gamble$ or
“willingness to pay”).ti,ab,ot. (6245)
71. 15d.ti,ab,ot. (1802)
72. (HSUV$ or health state$ value$ or health state$ preference$ or HSPV$).ti,ab,ot. (340)
73. (utilit$ adj3 (“quality of life” or valu$ or scor$ or measur$ or health or life or estimat$ or elicit$ or
disease$)).ti,ab,ot. (11,429)
74. (utilities or disutili$).ti,ab,ot. (7194)
75. or/50-74 (108,471)
76. letter.pt. (896,144)
77. editorial.pt. (482,372)
78. note.pt. (606,238)
79. or/76-78 (1,984,754)
80. 75 not 79 (105,171)
81. 49 and 80 (433)
Health-related quality of life free-text terms based on:
l Figure 4 Common free-text terms for electronic database searching for HSUVs in Papaioannou D,
Brazier JE, Paisley S. NICE DSU Technical Support Document 9: the identification, review and synthesis
of health-state utility values from the literature (internet), 2011 (accessed 18 August 2011). Available
from: www.nicedsu.org.uk.
MEDLINE (via OvidSP): 1946–week 3 June 2015
Searched: 30 June 2015
1. (food$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$
or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (16,959)
2. ((Cereal$ or wheat or rye or barley or oat or oats or rice or maize or spelt or buckwheat or soybean or
millet or sorghum or corn or Kamut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$
or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$
or paucisensiti$)).ti,ab,ot,hw. (1605)
3. ((Gluten or (glutenin adj3 gliadin) or prolamins) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (876)
4. ((Dairy or milk or yog?urt$ or cream or butter$ or cheese$ or ice cream$ or kefir) adj4 (allerg$ or
sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$
or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (3865)
5. ((Casein or whey or lactose) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (3292)
6. (Egg$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$
or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1416)
7. ((Peanut$ or arachid or Arachis hypog?ea or groundnut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1419)
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8. ((ground or earth or monkey) adj3 nut$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$
or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$
or paucisensiti$)).ti,ab,ot,hw. (0)
9. (arachis oil adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$
or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (0)
10. ((Nut or nuts or hazelnut$ or cashew$ or walnut$ or pecan$ or almond$ or Macadamia$ or pistachio$
or chestnut$ or coconut$ or Candlenut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (643)
11. ((Brazil or pine or hickory or betel) adj3 nut$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (63)
12. ((Crustacea$ or Mollusc$ or mollusk$ or shellfish or seafood or sea food or Lobster or crab$ or shrimp$
or prawn$ or squid$ or oyster$ or crayfish or cuttlefish or abalone or limpet$ or mussel$ or scallop$
or clam or clams or whelk$ or scampi or octopus or langoustine$ or cockle$ or winkles or krill) adj4
(allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or
anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (636)
13. ((Fish or finfish or sole or mackerel$ or hake or whiting or dab or plaice or Anchov$ or Catfish or Eel$
or Haddock or Halibut or Sardine$ or Scad or Snapper or Tilapia or Trout or shark or swordfish or cod
or tuna or herring$ or flounder or mullet or salmon or kipper$ or caviar or seer or mackerel or tilefish or
Pollock or whitebait or flatfish or john dory or carp) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1154)
14. (Fish adj3 roe adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse
reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (2)
15. ((Surimi or sashimi or sushi or cerviche or gravlax) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (2)
16. ((Snail$ or frog$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or
adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).
ti,ab,ot,hw. (173)
17. ((Sulfites or sulphites) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or
adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).
ti,ab,ot,hw. (36)
18. (((sulphiting adj2 agents) or (sulphur adj2 dioxide)) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (3)
19. ((Lentil$ or chickpea$ or pea or peas or garbanzo or bengal gram or chana or channa or leblebi) adj4
(allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or
anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (84)
20. ((poppy or sunflower or cotton or flax) adj3 seed$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (27)
21. ((fruit or fruits or vegetable$ or legume$ or kiwi or melon or banana$ or Carrot$ or apple$ or tomato$
or Apricot$ or pepper$ or Cabbage$ or Celery or Celeriac or Cherry or cherries or Courgette$ or
zucchini or Aubergine$ or Dates or Fig or figs or plum or plums or garlic$ or grape$ or Lettuce$ or
Lychee$ or Mango$ or Peach$ or Pear or pears or Pineapple$ or Pomegranate or Potato$ or Pumpkin$
or Strawberry or strawberries or Turnip$ or Avocado$ or Persimmon) adj4 (allerg$ or sensitivit$ or
hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$
or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1449)
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22. ((Acerola or Aniseed or Camomile or Castor bean$ or Cocoa or linseed or Lupin$ or Lupine or Sesame
or soy$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse
reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,
hw. (743)
23. ((Condiment$ or spice$ or Mustard$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$, or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (166)
24. or/1-23 (27,183)
25. exp Food Hypersensitivity/ (15,608)
26. exp Food/ (1,100,276)
27. exp Food Additives/ (239,057)
28. or/26-27 (1,101,303)
29. allergens/ or exp Hypersensitivity/ (288,187)
30. (allerg$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or
pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$).ti,ab,ot,hw. (324,188)
31. or/29-30 (442,055)
32. 28 and 31 (28,934)
33. 24 or 25 or 32 (45,050)
34. Rhinitis, Allergic, Seasonal/ (12,580)
35. ((Pollen or seasonal) adj3 (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (15,942)
36. (hayfever or hay fever or pollinosis or pollinoses).ti,ab,ot,hw. (3989)
37. (rhiniti$ adj3 (season$ or spring or summer or pollen$ or grass$ or birch or ragweed or tree$ or weed$
or mugwort or willow or alder)).ti,ab,ot,hw. (12,979)
38. or/34-37 (17,192)
39. 33 or 38 (60,503)
40. quality-adjusted life years/ or quality of life/ (133,433)
41. (sf36 or sf 36 or sf-36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform
thirtysix or shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,
ab,ot. (16,140)
42. (sf6 or sf 6 or sf-6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,
ab,ot. (1038)
43. (sf12 or sf 12 or sf-12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or
short form twelve).ti,ab,ot. (2869)
44. (sf6D or sf 6D or sf-6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or
short form six D).ti,ab,ot. (460)
45. (sf20 or sf 20 or sf-20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty
or short form twenty).ti,ab,ot. (336)
46. (sf8 or sf 8 or sf-8 or short form 8 or shortform 8 or sf eight or sfeight or shortform eight or short
form eight).ti,ab,ot. (265)
47. “health related quality of life”.ti,ab,ot. (22,368)
48. (Quality adjusted life or Quality-adjusted-life).ti,ab,ot. (6465)
49. “assessment of quality of life”.ti,ab,ot. (1174)
50. (euroqol or euro qol or eq5d or eq 5d).ti,ab,ot. (4266)
51. (hql or hrql or hqol or h qol or hrqol or hr qol).ti,ab,ot. (10,537)
52. (hye or hyes).ti,ab,ot. (54)
53. health$ year$ equivalent$.ti,ab,ot. (38)
54. (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3).ti,ab,ot. (901)
55. (quality time or qwb or quality of well being or “quality of wellbeing” or “index of wellbeing” or
“index of well being”).ti,ab,ot,hw. (617)
56. (Disability adjusted life or Disability-adjusted life or health adjusted life or health-adjusted life or “years
of healthy life” or healthy years equivalent or “years of potential life lost” or “years of health life
lost”).ti,ab,ot. (1788)
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57. (QALY$ or DALY$ or HALY$ or YHL or HYES or YPLL or YHLL or qald$ or qale$ or qtime$ or AQoL$).
ti,ab,ot. (7212)
58. (timetradeoff or time tradeoff or time trade-off or time trade off or TTO or Standard gamble$ or
“willingness to pay”).ti,ab,ot. (3886)
59. 15d.ti,ab,ot. (1173)
60. (HSUV$ or health state$ value$ or health state$ preference$ or HSPV$).ti,ab,ot. (238)
61. (utilit$ adj3 (“quality of life” or valu$ or scor$ or measur$ or health or life or estimat$ or elicit$ or
disease$)).ti,ab,ot. (6934)
62. (utilities or disutili$).ti,ab,ot. (4124)
63. or/40-62 (158,071)
64. letter.pt. (854,881)
65. editorial.pt. (359,484)
66. historical article.pt. (317,628)
67. or/64-66 (1,516,490)
68. 63 not 67 (150,867)
69. 39 and 68 (739)
Health-related quality of life free-text terms based on:
l Figure 4 Common free-text terms for electronic database searching for HSUVs in Papaioannou D,
Brazier JE, Paisley S. NICE DSU Technical Support Document 9: the identification, review and synthesis
of health state utility values from the literature (internet), 2011 (accessed 18 August 2011). Available
from: www.nicedsu.org.uk.
MEDLINE In-Process & Other Non-Indexed Citations (via OvidSP): up to
29 June 2015; MEDLINE Daily Update (via OvidSP): up to 29 June 2015
Searched: 30 June 2015
1. (food$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$
or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1007)
2. ((Cereal$ or wheat or rye or barley or oat or oats or rice or maize or spelt or buckwheat or soybean
or millet or sorghum or corn or Kamut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (204)
3. ((Gluten or (glutenin adj3 gliadin) or prolamins) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-
sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or
polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (115)
4. ((Dairy or milk or yog?urt$ or cream or butter$ or cheese$ or ice cream$ or kefir) adj4 (allerg$ or
sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or
pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (229)
5. ((Casein or whey or lactose) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (76)
6. (Egg$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or
anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (126)
7. ((Peanut$ or arachid or Arachis hypog?ea or groundnut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (155)
8. ((ground or earth or monkey) adj3 nut$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$
or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$
or paucisensiti$)).ti,ab,ot,hw. (0)
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9. (arachis oil adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse
reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,
hw. (0)
10. ((Nut or nuts or hazelnut$ or cashew$ or walnut$ or pecan$ or almond$ or Macadamia$ or pistachio$
or chestnut$ or coconut$ or Candlenut) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (51)
11. ((Brazil or pine or hickory or betel) adj3 nut$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (5)
12. ((Crustacea$ or Mollusc$ or mollusk$ or shellfish or seafood or sea food or Lobster or crab$ or shrimp$
or prawn$ or squid$ or oyster$ or crayfish or cuttlefish or abalone or limpet$ or mussel$ or scallop$
or clam or clams or whelk$ or scampi or octopus or langoustine$ or cockle$ or winkles or krill) adj4
(allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or
anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (44)
13. ((Fish or finfish or sole or mackerel$ or hake or whiting or dab or plaice or Anchov$ or Catfish or Eel$
or Haddock or Halibut or Sardine$ or Scad or Snapper or Tilapia or Trout or shark or swordfish or cod
or tuna or herring$ or flounder or mullet or salmon or kipper$ or caviar or seer or mackerel or tilefish or
Pollock or whitebait or flatfish or john dory or carp) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (83)
14. (Fish adj3 roe adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse
reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,
hw. (1)
15. ((Surimi or sashimi or sushi or cerviche or gravlax) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1)
16. ((Snail$ or frog$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or
adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).
ti,ab,ot,hw. (4)
17. ((Sulfites or sulphites) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or
adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).
ti,ab,ot,hw. (0)
18. (((sulphiting adj2 agents) or (sulphur adj2 dioxide)) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (1)
19. ((Lentil$ or chickpea$ or pea or peas or garbanzo or bengal gram or chana or channa or leblebi)
adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or
anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (9)
20. ((poppy or sunflower or cotton or flax) adj3 seed$ adj4 (allerg$ or sensitivit$ or hypersensitiv$ or
hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$
or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (3)
21. ((fruit or fruits or vegetable$ or legume$ or kiwi or melon or banana$ or Carrot$ or apple$ or tomato$
or Apricot$ or pepper$ or Cabbage$ or Celery or Celeriac or Cherry or cherries or Courgette$ or
zucchini or Aubergine$ or Dates or Fig or figs or plum or plums or garlic$ or grape$ or Lettuce$ or
Lychee$ or Mango$ or Peach$ or Pear or pears or Pineapple$ or Pomegranate or Potato$ or Pumpkin$
or Strawberry or strawberries or Turnip$ or Avocado$ or Persimmon) adj4 (allerg$ or sensitivit$ or
hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$
or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (130)
22. ((Acerola or Aniseed or Camomile or Castor bean$ or Cocoa or linseed or Lupin$ or Lupine or Sesame
or soy$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse
reaction$ or anaphyla$ or pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$)).ti,ab,ot,
hw. (65)
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23. ((Condiment$ or spice$ or Mustard$) adj4 (allerg$ or sensitivit$ or hypersensitiv$ or hyper-sensiti$ or
intolerance$ or adverse reaction$ or anaphyla$ or pseudoanaphyla$, or poly-sensiti$ or polysensiti$ or
paucisensiti$)).ti,ab,ot,hw. (8)
24. or/1-23 (1826)
25. exp Food Hypersensitivity/ (16)
26. exp Food/ (1220)
27. exp Food Additives/ (177)
28. or/26-27 (1220)
29. allergens/ or exp Hypersensitivity/ (201)
30. (allerg$ or hypersensitiv$ or hyper-sensiti$ or intolerance$ or adverse reaction$ or anaphyla$ or
pseudoanaphyla$ or poly-sensiti$ or polysensiti$ or paucisensiti$).ti,ab,ot,hw. (15,177)
31. or/29-30 (15,275)
32. 28 and 31 (28)
33. 24 or 25 or 32 (1845)
34. Rhinitis, Allergic, Seasonal/ (1)
35. ((Pollen or seasonal) adj3 (allerg$ or anaphyla$ or hypersensiti$ or hyper-sensiti$ or poly-sensiti$ or
polysensiti$ or paucisensiti$)).ti,ab,ot,hw. (324)
36. (hayfever or hay fever or pollinosis or pollinoses).ti,ab,ot,hw. (194)
37. (rhiniti$ adj3 (season$ or spring or summer or pollen$ or grass$ or birch or ragweed or tree$ or weed$
or mugwort or willow or alder)).ti,ab,ot,hw. (97)
38. or/34-37 (502)
39. 33 or 38 (2301)
40. quality-adjusted life years/ or quality of life/ (282)
41. (sf36 or sf 36 or sf-36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform
thirtysix or shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,
ab,ot. (1709)
42. (sf6 or sf 6 or sf-6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,
ab,ot. (448)
43. (sf12 or sf 12 or sf-12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or
short form twelve).ti,ab,ot. (418)
44. (sf6D or sf 6D or sf-6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or
short form six D).ti,ab,ot. (50)
45. (sf20 or sf 20 or sf-20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty
or short form twenty).ti,ab,ot. (14)
46. (sf8 or sf 8 or sf-8 or short form 8 or shortform 8 or sf eight or sfeight or shortform eight or short
form eight).ti,ab,ot. (39)
47. “health related quality of life”.ti,ab,ot. (3142)
48. (Quality adjusted life or Quality-adjusted-life).ti,ab,ot. (927)
49. “assessment of quality of life”.ti,ab,ot. (121)
50. (euroqol or euro qol or eq5d or eq 5d).ti,ab,ot. (723)
51. (hql or hrql or hqol or h qol or hrqol or hr qol).ti,ab,ot. (1442)
52. (hye or hyes).ti,ab,ot. (2)
53. health$ year$ equivalent$.ti,ab,ot. (1)
54. (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3).ti,ab,ot. (109)
55. (quality time or qwb or quality of well being or “quality of wellbeing” or “index of wellbeing” or
“index of well being”).ti,ab,ot,hw. (48)
56. (Disability adjusted life or Disability-adjusted life or health adjusted life or health-adjusted life or “years
of healthy life” or healthy years equivalent or “years of potential life lost” or “years of health life
lost”).ti,ab,ot. (331)
57. (QALY$ or DALY$ or HALY$ or YHL or HYES or YPLL or YHLL or qald$ or qale$ or qtime$ or AQoL$).
ti,ab,ot. (1076)
58. (timetradeoff or time tradeoff or time trade-off or time trade off or TTO or Standard gamble$ or
“willingness to pay”).ti,ab,ot. (541)
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59. 15d.ti,ab,ot. (116)
60. (HSUV$ or health state$ value$ or health state$ preference$ or HSPV$).ti,ab,ot. (21)
61. (utilit$ adj3 (“quality of life” or valu$ or scor$ or measur$ or health or life or estimat$ or elicit$ or
disease$)).ti,ab,ot. (832)
62. (utilities or disutili$).ti,ab,ot. (552)
63. or/40-62 (8337)
64. letter.pt. (30,812)
65. editorial.pt. (22,136)
66. historical article.pt. (227)
67. or/64-66 (53,144)
68. 63 not 67 (8298)
69. 39 and 68 (20)
Health-related quality of life free-text terms based on:
l Figure 4 Common free-text terms for electronic database searching for HSUVs in Papaioannou D,
Brazier JE, Paisley S. NICE DSU Technical Support Document 9: the identification, review and synthesis
of health state utility values from the literature (internet), 2011 (accessed 18 August 2011). Available
from: www.nicedsu.org.uk.
NHS EED (via Wiley): 2015/April/Iss2
Searched: 1 July 2015
#1 food* near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance* or “adverse
reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or paucisensiti*) (1044)
#2 (Cereal* or wheat or rye or barley or oat or oats or rice or maize or spelt or buckwheat or soybean or
millet or sorghum or corn or Kamut) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*”
or intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti*
or paucisensiti*) (103)
#3 (Gluten or glutenin or prolamins) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or
intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or
paucisensiti*) (24)
#4 (Dairy or milk or yog*urt* or cream or butter* or cheese* or ice cream* or kefir) near/4 (allerg* or
sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance* or “adverse reaction*” or anaphyla* or
pseudoanaphyla* or “poly-sensiti*” or polysensiti* or paucisensiti*) (532)
#5 (Casein or whey or lactose) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or
intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or
paucisensiti*) (278)
#6 Egg* near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance* or “adverse
reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or paucisensiti*) (266)
#7 (Peanut* or arachid or “Arachis hypog*ea” or groundnut) near/4 (allerg* or sensitivit* or hypersensitiv*
or “hyper-sensiti*” or intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or
“poly-sensiti*” or polysensiti* or paucisensiti*) (150)
#8 “arachis oil” near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance*
or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or
paucisensiti*) (1)
DOI: 10.3310/hta20670 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 67
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
113
#9 (Nut or nuts or hazelnut* or cashew* or walnut* or pecan* or almond* or Macadamia* or pistachio*
or chestnut* or coconut* or Candlenut) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or
intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or
paucisensiti*) (55)
#10 (Crustacea* or Mollusc* or mollusk* or shellfish or seafood or “sea food” or Lobster or crab* or
shrimp* or prawn* or squid* or oyster* or crayfish or cuttlefish or abalone or limpet* or mussel* or
scallop* or clam or clams or whelk* or scampi or octopus or langoustine* or cockle* or winkles or krill)
near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance* or “adverse reaction*”
or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or paucisensiti*) (22)
#11 (Fish or finfish or sole or mackerel* or hake or whiting or dab or plaice or Anchov* or Catfish or Eel*
or Haddock or Halibut or Sardine* or Scad or Snapper or Tilapia or Trout or shark or swordfish or cod or
tuna or herring* or flounder or mullet or salmon or kipper* or caviar or seer or mackerel or tilefish or
Pollock or whitebait or flatfish or “john dory” or carp) near/4 (allerg* or sensitivit* or hypersensitiv*
or “hyper-sensiti*” or intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or
“poly-sensiti*” or polysensiti* or paucisensiti*) (89)
#12 roe near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance* or “adverse
reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or paucisensiti*) (1)
#13 (Surimi or sashimi or sushi or cerviche or gravlax) near/4 (allerg* or sensitivit* or hypersensitiv* or
“hyper-sensiti*” or intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or
“poly-sensiti*” or polysensiti* or paucisensiti*) (0)
#14 (Snail* or frog*) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance*
or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or
paucisensiti*) (0)
#15 (Sulfites or sulphites) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance*
or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or
paucisensiti*) (6)
#16 (sulphating or sulphur) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or
intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti*
or paucisensiti*) (5)
#17 (Lentil* or chickpea* or pea or peas or garbanzo or “bengal gram” or chana or channa or leblebi)
near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance* or “adverse reaction*”
or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or paucisensiti*) (8)
#18 (poppy or sunflower or cotton or flax) near/3 seed* near/4 (allerg* or sensitivit* or hypersensitiv*
or “hyper-sensiti*” or intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or
“poly-sensiti*” or polysensiti* or paucisensiti*) (0)
#19 (fruit or fruits or vegetable* or legume* or kiwi or melon or banana* or Carrot* or apple* or tomato*
or Apricot* or pepper* or Cabbage* or Celery or Celeriac or Cherry or cherries or Courgette* or zucchini
or Aubergine* or Dates or Fig or figs or plum or plums or garlic* or grape* or Lettuce* or Lychee* or
Mango* or Peach* or Pear or pears or Pineapple* or Pomegranate or Potato* or Pumpkin* or Strawberry
or strawberries or Turnip* or Avocado* or Persimmon) near/4 (allerg* or sensitivit* or hypersensitiv*
or “hyper-sensiti*” or intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla* or
“poly-sensiti*” or polysensiti* or paucisensiti*) (101)
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#20 (Acerola or Aniseed or Camomile or “Castor bean*” or Cocoa or linseed or Lupin* or Lupine or
Sesame or soy*) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*” or intolerance*
or “adverse reaction*” or anaphyla* or pseudoanaphyla* or “poly-sensiti*” or polysensiti* or
paucisensiti*) (83)
#21 (Condiment* or spice* or Mustard*) near/4 (allerg* or sensitivit* or hypersensitiv* or “hyper-sensiti*”
or intolerance* or “adverse reaction*” or anaphyla* or pseudoanaphyla*, or “poly-sensiti*” or
polysensiti* or paucisensiti*) (8)
#22 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or
#16 or #17 or #18 or #19 or #20 or #21 (2007)
#23 MeSH descriptor: [Food Hypersensitivity] explode all trees (618)
#24 MeSH descriptor: [Food] explode all trees (22,580)
#25 MeSH descriptor: [Food Additives] explode all trees (545)
#26 #24 or #25 (22,598)
#27 MeSH descriptor: [Allergens] explode all trees (1554)
#28 MeSH descriptor: [Hypersensitivity] explode all trees (15,778)
#29 allerg* or hypersensitiv* or “hyper-sensiti*” or intolerance* or “adverse reaction*” or anaphyla* or
pseudoanaphyla* or “poly-sensiti*” or polysensiti* or paucisensiti* (36,164)
#30 #27 or #28 or #29 (43,237)
#31 #26 and #30 (1384)
#32 #22 or #23 or #31 (2743)
#33 MeSH descriptor: [Rhinitis, Allergic, Seasonal] explode all trees 1611)
#34 (Pollen or seasonal) near/3 (allerg* or anaphyla* or hypersensiti* or “hyper-sensiti*” or “poly-sensiti*”
or polysensiti* or paucisensiti*) (3657)
#35 hayfever or “hay fever” or pollinosis or pollinoses (951)
#36 rhiniti* near/3 (season* or spring or summer or pollen* or grass* or birch or ragweed or tree* or
weed* or mugwort or willow or alder) (2962)
#37 #33 or #34 or #35 or #36 (4095)
#38 #32 or #37 (6656)
#39 MeSH descriptor: [Quality-Adjusted Life Years] this term only (3930)
#40 MeSH descriptor: [Quality of Life] this term only (15,292)
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#41 sf36 or sf 36 or “sf-36” or “short form 36” or “shortform 36” or “sf thirtysix” or “sf thirty six” or
“shortform thirtysix” or “shortform thirty six” or “short form thirty six” or “short form thirtysix” or “short
form thirty six” (6646)
#42 sf6 or “sf 6” or sf-6 or “short form 6” or “shortform 6” or “sf six” or sfsix or “shortform six” or
“short form six” (137)
#43 sf12 or “sf 12” or “sf-12” or “short form 12” or “shortform 12” or “sf twelve” or sftwelve or
“shortform twelve” or “short form twelve” (975)
#44 sf6D or “sf 6D” or “sf-6D” or “short form 6D” or “shortform 6D” or “sf six D” or sfsixD or
“shortform six D” or “short form six D” (186)
#45 sf20 or “sf 20” or “sf-20” or “short form 20” or “shortform 20” or “sf twenty” or sftwenty or
“shortform twenty” or “short form twenty” (74)
#46 sf8 or “sf 8” or “sf-8” or “short form 8” or “shortform 8” or “sf eight” or sfeight or “shortform
eight” or “short form eight” (58)
#47 “health related quality of life” (6922)
#48 “Quality adjusted life” or “Quality-adjusted-life” (6557)
#49 “assessment of quality of life” (318)
#50 euroqol or “euro qol” or eq5d or “eq 5d” (2744)
#51 hql or hrql or hqol or “h qol” or hrqol or “hr qol” (2599)
#52 hye or hyes (53)
#53 “health* year* equivalent*” (5)
#54 hui or hui1 or hui2 or hui3 or hui4 or “hui-4” or “hui-1” or “hui-2” or “hui-3” (1262)
#55 “quality time” or qwb or “quality of well being” or “quality of wellbeing” or “index of wellbeing” or
“index of well being” (231)
#56 “Disability adjusted life” or “Disability-adjusted life” or “health adjusted life” or “health-adjusted life”
or “years of healthy life” or “healthy years equivalent” or “years of potential life lost” or “years of health
life lost” (350)
#57 QALY* or DALY* or HALY* or YHL or HYES or YPLL or YHLL or qald* or qale* or qtime* or
AQoL* (5218)
#58 timetradeoff or “time tradeoff” or “time trade-off” or “time trade off” or TTO or “Standard
gamble*” or “willingness to pay” (1916)
#59 15d (107)
#60 HSUV* or “health state* value*” or “health state* preference*” or HSPV* (83)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
#61 utilit* near/3 (“quality of life” or valu* or scor* or measur* or health or life or estimat* or elicit* or
disease*) (4632)
#62 utilities or disutili* (1656)
#63 #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or
#53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 (33,724)
#64 #38 and #63 (393)
NHS EED search retrieved 34 records.*
*Please note: Records ceased to be added to the NHS EED resource on 31 March 2015, this search was for
archival material only.
CEA Registry (internet): up to 1 July 2015
https://research.tufts-nemc.org/cear4/SearchingtheCEARegistry/SearchtheCEARegistry.aspx
Searched: 1 July 2015
Basic search for ‘articles’.
Search term Hits
Allergy 16
Allergies 0
Allergens 0
Allergic 20
Intolerance 6
Intolerances 0
Hypersensitivity 4
Hypersensitivities 0
Hyper-sensitivity 0
Hyper-sensitivities 0
Anaphylaxis 4
Anaphylactic 1
Pollen 5
Rhinitis 9
Hay fever 0
Hayfever 0
pollinosis 0
pollinoses 0
Total 65 (including duplicates)
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PROQOLID (internet): up to 1 July 2015
www.proqolid.org/
Searched: 1 July 2015
Basic search
Search term Hits
Allergy 0
Allergies 0
Allergens 0
Allergic 0
Intolerance 0
Intolerances 0
Hypersensitivity 0
Hypersensitivities 0
Hyper-sensitivity 0
Hyper-sensitivities 0
Anaphylaxis 0
Anaphylactic 0
Pollen 0
Rhinitis 9
Hay fever 0
Hayfever 0
pollinosis 0
pollinoses 0
Total 9
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Appendix 2 Data extraction tables
A Baseline details (studies of change to management,
treatment or diagnostic classification)
Study details Selection criteria Participant details (allergic)
Participant details
(healthy controls)
Gay-Crosier 201036
Country: NR
Funding: NR
Study design: Observational
before-and-after study
Recruitment: Participants
undergoing subcutaneous
immunotherapy. No further
details reported
No. of participants: 9
Inclusion criteria:
Participants undergoing
subcutaneous
immunotherapy
Exclusion criteria: None
reported
n: 9
Mean age, years (SD): NR
Male (%): NR
Median duration of allergy, years
(range): NR
n with oral allergy syndrome (%): NR
n with gastrointestinal symptoms
(%): NR
n with respiratory symptoms (%): NR
n with urticaria (%): NR
n with atopic eczema (%): NR
n with anaphylaxis (%): NR
NA
Heaps 2014,39 201035
Country: UK
Funding: Reagents and
consumables provided by
Thermo Fisher Scientific
Study design: Prospective,
observational before-and-after
study
Recruitment: Participants
recruited from five specialist
allergy centres. No further
details reported
No. of participants: 110
Inclusion criteria: Adult
patients diagnosed with
idiopathic anaphylaxis
Exclusion criteria: None
reported
n: 110
Mean age, years (range): 42 (20–76)
Male (%): 37 (33.6)
Median duration of allergy, years
(range): NR
n with oral allergy syndrome (%): NR
n with gastrointestinal symptoms
(%): NR
n with respiratory symptoms (%): NR
n with urticaria (%): NR
n with atopic eczema (%): NR
n with anaphylaxis (%): 110 (100)
NA
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Study details Selection criteria Participant details (allergic)
Participant details
(healthy controls)
Hermansson 201433,34
Country: Finland
Funding: NR
Study design: Prospective,
observational
Recruitment: Database of
2317 primary school children
used to identify 199 children
who were on restrictive diets,
of whom 85 agreed to
participate in the study and
were still classified as allergic
following nurse interview
No. of participants: 85
Inclusion criteria:
Children who were on
a restrictive diet in
school catering
Exclusion criteria:
Coeliac disease
n: 85
Mean age, years (range): NR
Male (%): NR
Median duration of allergy, years
(range): NR
n with oral allergy syndrome (%): NR
n with gastrointestinal symptoms
(%): NR
n with respiratory symptoms (%): NR
n with urticaria (%): NR
n with atopic eczema (%): NR
n with anaphylaxis (%): NR
NA
Luengo 201037
Country: Spain,
‘Mediterranean population’
Funding: NR
Study design: observational
before-and-after study
Recruitment: No details
reported
No. of participants: 55
Inclusion criteria:
Well characterised,
multisensitised, allergic
patients
Exclusion criteria: None
reported
n: 55
Mean age, years (range): NR
Male (%): NR
Median duration of allergy, years
(range): NR
n with oral allergy syndrome (%): NR
n with gastrointestinal symptoms
(%): NR
n with respiratory symptoms (%): NR
n with urticaria (%): NR
n with atopic eczema (%): NR
n with anaphylaxis (%): NR
NA
Noimark 201240
Country: UK
Funding: NR
Study design: Case series,
abstract only, no details
reported
Recruitment: Selected
participants from a specialist
allergy centre. No further
details reported
No. of participants: 12
Inclusion criteria:
Children with moderate
to severe eczema and
multiple food allergies
Exclusion criteria: None
reported
n: 12
Mean age, years (range): NR
Male (%): NR
Median duration of allergy, years
(range): NR
n with oral allergy syndrome (%): NR
n with gastrointestinal symptoms
(%): NR
n with respiratory symptoms (%): NR
n with urticaria (%): NR
n with atopic eczema (%): 12 (100)
n with anaphylaxis (%): NR
NA
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Study details Selection criteria Participant details (allergic)
Participant details
(healthy controls)
Passalacqua 201338
Country: Italy
Funding: Phadia AB/Thermo
Fisher Scientific
Study design: Prospective,
observational before-and-after
study
Recruitment: Participants
recruited from six allergy
centres. No further details
reported
No. of participants: 409
(318 allergy patients and
91 healthy controls)
Inclusion criteria:
Patients referred for
respiratory allergic
diseases who had at
least two positive SPTs.
Controls had negative
SPTs
Exclusion criteria: None
reported
n: 318
Mean age, years (range): 37 (12–78)
Male (%): 148 (46.5)
Median duration of allergy, years
(range): NR
n with oral allergy syndrome (%):
51 (16)
n with gastrointestinal symptoms
(%): 14 (4.4)
n with respiratory symptoms (%):
318 (100)
n with urticaria (%): 36 (11.3)
n with atopic eczema (%): 4 (1.3)
n with anaphylaxis (%): 6 (1.9)
n: 91
Mean age, years
(range): 40 (15–83)
Male (%): 19 (20.9)
Median duration of
allergy, years (range):
NA
n with oral allergy
syndrome (%): 0 (0)
n with
gastrointestinal
symptoms (%): 0 (0)
n with respiratory
symptoms (%): 0 (0)
n with urticaria (%):
0 (0)
n with atopic eczema
(%): 0 (0)
n with anaphylaxis
(%): 0 (0)
Sastre 201230–32,59
Country: Spain
Funding: CIBER de
Enfermedades Respiratorias
and Instituto de Salud Carlos
III of the Ministry of Science
and Information, Spain
Study design: Observational
before-and-after study
Recruitment: Participants
attending an outpatient
allergy clinic. No further
details reported
No. of participants: 141
Inclusion criteria:
Patients with allergic
rhinoconjunctivitis
and/or asthma who
were sensitised to
pollen, with or without
concomitant food
allergy
Exclusion criteria: None
reported
n: 141
Mean age, years (SD): 31 (13.6)
Male (%): 58 (41)
Median duration of allergy, years
(range): NR
n with oral allergy syndrome (%): NR
n with gastrointestinal symptoms
(%): NR
n with respiratory symptoms (%):
141 (100)
n with urticaria (%): NR
n with atopic eczema (%): NR
n with anaphylaxis (%): NR
NA
NA, not applicable; NR, not reported; SD, standard deviation.
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B Baseline accuracy study details (diagnostic case–control)
Study details Selection criteria Participant details (allergic)
Participant details
(tolerant)
Alessandri 201142
Country: Italy
Funding: Italian Ministry
of Health, Programma
Ricerca Corrente
2008–2010
Recruitment: January
2008 to September 2010
No. of participants: 68
Inclusion criteria: Children
referred for suspected
hen’s egg allergy (based
on history of reactions
after ingestion and
positive SPT or IgE to
hen’s egg white extracts).
All patients were
following a hen’s egg
elimination diet
Exclusion criteria: Steroid
treatment
Recruitment site: Centre
for Molecular Allergology,
IDI-IRCCS, Rome, Italy
n: 19
Median age, years (range):
4.3 (NR)
Male (%): 15 (79)
Median duration of allergy,
years (range): NR
n with atopic eczema (%): NR
n with oral allergy syndrome
(%): 3 (16)a
n with asthma (%): 7 (37)a
n with anaphylaxis (%): 1 (5)
n with gastritis/vomiting (%):
11(58)
n with skin symptom (%): NR
n with respiratory symptoms
(%): NR
n:
l 14 (tolerant to boiled,
not raw)
l 35 (tolerant to raw and
boiled)
Median age, years (range):
l 3.17 (NR) (tolerant to
boiled, not raw)
l 4.42 (NR) (tolerant to raw
and boiled)
Male (%):
l 9 (64) (tolerant to boiled,
not raw)
l 23 (66) (tolerant to raw
and boiled)
Median duration of allergy,
years (range): NR
n with oral allergy syndrome
(%):
l 3 (21) (tolerant to boiled,
not raw)a
l 0 (0) (tolerant to raw and
boiled)a
n with asthma (%):
l 3 (21) (tolerant to boiled,
not raw)a
l 0 (0) (tolerant to raw and
boiled)a
n with anaphylaxis (%):
l 0 (0) (tolerant to boiled,
not raw)a
l 0 (0) (tolerant to raw and
boiled)a
n with gastritis/vomiting (%):
l 10 (71) (tolerant to
boiled, not raw)a
l 0 (0) (tolerant to raw and
boiled)a
n with atopic eczema (%): NR
n with skin symptom (%): NR
n with respiratory symptoms
(%): NR
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Study details Selection criteria Participant details (allergic)
Participant details
(tolerant)
Cabrera-Freitag 2011,43
2010,94 201148
Country: Spain
Funding: Spanish Society
of Allergy and Clinical
Immunology Foundation;
Spanish Research
Network on Adverse
Reactions to Allergens
and Drugs
Recruitment: March 2008
to May 2009
No. of participants: 173
Inclusion criteria: Allergic
patients had (1) an
allergen-specific history
(rhinitis, rhinoconjunctivitis
and/or bronchial asthma)
during the season of
pollinisation of grass
pollen and/or cypress
pollen and (2) a positive
SPT to the corresponding
pollen, P. pratense and/or
C. arizonica. Controls had
no pollen allergen-specific
history and had negative
SPT to the corresponding
pollen
Exclusion criteria: Patients
showing clinical history
during the season of
pollinisation of grass pollen
and showing SPT-positive
to grass pollen and to
other pollen that
pollinated in the same
season (i.e. olive)
Recruitment site: Clínica
Universidad de Navarra,
Pamplona, Spain
l n: 43 (grass), 12 (cypress)
Mean age, years (25th–75th
percentile):
l Grass 29 (20–37)
l Cypress 32 (21–44)
Male (%):
l Grass 21 (49)
l Cypress 4 (33.3)
Median duration of allergy,
years (range): NR
n with oral allergy syndrome
(%): NR
n with asthma (%):
l Grass 15 (35)
l Cypress 3 (25)
n with anaphylaxis (%): NR
n with gastritis/vomiting (%):
NR
n with atopic eczema (%): NR
n with skin symptom (%): NR
n with respiratory symptoms
(%): NR
l n: 26 (grass), 92 (cypress)
Control definition: Negative
history and SPT
Mean age, years (25th–75th
percentile):
l Grass 27 (17–35)
l Cypress 29 (20–38)
Male (%):
l Grass 10 (39)
l Cypress 46 (50)
Median duration of allergy,
years (range): NR
n with oral allergy syndrome
(%): NR
n with asthma (%):
l Grass 7 (27)
l Cypress 2 (35)
n with anaphylaxis (%): NR
n with gastritis/vomiting (%):
NR
n with atopic eczema (%): NR
n with skin symptom (%): NR
n with respiratory symptoms
(%): NR
De Swert 201241
Country: Belgium
Funding: NR
Recruitment: NR
No. of participants: 15
Inclusion criteria: Subjects
with birch pollen allergy
(typical allergic symptoms
during the birch pollen
season in combination
with a positive IgE
response to birch or rBet
v1), suspected of also
being soy allergic
Exclusion criteria: NR
Recruitment site:
Outpatient allergy clinic,
Paediatric Department,
University Hospital
Gasthuisberg, Leuven,
Belgium
n: 8
Median age, years (range):
10.3 (4.8–15.6)
Male (%): NR
Median duration of allergy,
years (range): tree 3.7 (1–9)
n with oral allergy syndrome
(%): 7 (88)
n with asthma (%): NR
n with atopic eczema (%): NR
n with anaphylaxis (%): NR
n with gastritis/vomiting (%):
NR
n with skin symptom (%): NR
n with respiratory symptoms
(%): NR
n: 7
Median age, years (range):
10.1 (4.7–16)
Male (%): NR
Median duration of allergy,
years (range): tree 3.5 (1–10)
n with oral allergy syndrome
(%): 4 (57)
n with asthma (%): NR
n with atopic eczema (%): NR
n with anaphylaxis (%): NR
n with gastritis/vomiting (%):
NR
n with skin symptom (%): NR
n with respiratory symptoms
(%): NR
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Study details Selection criteria Participant details (allergic)
Participant details
(tolerant)
Sokolova 200946
Country: Portugal
Funding: Phadia, Portugal
Recruitment: NR
No. of participants: 41
Inclusion criteria: Patients
from Food Allergy
Outpatient Clinic who,
at the time of diagnosis,
had a clinical picture
compatible with
IgE-mediated CMPA,
documented by SPT and
positive specific IgE
(> 0.35 kU/l) to whole milk
and/or its protein fractions
(α-LA, β-LG and casein).
Control group consisted
of four atopic individuals
with no history of CMPA
and who ingested cow’s
milk daily
Exclusion criteria: NR
Recruitment site:
Food Allergy Outpatient
Clinic, Centro Hospitalar
Lisboa Norte, Lisbon,
Portugal
n: 17
Mean age, years (range): 9.25
(2–19)
Male (%): 10 (58.5)
Median duration of allergy,
years (range): NR
n with oral allergy syndrome
(%): NR
n with asthma (%): NR
n with anaphylaxis (%): NR
n with gastritis/vomiting (%):
NR
n with atopic eczema (%):
2 (12)
n with skin symptom (%): NR
n with respiratory symptoms
(%): NR
n: 20
Control definition: Negative
OFC
Mean age, years (range): 6.15
(2–22)
Male (%): 7 (65)
Median duration of allergy,
years (range): NR
n with oral allergy syndrome
(%): NR
n with asthma (%): NR
n with anaphylaxis (%): NR
n with gastritis/vomiting (%):
NR
n with atopic eczema (%):
6 (30)
n with skin symptom (%): NR
n with respiratory symptoms
(%): NR
CMPA, cow’s milk protein allergy; kU/l, kilo International Unit per litre; NR, not reported.
a After oral challenge.
C Baseline accuracy study details (diagnostic cohort studies)
Study details Selection criteria Participant details
Albarini 201347
Country: NR
Funding: NR
Recruitment: April 2007 to
May 2012
No. of participants: 35
Inclusion criteria: Children
with immediate reaction to
hazelnut ingestion
Exclusion criteria: NR
Recruitment site: NR
n: 35
Median age, years (range): 8.3 (2.2–14.2)
Male (%): 26 (74)
Median duration of allergy, years (range): NR
n with oral allergy syndrome (%): NR
n with asthma (%): NR
n with anaphylaxis (%): NR
n with gastritis/vomiting (%): NR
n with atopic eczema (%): NR
n with skin symptom (%): NR
n with respiratory symptoms (%): NR
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Study details Selection criteria Participant details
D’Urbano 201044
Country: Italy
Funding: IRCCS Children’s
Hospital Bambino Gesù
Recruitment: NR
No. of participants: 104
(58 cow’s milk and 46 hen’s
egg)
Inclusion criteria: Infants and
children referred for
evaluation of suspected
IgE-mediated food
hypersensitivity (history
related to cow’s milk or
hen’s egg consumption, of
severe and/or immediate
reactions)
Exclusion criteria: Atopic
eczema as the only
indication for suspected
allergy
Recruitment site:
Department of Paediatric
Medicine–Allergy Unit,
IRCCS Children’s Hospital
Bambino Gesù, Rome, Italy
n: 104
Median age, years (range): 4.9 (0.7–15.1)
Male (%): 62 (60)
Median duration of allergy, years (range): NR
n with oral allergy syndrome (%): NR
n with asthma (%): NR
n with atopic eczema (%): NR
n with skin symptom (%): 44 (42)
n with respiratory symptoms (%): 6 (96)
n with gastrointestinal symptoms (%): 33 (32)
n with anaphylaxis (%): 4 (4)
Ott 200849
Country: Germany
Funding: START programme
of the Medical Faculty of the
Rheinisch-Westfälische
Technische Hochschule
(RWTH) Aachen
Recruitment: NR
No. of participants: 130
Inclusion criteria: Children
referred for evaluation of
suspected IgE-mediated food
hypersensitivity
Exclusion criteria: NR
Recruitment site: Charité
Allergy Center,
Universitätsmedizin Berlin,
Germany
n: 130
Median age, months (range): NR [total= 14 (5–150)]
Male (%): 70 (54)
Median duration of allergy, years (range): NR
n with oral allergy syndrome (%): NR
n with asthma (%): NR
n with atopic eczema (%): NR
n with anaphylaxis (%): NR
n with vomiting (%): 23 (16)
n with skin symptom (%): NR
n with respiratory symptoms (%): NR
Wohrl 200645
Country: Austria
Funding: ISAC and IgE were
performed in the laboratories
of VBC-GENOMICS, Vienna,
Austria
Recruitment: September to
October 2004
No. of participants: 120
patients with allergic rhinitis
Inclusion criteria: Adults at
the end of the pollen season
Exclusion criteria: Total
serum IgE > 1000 kU/l
(to minimise non-specific
binding in the ImmunoCAP
system)
Recruitment site: Allergy
Outpatient Clinic of the
Division of Immunology,
Allergy and Infectious
Diseases, Medical University
of Vienna, and at a private
outpatient allergy clinic
FAZ–Floridsdorf Allergy
Center, Vienna
n: 120
Mean age, years (SD): 35.9 (14.4)
Male (%): 50 (42)
Median duration of allergy, years (range): NR
n with oral allergy syndrome (%): NR
n with asthma (%): NR
n with atopic eczema (%): NR
n with skin symptom (%): NR
n with respiratory symptoms (%): NR
n with gastrointestinal symptoms (%): NR
n with anaphylaxis (%): NR
CMPA, cow’s milk protein allergy; kU/l, kilo International Unit per litre; NR, not reported; SD, standard deviation.
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D Index test and comparator details (studies of change to
management, treatment or diagnostic classification)
Study details Index test details Standard care details
Heaps 201439 Version: ImmunoCAP ISAC 103
Manufacturer: Phadia/Thermo Fisher Scientific,
Milan, Italy
Method: ‘According to the manufacturer’s
instructions.’ Slides were scanned using a
GenePix 4000B microarray scanner (Molecular
Devices, Sunnyvale, CA, USA). Image analysis was
performed using the Microarray Image Analyser
(MIA: Thermo Fisher Scientific/Phadia, Uppsala,
Sweden). All new positive ISAC results were
retested for confirmation
Allergens (components) assessed: NR
Definition of a positive result: ‘According to the
manufacturer’s instructions’ ISU> 0.3
Positive control: NR
Negative control: NR
Method: SPT and clinical history, and sIgE and MCT
SPT: NR
sIgE and MCT: FEIA auto-analyser, ImmunoCAP
250 platform (Thermo Fisher Scientific/Phadia AB,
Uppsala, Sweden), ‘according to the manufacturer’s
instructions’
Hermansson
201433,34
Version: ImmunoCAP ISAC 112
Manufacturer: NR
Method: NR
Allergens (components) assessed: NR
Definition of a positive result: NR
Positive control: NR
Negative control: NR
Method: Clinical history/parental report, and sIgE
sIgE: RAST
Luengo 201037 Version: ImmunoCAP ISAC 103
Manufacturer: NR
Method: NR
Allergens (components) assessed: NR
Definition of a positive result: NR
Positive control: NR
Negative control: NR
Method: SPT and sIgE
SPT: NR
sIgE: NR
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Study details Index test details Standard care details
Noimark
201240
Version: ImmunoCAP ISAC unspecified version
Manufacturer: NR
Method: NR
Allergens (components) assessed: NR
Definition of a positive result: NR
Positive control: NR
Negative control: NR
Method: SPT and/or sIgE
SPT: NR
sIgE: NR
Passalacqua
201338
Version: ImmunoCAP ISAC 103
Manufacturer: Thermo Fisher Scientific, Milan,
Italy
Method: According to the manufacturer’s
instructions. Slides were read automatically using
a Laser Scan Confocal microarray reader (LuxScan
10K/A, CapitalBio, Beijing, China)
Allergens (components) assessed: NR
Definition of a positive result: ≥ 0.35 ISU
Positive control: NR
Negative control: NR
Method: SPT and clinical history, with sIgE as
required
SPT: Standard panel of commercial extractive
preparations (ALK-Abelló, Milan, Italy), including
mites, grass, olive, Parietaria, birch, cypress,
ragweed, mugwort, cat and dog dander, Alternaria
and Aspergillus. A positive result was defined as a
weal reaction of ≥ 3mm in diameter. 1% histamine
was used as a positive control and diluent as a
negative control
sIgE: Commercial immunoenzymatic method
(Thermo Fisher Scientific/Phadia AB, Uppsala,
Sweden). A positive result was defined as
> 0.35 kU/l
Sastre 201232 Version: ImmunoCAP ISAC 96
Manufacturer: Phadia, Sweden
Method: ‘According to the manufacturer’s
instructions’
Allergens (components) assessed: Olive (Ole 1);
cypress (Cup s 1); plane (pla a1, Pla a2); grass
(Phl p1, phl p5); cynodon (Cyn d1)
Definition of a positive result: ‘According to the
manufacturer’s instructions’
Positive control: NR
Negative control: NR
Method: SPT and clinical history, taking into
consideration the time of year of respiratory
symptoms and European Academy of Allergy and
Clinical Immunology guidelines
SPT: Standard panel of commercial inhalants
(ALK-Abelló, Madrid, Spain), including Olea e,
Platanus a, Cupressus a, grass mix, Cynodon d,
Phragmites c, Artemisia v, Salsola k, and Plantago l.
A positive result was defined as a weal reaction
≥ 3mm more than negative control. Histamine
(10mg/ml) was used as a positive control and
glycerol–saline solution as a negative control
FEIA, fluoroenzyme immunoassay; kU/l, kilo International Unit per litre; NR, not reported; RAST, radioallergosorbent test.
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E Index test and reference standard details (accuracy studies)
Study
details
Index test details
Reference standard
details: oral challengeImmunoCAP/Microtest Specific IgE tests SPT
Albarini
201347
Version: ImmunoCAP
ISAC unspecified version
Manufacturer: NR
Method: NR
Definition of positive
result: NR
Positive control: NR
Negative control: NR
Version: ImmunoCAP
Manufacturer: NR
Method: NR
Definition of positive
result: > 0.35 kUI/l
Positive control: NR
Negative control: NR
Method: NR
Allergen: NR
Positive result: Mean
weal diameter > 3mm
Positive control: NR
Negative control: NR
DBPCFC
Alessandri
201142
Version: ImmunoCAP
ISAC 103
Manufacturer: Phadia
AB, Uppsala, Sweden
Method: ‘According to
the manufacturer’s
instructions’
Definition of a positive
result: Thresholds for
each allergen/
component derived from
ROC analyses, but not
reported
Positive control: NR
Negative control: NR
Version: ImmunoCAP
Manufacturer: Phadia
AB, Uppsala, Sweden
Method: ‘According to
the manufacturer’s
instructions’
Definition of a positive
result: Thresholds for
each allergen/
component derived
from ROC analyses, but
not reported
Positive control: NR
Negative control: NR
Method: Performed in
duplicate on the
volar surface of the
forearm by the same
investigator, following
European Academy of
Allergy and Clinical
Immunology
recommendations,
using 1-mm-tipped
lancets. Weal reactions
were recorded after
15 minutes, by
outlining with pen onto
paper sheets, which
were scanned to
digitally measure areas
Allergen: Commercial
extracts (Allergopharma,
Reinbek, Germany)
and freshly prepared
egg reagents
Positive result: Mean
weal diameter of
≥ 7mm
Positive control:
Histamine diphosphate
(10mg/ml)
Negative control:
Glycerol–saline solution
Double-blind placebo-
controlled hen’s egg
challenges were carried
out using commercially
available eggs
Boiled egg: Administering
an initial dose of 0.1ml,
and, in case of no reactions
in the next 20 minutes, by
progressively increasing the
egg amount by a factor 5
(0.5, 2, 10 and 50ml) up
to the ingestion of one egg
(approximately 6 g)
Patients tolerating boiled
egg were then challenged
with raw egg in a similar
way
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Study
details
Index test details
Reference standard
details: oral challengeImmunoCAP/Microtest Specific IgE tests SPT
De Swert
201241
Version: ImmunoCAP
ISAC unspecified version
Manufacturer: Phadia
AB, Uppsala, Sweden
Method: ‘According to
the manufacturer’s
instructions’
Definition of a positive
result: ≥ 0.3 ISU,
≥ 1.0 ISU for rGly m4
Positive control: NR
Negative control: NR
Version: ImmunoCAP
FEIA
Manufacturer: Phadia
AB, Uppsala, Sweden
Method: ‘According to
the manufacturer’s
instructions’
Definition of a positive
result: ≥ 0.10 kU/l,
≥ 17.6 kU/I for rGly m4
Positive control: NR
Negative control: NR
Method: Performed
using a microlance.
Weal reactions were
recorded after
15 minutes; orthogonal
diameters were
measured and mean
diameters were
calculated
Allergen: 1/10 w/v
dilution of soy flour
(Sojameel, Biofresh,
Genk, Belgium)
Positive result: Mean
weal diameter ≥ 3mm,
(cut-off point ≥ 7mm
rGly m4)
Positive control:
Histamine diphosphate
(1mg/ml)
Negative control: Coca
solution in 50%
glycerol
Subjects were on a
soy-free diet for at least
8 weeks
Challenge performed with
Alpro soya natural drink;
one drop of soy drink at
the inner side of the lower
lip
If no reaction occurred
within 15 minutes,
increasing doses of 1, 2, 5,
10, 20, 40 and 80ml of
soy drink were given at
20-minute intervals, until
appearance of objective
allergic symptoms (or until
158ml)
If no symptoms after
2 hours, the parents were
asked to give the child
daily volumes of 120ml of
soy drink in the next
2 weeks, while continuing
their diet otherwise
unchanged
Re-evaluation was
provided after 2 weeks or
earlier if required
D’Urbano
201044
Version: ImmunoCAP
ISAC 89
Manufacturer: Phadia
AB, Uppsala, Sweden
Method: ‘according to
the manufacturer’s
instructions’
Definition of positive
result: NR
Positive control: NR
Negative control: NR
Version: ImmunoCAP
Manufacturer: Phadia
AB, Uppsala, Sweden
Method: ‘according to
the manufacturer’s
instructions’
Definition of positive
result: NR
Positive control: NR
Negative control: NR
Method: The response
was read 15 min after
puncture and results
were expressed as the
mean weal diameter
(mm)
Allergen: Natural food
and commercial natural
extracts to milk,
α-lactalbumin,
β-lactoglobulin, casein,
egg white, egg yolk
(Lofarma, Milan, Italy)
Positive result: Mean
weal diameter of
> 3mm with erythema
Positive control:
Histamine hydrochloride
Negative control:
Sodium chloride (0.9%)
Performed in an open
fashion
The material was
pasteurised cow’s milk and
cooked egg (boiled for
10 minutes) or raw egg in
the case of negative result
to cooked egg
When the patient
tolerated the first dose,
the subsequent doses
were given every
15 minutes until objective
symptoms developed or
when the entire dose was
ingested (equivalent to
one egg; or up to 250ml
of milk)
Positive result was scored
if anaphylactic shock or
two or more of the
following objective clinical
reactions were noted:
bronchial asthma,
lips/periorbital oedema,
urticaria/angioedema,
rhinitis, conjunctivitis,
diarrhoea and repetitive
vomiting
DOI: 10.3310/hta20670 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 67
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
Study
details
Index test details
Reference standard
details: oral challengeImmunoCAP/Microtest Specific IgE tests SPT
Ott 200849 Version: ImmunoCAP
ISAC 51
Manufacturer: VBC
Genomics Bioscience
Research, Vienna,
Austria
Method: ‘According to
the manufacturer’s
instructions’
Definition of positive
result: Cut-off points
used for analyses
derived from ROC
analyses
Positive control: NR
Negative control: NR
Version: UniCAP®
Manufacturer: Phadia
AB, Uppsala, Sweden
Method: ‘According to
the manufacturer’s
instructions’
Definition of positive
result: > 0.35 kU/l
(derived from ROC
analyses)
Positive control: NR
Negative control: NR
Method: One drop of
either milk or native
hen’s egg was applied
to the patient’s forearm
with 1-mm single-peak
lancets (ALK,
Copenhagen, Denmark)
Allergen: Fresh cow’s
milk (3.5% fat) or
native hen’s egg
(whisked white of egg
and yolk).
Definition of positive
result: Mean weal
diameter > 3mm, or
greater than negative
control. Cut-off points
used for analyses
derived from ROC
analyses
Positive control:
Histamine hydrochloride
(1%)
Negative control: Saline
OFCs with either cow’s
milk and/or hen’s egg
The food challenges were
scored as positive by a
paediatric allergologist if
one or more of the
following objective clinical
reactions were noted:
urticaria, flushing, pruritus,
angioedema, exacerbation
of AE, vomiting, diarrhoea,
stridor or other respiratory
symptoms
FEIA, fluoroenzyme immunoassay; kU/l, kilo International Unit per litre; w/v, weight/volume.
Study details
Index test details Reference standard details
ImmunoCAP®/Microtest Specific IgE tests Oral challenge
Sokolova 200946 Version: ImmunoCAP ISAC
NR
Manufacturer: VBC
Genomics Bioscience
Research, Vienna, Austria
Method: ‘According to the
manufacturer’s instructions’
Definition of positive result:
Cut-off points NR
Positive control: NR
Negative control: NR
Version: UniCAP
Manufacturer: Phadia,
Uppsala, Sweden
Method: ‘According to
the manufacturer’s
instructions’
Definition of positive
result: > 0.35 kU/l
Positive control: NR
Negative control: NR
Patients complaining of anaphylaxis after
accidental ingestion of milk or its derivatives
were considered persistent
A diagnosis of persistent CMPA was
confirmed in the remaining patients via a
positive oral challenge test, performed
following current recommendations.
The initial dose administered was 0.1ml
with posterior duplication of the doses and
administration at 30-minute intervals. It was
considered positive if cutaneous (urticaria/
angioedema), respiratory or gastrointestinal
(vomiting, diarrhoea) symptoms occurred.
A negative open oral challenge to cow’s
milk was defined as a cumulative dose of
200ml
The control group consisted of four atopic
individuals with no history of CMPA and
who ingested cow’s milk daily
CMPA, cow’s milk protein allergy; FEIA, fluoroenzyme immunoassay; kU/l, kilo International Unit per litre; NR, not reported;
w/v, weight/volume.
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Study details
Index test details
Reference standard details:
SPT+ allergen-specific historyImmunoCAP/Microtest Specific IgE tests
Cabrera-Freitag
201143
Version: ImmunoCAP ISAC 103
Manufacturer: Phadia, Uppsala,
Sweden
Method: ‘According to the
manufacturer’s instructions’
Definition of positive result:
≥ 0.3 ISU. Thresholds for each
allergen/component derived
from ROC analyses, but not
clearly reported
Positive control: NR
Negative control: NR
Version: ImmunoCAP FEIA
Manufacturer: Phadia,
Uppsala, Sweden
Method: ‘According to the
manufacturer’s instructions’
Definition of positive result:
> 0.35 kU/l. Thresholds for
each allergen/component
derived from ROC analyses,
but not clearly reported
Positive control: NR
Negative control: NR
Method: 1-mm-tip lancet
(ALK-Abelló) on the volar side of
the forearm. Read after 20 minutes.
Performed by the same experienced
nurses
Allergen: Commercial, natural
extracts (ALK-Abelló, Madrid,
Spain)
Definition of positive result: Mean
weal diameter of > 3mm
Positive control: Histamine
hydrochloride (10mg/ml)
Negative control: Sodium chloride
(0.9%)
Allergen history: Rhinoconjunctivitis
and/or bronchial asthma
Controls had no pollen allergen-
specific history and had negative
SPT to the corresponding pollen
Wohrl 200645 Version: ImmunoCAP ISAC
CRD 50
Manufacturer: Genomics
Bioscience Research, Vienna,
Austria
Method: ‘According to the
manufacturer’s instructions’.
Slides were scanned in an
Affymetrix 428 microarray
scanner (Affymetrix, Santa
Clara, CA, USA). Images were
analysed using the GenePix
image analysis software
(version 3.0.6.89; Axon
Instruments, Union City, CA,
USA)
Definition of a positive result:
Thresholds for each allergen/
component derived from ROC
analyses, but not reported
Positive control: NR
Negative control: NR
Version: ImmunoCAP
Manufacturer: Phadia,
Uppsala, Sweden
Method: ‘According to the
manufacturer’s instructions’
Definition of a positive result:
Thresholds for each allergen/
component derived from ROC
analyses, but not reported
Positive control: NR
Negative control: NR
Method: SPTs were read after
20 minutes. Weals and flares were
pen-marked, transferred to a paper
with transparent adhesive tape
and analysed with an investigator-
independent system calculating the
weal size in mm2
Allergen: Commercial extracts
(HAL Allergie GmbH, Germany, and
ALK, Hørsholm, Denmark)
Positive result: Mean weal area of
≥ 7mm2 or > 3mm diameter
Positive control: Histamine
hydrochloride (ALK)
Negative control: Sodium chloride
(0.9%)
Allergen history: Obtained in all
subjects using a questionnaire that
gave special regard to the clinical
relevance of the sensitisation to
each allergen (e.g. clinical relevance
of the sensitisation to birch pollen
was affirmed by asking for an oral
allergy syndrome to apple and
other Rosaceae fruits)
All subjects without allergen-specific
history (atopics) and those with
additional negative SPTs (non-allergic)
served as controls
FEIA, fluoroenzyme immunoassay; kU/l, kilo International Unit per litre; NR, not reported.
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Appendix 3 Table of excluded studies with
rationale
Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Ackerbauer
201595
Food Yes ImmunoCAP
ISAC 112
Other Concordance
only
No relevant outcomes
Correlation of specific serum
IgE levels measured by single
ImmunoCAP sIgE and
ImmunoCAP ISAC 112, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and specificity)
of the two methods
Acosta Rivera
201296
Food Yes ImmunoCAP
ISAC 103
SPT No relevant
outcomes
Insufficient information for
accuracy
Alessandri
201197
Food Yes ImmunoCAP
ISAC 103
OFC No relevant
outcomes
Insufficient information for
accuracy
Alonso 201498 Food ImmunoCAP
ISAC 112
Other No relevant
outcomes
Method of diagnosis not
adequately reported;
insufficient information for
accuracy
Alvarado
201399
Food Yes ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Antonicelli
2014100
Food Unclear Other Other No relevant
outcomes
Microarray and reference
standard not specified and
no relevant outcomes
Araujo 2012101 Pollen Unclear ImmunoCAP
ISAC other
Other No relevant
outcomes
Unspecified version ISAC,
diagnosis according to
Allergic Rhinitis and its
Impact on Asthma (ARIA)
guidelines; insufficient
information for accuracy
Asero 2014102 Pollen Unclear Other NA No relevant
outcomes
Not ISAC or Microtest
Bauermeister
2009103
Food Unclear Other NA No relevant
outcomes
ImmunoCAP® 250 – not
ISAC or Microtest
Berneder
2013104
Food Unclear ImmunoCAP
ISAC 112
NA Concordance
only
No relevant outcomes
Correlation of specific serum
IgE levels measured by single
ImmunoCAP sIgE and
ImmunoCAP ISAC 112, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and specificity)
of the two methods
Blankestijn
2014105
Yes ImmunoCAP
ISAC other
NA No relevant
outcomes
Unspecified version ISAC,
prevalence only
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Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Bokanovic
2013106
Pollen Yes ImmunoCAP
ISAC 103
SPT Accuracy
only
Comparative accuracy:
whole panel ISAC vs. sIgE vs.
inhaled challenge. Some
patients tested with ISAC
112. However, sIgE were
reported as measured with
ImmunoCAP component
assays and ISAC, and
accuracy data appeared to
relate to the component
measured rather than
the test (i.e. included
participants could have been
tested using either method)
Bonini 2010107 Other Unclear ImmunoCAP
ISAC 103
SPT No relevant
outcomes
Insufficient information for
accuracy
Bonini 2010108 Other Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Bonini 2012109 Other Yes ImmunoCAP
ISAC 103
NA Concordance
only
No relevant outcomes
Correlation of specific serum
IgE levels measured by single
ImmunoCAP sIgE and
ImmunoCAP ISAC 103, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and
specificity) of the two
methods
Brans 2012110 Food Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Concordance only, FEIA vs.
single IgE derived from ISAC
Comparison of levels of sIgE
against omega-5-gliadin, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and
specificity) of the two
methods
Cabrera-Freitag
2011111
Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
Technical reproducibility
data only
Caimmi 2011112 Food ImmunoCAP
ISAC other
SPT No relevant
outcomes
Unspecified version ISAC,
insufficient information for
accuracy or concordance
Caimmi 2011113 Other Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Unspecified version ISAC,
insufficient information for
concordance or accuracy
Caimmi 2013114 Other Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Carter 2012115 Other Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Cavagni
2009116
Food Unclear ImmunoCAP
ISAC 89
OFC No relevant
outcomes
Insufficient information for
accuracy
Cavagni
2010117
Food Unclear ImmunoCAP
ISAC 89
OFC No relevant
outcomes
Insufficient information for
accuracy
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Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Chambel
2011118
Pollen Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Unspecified version ISAC;
insufficient information for
accuracy or concordance
Chambel
2012119
Pollen Yes ImmunoCAP
ISAC 103
SPT No relevant
outcomes
Insufficient information for
accuracy; includes only
patients with a positive
reference standard diagnosis
Charalambous
2014120
Other Yes ImmunoCAP
ISAC other
NA No relevant
outcomes
Exclude
‘Audit’ of clinical records
information on patients
previously tested with ISAC;
no details of test results
or their effects on
decision-making
Chevallier
2013121
Food Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Chia 2013122 Food Unclear Other Other
challenge
test
No relevant
outcomes
Intervention was unspecified
version ISAC or ImmunoCAP;
not enough detail for
accuracy data
Cho 2014123 Pollen Yes Other NA Concordance
only
No relevant outcomes
Comparison of positive rates
between SPT, AdvanSure
and ImmunoCAP sIgE
Choi 2014124 Other Yes ImmunoCAP
ISAC other
SPTs No relevant
outcomes
Unspecified version ISAC;
insufficient information for
patient level accuracy
Choi 2014125 Other Unclear ImmunoCAP
ISAC other
SPTs No relevant
outcomes
Unspecified version ISAC;
insufficient details for
accuracy
De Amici
2014126
Other Unclear ImmunoCAP
ISAC 112
NA No relevant
outcomes
Comparison with ISAC 103,
outcome was described as
‘diagnostic utility’ and
‘therapeutic utility’ scores,
but no further details were
reported
De Boer 2012127 Other Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
Technical reproducibility and
limit of detection only, using
a single pooled QC sample.
Intra-assay and inter-assay
variation
De Boer 2013128 Other Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
De Boer 2013128 Food Yes ImmunoCAP
ISAC 112
NA No relevant
outcomes
No relevant outcomes
De Knop
2011129
Food Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Doyen 2011130 Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
Interference of omalizunab
with ISAC and ImmunoCAP
Ebo 2010131 Latex Yes ImmunoCAP
ISAC 103
SPT No relevant
outcomes
Insufficient information for
accuracy
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Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Ebo 2010132 Pollen Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Eller 2013133 Food Yes Other SPT Accuracy
only
ImmuoCAP sIgE only
Fernandez
2011134
Pollen Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Unspecified version ISAC,
insufficient information for
concordance
Flores 2014135 Pollen Yes ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Fung 2012136 Food Unclear ImmunoCAP
ISAC other
Other No relevant
outcomes
No relevant outcomes
Gadisseur
2009137
Other Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
Insufficient information for
concordance or accuracy
Gadisseur
2011138
Other Unclear ImmunoCAP
ISAC 103
NA Concordance
only
No relevant outcomes
Reports agreement on
allergen source between
specific serum IgE levels
measured by single
ImmunoCAP sIgE and
ImmunoCAP ISAC 103, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and
specificity) of the two
methods
Gadisseur
2011138
Other Yes ImmunoCAP
ISAC 103
NA Concordance
only
No relevant outcomes
Reports agreement between
sIgE and ImmunoCAP ISAC
103, but insufficient data
to compare diagnostic
performance (e.g. sensitivity
and specificity) of the two
methods
Gadisseur
2012139
Food Unclear ImmunoCAP
ISAC 112
NA No relevant
outcomes
Refers to additional
information provided by
ISAC, but no details given
Garriga Baraut
2010140
Pollen Unclear ImmunoCAP
ISAC other
SPT No relevant
outcomes
Unspecified version ISAC;
insufficient information
for accuracy
Goikoetxea
2013141
No Other NA No relevant
outcomes
Review article
Goikoetxea
2015142
Yes ImmunoCAP
ISAC 112
NA No relevant
outcomes
No relevant outcomes
Hermansson
201260
Pollen ImmunoCAP
ISAC other
Other Economics
only
No relevant outcomes
Hoffmann
2014143
Pollen Unclear Other NA No relevant
outcomes
Intervention was SIT: use of
ISAC and IgE/IgG4 to
measure response to SIT
Hong 2011144 Food Unclear ImmunoCAP
ISAC 103
Other No relevant
outcomes
Insufficient information for
accuracy
Hong 2012145 Food Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
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Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Javaloyes
2012146
Food Yes ImmunoCAP
ISAC 103
Other No relevant
outcomes
No relevant outcomes
Jung 2012147 Pollen Unclear ImmunoCAP
ISAC other
SPT No relevant
outcomes
Insufficient information for
accuracy or concordance
and unspecified version of
ISAC
Kattan 2013148 Food Yes ImmunoCAP
ISAC 112
OFC No relevant
outcomes
Insufficient information for
accuracy
Kattan 2014149 Food Yes ImmunoCAP
ISAC 112
OFC Accuracy
only
Accuracy of components of
ISAC for peanut allergy only
(no comparative data)
Kim 2015150 Pollen Unclear ImmunoCAP
ISAC other
SPT No relevant
outcomes
Insufficient detail on
accuracy data
Klemans
2013151
Food Yes ImmunoCAP
ISAC 103
SPT No relevant
outcomes
No relevant outcomes,
incomplete accuracy data
Klemans
2014152
Food Yes ImmunoCAP
ISAC 112
OFC Accuracy
only
ISAC only, no comparative
accuracy data
Konradsen
2015153
Other Unclear Microtest NA Concordance
only
No relevant outcomes
Correlation of specific serum
IgE levels measured by
Microtest, single ImmunoCAP
sIgE and ImmunoCAP ISAC
112, but insufficient data to
compare diagnostic
performance (e.g. sensitivity
and specificity) of the three
methods
Lee 2013154 Food Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Liso 2011155 Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Experimental ISAC with
omalizumab added and no
relevant outcomes
Liu 2011156 Food Unclear ImmunoCAP
ISAC other
OFC Accuracy
only
Accuracy reported for the
allergen component
(measured by a variety of
methods). Data reported
only for ISAC; no
comparative accuracy data
Lizaso 2011157 Pollen Yes ImmunoCAP
ISAC 89
NA Concordance
only
No relevant outcomes
Reports percentage
agreement between
single ImmunoCAP sIgE,
ImmunoCAP ISAC 89,
and an Avida-Centaur
component resolved assay,
but insufficient data to
compare diagnostic
performance (e.g. sensitivity
and specificity) of the two
methods
Lohman
2013158
Other NA No relevant
outcomes
Not ISAC, development of a
microarray
DOI: 10.3310/hta20670 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 67
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
137
Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Luengo 2011159 Food Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
Insufficient outcome
information
Mailhol 2013160 Unclear ImmunoCAP
ISAC 112
NA No relevant
outcomes
No relevant outcomes
Martinez-
Aranguren
2013161
Unclear ImmunoCAP
ISAC 112
NA No relevant
outcomes
Technical reproducibility
only, wrong comparator
Martinez-
Aranguren
2014162
Other Unclear ImmunoCAP
ISAC 112
NA Concordance
only
No relevant outcomes
Reports agreement on
sensitisations between
single ImmunoCAP sIgE,
ImmunoCAP ISAC112 and
SPT, but insufficient data
to compare diagnostic
performance (e.g. sensitivity
and specificity) of the two
methods
Martinez-
Aranguren
2014163
Food Yes ImmunoCAP
ISAC 112
SPT Accuracy
only
ISAC only, no comparative
accuracy
Martinez-
Aranguren
2014164
Other Yes ImmunoCAP
ISAC 112
NA No relevant
outcomes
Technical data, assay
reproducibility only
Mascialino
201359
Pollen Yes ImmunoCAP
ISAC other
NA Economics
only
No relevant outcomes
Mascialino
201358
Pollen Economics
only
No relevant outcomes
Melioli 2011165 Pollen Yes ImmunoCAP
ISAC 103
NA Concordance
only
No relevant outcomes
Reports percentage positive
agreement between single
ImmunoCAP sIgE and
ImmunoCAP ISAC 103, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and specificity)
of the two methods
Microtest DX
2014166
Other Unclear Microtest NA Concordance
only
No relevant outcomes
Correlation of specific
serum IgE levels measured by
Microtest, single ImmunoCAP
sIgE and ImmunoCAP ISAC
112, but insufficient data
to compare diagnostic
performance (e.g. sensitivity
and specificity) of the three
methods
Murng 2011167 Other Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Insufficient details of
outcomes reported,
unspecified version ISAC
Murng 2011168 Food Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Insufficient outcome
information
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Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Nanda 2015169 Food Unclear Other NA Concordance
only
No relevant outcomes
Correlation of specific serum
IgE levels measured by single
ImmunoCAP sIgE and an
unspecified version of
ImmunoCAP ISAC, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and specificity)
of the two methods
Nicaise-Rolland
2010170
Unclear ImmunoCAP
ISAC 103
Other No relevant
outcomes
Insufficient information for
accuracy
Nicolaou
2010171
Food Other NA No relevant
outcomes
Not ISAC or Microtest
Nicolaou
2010171
Food Yes Other NA No relevant
outcomes
Not ISAC or Microtest
Nystrand
2012172
Unclear ImmunoCAP
ISAC 112
NA No relevant
outcomes
Technical reproducibility and
limit of detection only
Olivieri 2010 173 Food Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Olivieri 2013174 Food Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Onell 2012175 Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Ott 2010176 Other Unclear Other NA No relevant
outcomes
No relevant outcomes,
unspecified microarray
Paes 2010177 Food Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Palomba
2013178
Other Unclear Microtest NA Concordance
only
No relevant outcomes
Correlation of specific serum
IgE levels measured by
Microtest and single
ImmunoCAP sIgE, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and specificity)
of the two methods
Palomba
2014179
Other Unclear Microtest NA No relevant
outcomes
Concordance between
Microtest and an unspecified
commercially available
system, insufficient detail
reported
Pascal 201693 Food Yes ImmunoCAP
ISAC 112
SPT, sIgE Accuracy
only
No comparison results for
sIgE or SPT
Passalacqua
201352
Other Unclear Other NA Treatment
change
Insufficient outcome details,
but abstract refers to
treatment change
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Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Patelis 2012180 Pollen Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Pedrosa 201292 Food Yes ImmunoCAP
ISAC 103
Other Accuracy
only
Accuracy of various
components on ISAC only
(no comparison with other
index tests, e.g. sIgE or SPT)
Pomponi
2013181
Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
Autoimmune disease
Raulf 2014182 No Other NA No relevant
outcomes
Review article
Röckmann
2014183
Food Yes ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Rodriguez-
Ferran 201161
Unclear Other NA No relevant
outcomes
Review article
Romano
2012184
Food Unclear Other Other No relevant
outcomes
No relevant outcomes
Sanchez-Lopez
2013185
Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Unclear whether results
were derived from an
unspecified version of ISAC
or UniCAP sIgE
Santos 2011186 Pollen Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Santosa 2015187 Other Yes ImmunoCAP
ISAC 112
NA No relevant
outcomes
No relevant outcomes
Sanz 201094 Pollen Unclear ImmunoCAP
ISAC 103
SPT Accuracy
only
Accuracy of various
components on ISAC only
(no comparison with other
index tests, e.g. sIgE or SPT)
Sastre 2014188 Pollen Yes ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Scala 2011189 Food Unclear ImmunoCAP
ISAC 103
Other No relevant
outcomes
Method of diagnosis not
specified, insufficient
information for accuracy
Scala 2011190 Other Unclear ImmunoCAP
ISAC 103
NA No relevant
outcomes
No relevant outcomes
Schuler 2013191 Latex Yes Other SPT No relevant
outcomes
Intervention either
ImmunoCAP sIgE or ISAC
Seyfarth
2011192
Latex Unclear ImmunoCAP
ISAC 103
Other No relevant
outcomes
Partial accuracy only, no
reference standard defined,
non-clinical spiked sample
Seyfarth
2011192
Latex Unclear ImmunoCAP
ISAC other
Other No relevant
outcomes
Partial accuracy only, no
reference standard defined,
non-clinical spiked sample
Seyfarth
2011193
Latex Unclear ImmunoCAP
ISAC 103
Other No relevant
outcomes
Partial accuracy only, no
reference standard defined,
non-clinical spiked sample
Seyfarth
2014194
Latex Yes ImmunoCAP
ISAC 103
SPT No relevant
outcomes
Partial accuracy only,
non-clinical spiked sample
Shibata 2014195 Food Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
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Study details
Allergy
type
Secondary
or tertiary
care? Intervention Reference Outcome
Reason for exclusion and
comments
Sousa 2009196 Pollen Unclear ImmunoCAP
ISAC other
SPT Accuracy
only
ISAC only, no comparative
accuracy
Stringari 201451 Pollen Yes Other NA Clinical Not ISAC or Microtest,
ImmunoCAP FEIA
Tolkki 2013197 Food Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Tolkki 2013198 Food Yes ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Tripathi 2012199 Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
Eosinophilic esophagitis and
no relevant outcomes
Tripathi 2014200 Food Unclear ImmunoCAP
ISAC 112
NA No relevant
outcomes
Eosinophilic esophagitis and
no relevant outcomes
Tripathi 2014201 Food ImmunoCAP
ISAC 112
NA No relevant
outcomes
Mixed population
Uriarte 2013202 Other Unclear Other NA No relevant
outcomes
Intervention was sIgE
ImmunoCAP or ISAC
Vitte 2014203 Other Unclear ImmunoCAP
ISAC other
NA No relevant
outcomes
No relevant outcomes
Weimann
2011204
Unclear ImmunoCAP
ISAC other
Other Concordance
only
No relevant outcomes
Correlation of specific serum
IgE levels measured by single
ImmunoCAP sIgE and an
unspecified version of
ImmunoCAP ISAC, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and specificity)
of the two methods
Williams205 Other Yes Microtest Other Concordance
only
No relevant outcomes
Correlation of specific serum
IgE levels measured by
Microtest and single
ImmunoCAP sIgE, but
insufficient data to compare
diagnostic performance
(e.g. sensitivity and specificity)
of the two methods
Yadzir 2014206 Other Yes ImmunoCAP
ISAC 112
SPT No relevant
outcomes
Insufficient information for
accuracy
Young 2012207 Other Yes ImmunoCAP
ISAC 112
NA No relevant
outcomes
No data
ARIA, Allergic Rhinitis and its Impact on Asthma; FEIA, fluoroenzyme immunoassay; NA, not applicable; QC, quality control.
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Appendix 4 Risk-of-bias assessments
A Review-specific assessments of ‘diagnostic before-and-after’
studies
Study ID: Heaps 201435,39
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Patients with idiopathic anaphylaxis (cause could not be established by standard
diagnostic work-up) recruited from five specialist allergy centres). No further details reported. No exclusion criteria reported
Was a consecutive or random sample of patients enrolled? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: UNCLEAR
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): The cause of anaphylaxis
could not be established using standard diagnostic work-up (including clinical history, SPT, single IgE). The study was
conducted in the UK
Do the included patients match the review question? CONCERN: LOW
DOMAIN 2: INDEX TEST(S)
A. Risk of bias
Describe how the index test was conducted and interpreted: ISAC used ‘according to the manufacturer’s instructions’
Was the index test method, including threshold, prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: LOW
DOMAIN 3: COMPARATOR
A. Risk of bias
Describe the comparator and how it was conducted and interpreted: Standard care, including clinical history, SPT and single
IgE. ISAC testing was conducted after routine diagnostic work-up
Was the diagnostic assessment, based on the comparator, made without knowledge of the results of
the index test?
Yes
Could the comparator, its conduct or its interpretation have introduced bias? RISK: LOW
B. Applicability
Is there concern that the comparator does not match current standard care, as defined in the
review question?
CONCERN: LOW
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DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test or comparator: Three patients did not receive MCT testing (part of
standard work-up). All patients were included in the analysis
Describe the time interval and any interventions between index and comparator: Not reported
Was there an appropriate interval between index test and comparator? Unclear
Did patients receive the same comparator/standard care? No
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: LOW
Study ID: Luengo 201037
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Abstract only, no details reported
Was a consecutive or random sample of patients enrolled? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: UNCLEAR
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Population described as ‘well
characterised, multi-sensitised’ and ‘Mediterranean’
Do the included patients match the review question? CONCERN: UNCLEAR
DOMAIN 2: INDEX TEST
A. Risk of bias
Describe how the index test was conducted and interpreted: Abstract only, no details reported
Was the index test method, including threshold, prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? RISK: UNCLEAR
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DOMAIN 3: COMPARATOR
A. Risk of bias
Describe the comparator and how it was conducted and interpreted: SPT and single IgE, abstract only, no further details
reported
Was the diagnostic assessment, based on the comparator, made without knowledge of the results of
the index test?
Unclear
Could the comparator, its conduct or its interpretation have introduced bias? RISK: UNCLEAR
B. Applicability
Is there concern that the comparator does not match current standard care, as defined in the review
question?
CONCERN: LOW
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, or comparator: All participants appear to have received ISAC and
standard diagnostic work-up
Describe the time interval and any interventions between index and comparator: Not reported
Was there an appropriate interval between index test and comparator? Unclear
Did patients receive the same comparator/standard care? Unclear
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: UNCLEAR
Study ID: Noimark 201240
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Abstract only, no details reported
Was a consecutive or random sample of patients enrolled? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: UNCLEAR
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Children with moderate to
severe atopic eczema and multiple food allergies. The study was conducted in a UK secondary care allergy clinic
Do the included patients match the review question? CONCERN: LOW
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DOMAIN 2: INDEX TEST
A. Risk of bias
Describe how the index test was conducted and interpreted: Abstract only, no details reported
Was the index test method, including threshold, prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? RISK: UNCLEAR
DOMAIN 3: COMPARATOR
A. Risk of bias
Describe the comparator and how it was conducted and interpreted: SPT and/or single IgE, abstract only, no further details
reported
Was the diagnostic assessment, based on the comparator, made without knowledge of the results of
the index test?
Unclear
Could the comparator, its conduct or its interpretation have introduced bias? RISK: UNCLEAR
B. Applicability
Is there concern that the comparator does not match current standard care, as defined in the
review question?
CONCERN: LOW
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, or comparator: All participants appear to have received ISAC and
standard diagnostic work-up
Describe the time interval and any interventions between index and comparator: ISAC was performed ‘alongside’ SPT and
single IgE
Was there an appropriate interval between index test and comparator? Yes
Did patients receive the same comparator/standard care? Unclear
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: LOW
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Study ID: Passalacqua 201338
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Patients with respiratory allergic disease prospectively recruited from six allergy
centres. No further details reported. No exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: UNCLEAR
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Polysensitised patients
(at least two positive SPTs). However, the study was conducted in Italy, where there is likely to be a different pattern of
pollen sensitisations to that observed in the UK
Do the included patients match the review question? CONCERN: HIGH
DOMAIN 2: INDEX TEST
A. Risk of bias
Describe how the index test was conducted and interpreted: ISAC 103, using manufacturer’s recommended threshold
Was the index test method, including threshold, prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: LOW
DOMAIN 3: COMPARATOR
A. Risk of bias
Describe the comparator and how it was conducted and interpreted: Standard care: SPT and clinical history, with single IgE(s)
as required. Diagnosis and treatment plans were formulated based on standard care without ISAC. Decisions were
then reviewed with ISAC results available. It was not clear how many participants received single IgE testing as part of
standard care
Was the diagnostic assessment, based on the comparator, made without knowledge of the
results of the index test?
Yes
Could the comparator, its conduct or its interpretation have introduced bias? RISK: LOW
B. Applicability
Is there concern that the comparator does not match current standard care, as defined in the
review question?
CONCERN: UNCLEAR
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DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, or comparator: All participants appear to have received both ISAC
and standard care. Standard care could include single IgE, but it was not clear in how many participants single IgE assay(s)
were performed
Describe the time interval and any interventions between index and comparator: Not reported
Was there an appropriate interval between index test and comparator? Unclear
Did patients receive the same comparator/standard care? No
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: HIGH
Study ID: Sastre 201230–32
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Patients with allergic rhinoconjunctivitis and/or asthma who were sensitised to
pollen, with or without concomitant food allergy. Patients were attending an allergy outpatient clinic. No further details
reported. No exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: UNCLEAR
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients sensitised to pollen,
with or without concomitant food allergy. The study does not specify polysensitised patients or difficult to manage allergic
disease. The study was conducted in Spain, where there is likely to be a different pattern of pollen sensitisations to that
observed in the UK
Do the included patients match the review question? CONCERN: HIGH
DOMAIN 2: INDEX TEST
A. Risk Of bias
Describe how the index test was conducted and interpreted: ISAC 96, used according to the manufacturer’s instructions
Was the index test method, including threshold, prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: LOW
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DOMAIN 3: COMPARATOR
A. Risk of bias
Describe the comparator and how it was conducted and interpreted: Standard care: SIT prescriptions were formulated
based on clinical history, current guidance and SPT results, without knowledge of ISAC results, then reformulated with
access to ISAC results. Standard care did not appear to have included single IgE testing
Was the diagnostic assessment, based on the comparator, made without knowledge of the
results of the index test?
Yes
Could the comparator, its conduct or its interpretation have introduced bias? RISK: LOW
B. Applicability
Is there concern that the comparator does not match current standard care, as defined in the
review question?
CONCERN: UNCLEAR
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test or comparator: All participants appear to have received both ISAC
and standard care
Describe the time interval and any interventions between index and comparator: Not reported
Was there an appropriate interval between index test and comparator? Unclear
Did patients receive the same comparator/standard care? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: LOW
B Critical Appraisal Skills Programme Cohort tool assessment
Gay-Crosier 201036
(a) Are the results of
the study valid?
1. Did the study address a clearly
focused issue?
Yes
‘We compared the clinical responses to SIT with
allergen specific IgE levels measured by Immuno-CAP
and by a new microarray-based assay’
2. Was the cohort recruited in an
acceptable way?
Unclear
Reported as an abstract
3. Was the exposure accurately
measured to minimise bias?
Unclear
Reported as an abstract. Subcutaneous
immunotherapy but no further details
4. Was the outcome accurately
measured to minimise bias?
Unclear
Reported as an abstract. Allergen-specific IgE and
IgG4 levels were also measured before and after SIT,
both by ImmunoCAP single IgE and by ISAC assays
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Gay-Crosier 201036
5a. Have the authors identified all
important confounding factors?
Unclear
5b. Have they taken account of the
confounding factors in the design
and/or analysis?
No
6a. Was the follow-up of subjects
complete enough?
Unclear
Reported as an abstract
6b. Was the follow-up of subjects
long enough?
Yes
Follow-up was 3 years
(b) What are the
results?
7. What are the results of this study? Results clearly reported in relevant section
8. How precise are the results? Unclear; no variation reported
9. Do you believe the results? Unclear; too little information provided to be clear
(c) Will the results help
locally?
10. Can the results be applied to the
local population?
It is unclear what the specific population was;
therefore, it is unclear if the results apply to patients
with complex allergy
11. Do the results of this study fit with
other available evidence?
Unclear
12. What are the implications of this
study for practice?
Unclear at present, although conclusions are that
‘allergen specific IgE levels and even more the
specific IgE/IgG4 ratio measured by a microarray
assay (ISAC) is significantly related in this study,
to the clinical outcome of SIT’
C QUADAS-2 assessments of comparative accuracy studies
Study ID: Albarini 201347
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Not reported. Children reported with immediate reactions to hazelnut ingestion
Was a consecutive or random sample of patients enrolled?
Was a case–control design avoided?
Unclear
Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: UNCLEAR
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients were allergic to
hazelnuts (response to ingestion). Patients were given an oral challenge and tests were compared between those who were
tolerant and those who were allergic. Did not specify patients with ‘difficult to manage’ allergic disease or similar
classification and only one allergy source was being investigated
Do the included patients match the review question? CONCERN: HIGH
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DOMAIN 2: INDEX TEST
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted: The article was reported as an
abstract with little methodological detail. The methods for ImmunoCAP ISAC (cut-off points: NR) and ImmunoCAP (positive
result: ≥ 0.35 kU/l) were not provided. SPT method was not reported (positive result: mean weal diameter ≥ 3mm)
Were the index test results interpreted without knowledge of the results of the reference
standard?
If a threshold was used, was it prespecified?
Unclear
Unclear
Could the conduct or interpretation of the index test have introduced bias? RISK: UNCLEAR
B. Applicability
Is there concern that the target condition as defined by the reference standard does
not match the review question?
CONCERN: UNCLEAR
DOMAIN 3: REFERENCE STANDARD
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: DBPCFC, no further details
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: LOW
B. Applicability
Is there concern that the target condition as defined by the reference standard does not
match the review question?
CONCERN: LOW
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded
from the 2 × 2 table(s): It appears that all patients were included in the analysis
Describe the time interval and any interventions between index, comparator(s) and reference standard: No time intervals
were reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: UNCLEAR
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Study ID: Alessandri 201142
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Not described
Was a consecutive or random sample of patients enrolled?
Was a case–control design avoided?
Unclear
Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: UNCLEAR
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients had suspected hen’s
egg allergy (history of reactions after ingestion and positive SPT or IgE to hen’s egg white extracts). Patients were given a
hen’s egg oral challenge and tests were compared between those who were tolerant, partially tolerant (allergic to raw egg
but not boiled) and those who were allergic. Did not specify patients with ‘difficult to manage’ allergic disease or similar
classification and only one allergy source was being investigated. The study was not conducted in the UK
Do the included patients match the review question? CONCERN: HIGH
DOMAIN 2: INDEX TEST
Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted: ImmunoCAP ISAC (positive result:
NR) and ImmunoCAP FEIA (positive result: NR) performed according to the manufacturer’s instructions. Standard SPT
was performed (positive result: mean weal diameter ≥ 7mm). All thresholds were optimised based on ROC analyses
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it prespecified?
Unclear
No
Could the conduct or interpretation of the index test have introduced bias? RISK: HIGH
B. Applicability
Is there concern that the index test, its conduct or interpretation differ from the review
question?
CONCERN: LOW
DOMAIN 3: REFERENCE STANDARD
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: Oral challenge performed with boiled or raw
hen’s egg. Increased egg amount until there was a reaction (or one egg or 6 g ingested)
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Unclear
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B. Applicability
Is there concern that the target condition as defined by the reference standard does not
match the review question?
CONCERN: LOW
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded
from the 2 × 2 table(s): Unclear if all patients received all index tests (applying reported sensitivity and specificity estimates
to the total numbers of participants who were positive to each of the reference standards does not result in whole numbers
for 2 × 2 data). All patients received OFC
Describe the time interval and any interventions between index, comparator(s) and reference standard: Timings were not
reported; no other interventions were reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? No
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? RISK: HIGH
Study ID: Cabrera-Freitag 201143
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Not reported. Patients from the Clínica Universidad de Navarra in Pamplona, Spain.
Patients with allergies to pollen other than grass or cypress were excluded, thereby excluding complex patients
Was a consecutive or random sample of patients enrolled?
Was a case–control design avoided?
Unclear
No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? RISK: HIGH
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients were allergic to
grass and cypress pollen (clinical history and SPTs). Control patients were negative to history and SPT. Both populations
were examined by ISAC 103 or single IgE for components specific to grass and cypress pollen. Did not specify patients with
‘difficult to manage’ allergic disease or similar classification and only two allergy sources were being investigated. The study
was not conducted in the UK
Do the included patients match the review question? CONCERN: HIGH
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DOMAIN 2: INDEX TEST
Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted: The method for ImmunoCAP ISAC
(cut-off points: reported) and ImmunoCAP (cut-off points: reported) were described as per the manufacturer’s methods
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it prespecified?
Unclear
No
Could the conduct or interpretation of the index test have introduced bias? RISK: HIGH
B. Applicability
Is there concern that the target condition as defined by the index test does not match the
review question?
CONCERN: LOW
DOMAIN 3: REFERENCE STANDARD
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: SPT (grass and cypress pollen) and clinical
history (rhinoconjunctivitis and/or bronchial asthma)
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: LOW
B. Applicability
Is there concern that the target condition as defined by the reference standard does not
match the review question?
CONCERN: LOW
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded
from the 2 × 2 table(s): All patients appear to have been included in the analysis
Describe the time interval and any interventions between index, comparator(s) and reference standard: No time intervals
were reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: UNCLEAR
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Study ID: De Swert 201241
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Unclear, ‘we selected subjects with birch pollen allergy who were suspected of also
being soy allergic’
Was a consecutive or random sample of patients enrolled?
Was a case–control design avoided?
Unclear
No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: HIGH
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients had been diagnosed
with birch pollen allergy (clinical history and positive IgE response to birch or rBet v1). Patients were given a soy oral
challenge and tests were compared between those who were tolerant and those who were allergic. Did not specify
patients with ‘difficult to manage’ allergic disease or similar classification and only one allergy source was being
investigated. The study was not conducted in the UK
Do the included patients match the review question? CONCERN: HIGH
DOMAIN 2: INDEX TEST
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted: The methods section described
ImmunoCAP ISAC (positive result: ≥ 0.3 ISU) and ImmunoCAP FEIA (positive result: ≥ 0.1 kU/l) performed according to the
manufacturer’s instructions. Standard SPT performed (positive result: mean weal diameter ≥ 3mm). However, the results
section reported different cut-off values for all three tests, suggesting that these may have been optimised for the study
population
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it prespecified?
Unclear
No
Could the conduct or interpretation of the index test have introduced bias? RISK: HIGH
B. Applicability
Is there concern that the index test, its conduct or interpretation differ from the review
question?
CONCERN: LOW
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DOMAIN 3: REFERENCE STANDARD
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: Oral challenge performed with Alpro soya
natural drink. Increased volumes of drink until there was a reaction (or until 158ml)
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: LOW
B. Applicability
Is there concern that the target condition as defined by the reference standard does not
match the review question?
CONCERN: LOW
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded
from the 2 ×2 table(s): SPT results for one patient and ISAC results for three patients were not included in the analysis
Describe the time interval and any interventions between index, comparator(s) and reference standard: Timings were not
reported, no other interventions were reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: HIGH
Study ID: D’Urbano 201044
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Not described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? RISK: HIGH
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B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients had suspected hen’s
egg or cow’s milk allergy (history of reactions after ingestion). Patients were given an OFC and tests were compared
between those who were tolerant and those who were allergic. Did not specify patients with ‘difficult to manage’ allergic
disease or similar classification and only one allergy source was being investigated. The study was not conducted in the UK
Do the included patients match the review question? CONCERN: HIGH
DOMAIN 2: INDEX TEST
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted: ImmunoCAP ISAC (positive result: NR)
and ImmunoCAP FEIA (positive result: NR) performed according to the manufacturer’s instructions. Standard SPT performed
(positive result: mean weal diameter of ≥ 3mm). Thresholds for single IgE and ISAC were derived from ROC analysis
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it prespecified?
Unclear
No
Could the conduct or interpretation of the index test have introduced bias? RISK: HIGH
B. Applicability
Is there concern that the index test, its conduct or interpretation differ from the review question? CONCERN: LOW
DOMAIN 3: REFERENCE STANDARD
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: Oral challenge performed with pasteurised cow’s
milk, boiled or raw hen’s egg. Increased egg amount until there was a reaction (or one egg or 6 g ingested or 250ml milk)
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Unclear
B. Applicability
Is there concern that the target condition as defined by the reference standard does not
match the review question?
CONCERN: LOW
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DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded
from the 2 × 2 table(s): All patients appeared to have received both index tests (separate testing for patients with suspected
cow’s milk and hen’s egg allergy). All patients received OFC. All patients appeared to have been included in the analyses
(separate for patients with suspected cow’s milk and hen’s egg allergy)
Describe the time interval and any interventions between index, comparator(s) and reference standard: Timings were not
reported, no other interventions were reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: LOW
Study ID: Ott 200849
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Retrospective, but no further methodology
Was a consecutive or random sample of patients enrolled?
Was a case–control design avoided?
Unclear
Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: UNCLEAR
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients had suspected
IgE-mediated food hypersensitivity. Patients were given a milk or hen’s egg oral challenge and tests were compared
between those who were tolerant and those who were allergic. Did not specify patients with ‘difficult to manage’ allergic
disease or similar classification and only one allergy source was being investigated. The study was not conducted in the UK
Do the included patients match the review question? CONCERN: HIGH
DOMAIN 2: INDEX TEST
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted: ImmunoCAP ISAC (positive result: NR)
and UniCAP (positive result: > 0.35 kU/l) performed according to the manufacturer’s instructions. Standard SPT performed
(positive result: mean weal diameter ≥ 3mm or greater than negative control). Thresholds were derived from ROC analyses for
all index tests
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it prespecified? No
Could the conduct or interpretation of the index test have introduced bias? RISK: HIGH
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B. Applicability
Is there concern that the index test, its conduct or interpretation differ from the review question? CONCERN: LOW
DOMAIN 3: REFERENCE STANDARD
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: Oral challenge performed with milk or hen egg
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Unclear
B. Applicability
Is there concern that the target condition as defined by the reference standard does not
match the review question?
CONCERN: LOW
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded
from the 2 × 2 table(s): Unclear if all patients received all index tests. All patients received OFC (applied separately for
suspected cow’s milk and suspected hen’s egg allergy)
Describe the time interval and any interventions between index, comparator(s) and reference standard: Timings were not
reported, no other interventions were reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? RISK: UNCLEAR
Study ID: Sokolova 200946
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Not reported. Patients from the food allergy clinic
Was a consecutive or random sample of patients enrolled?
Was a case–control design avoided?
Unclear
No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: HIGH
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B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients were allergic to
cow’s milk protein (SPTs and positive specific IgE). Patients were given an oral milk challenge and those who were positive
[cutaneous (urticaria/angioedema), respiratory or gastrointestinal (vomiting, diarrhoea) symptoms] vs. tolerant (no symptoms
to 200ml milk) or were controls (no history of allergy and drank milk) were examined by ISAC or UNICAP. Did not specify
patients with ‘difficult to manage’ allergic disease or similar classification and only one allergy source was being
investigated. The study was not conducted in the UK
Do the included patients match the review question? CONCERN: HIGH
DOMAIN 2: INDEX TEST
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted: The method for ImmunoCAP ISAC
(cut-off points: NR) and ImmunoCAP (cut-off points: NR) were described as per the manufacturer’s methods. Cut-off points
were not reported
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it prespecified?
Unclear
Unclear
Could the conduct or interpretation of the index test have introduced bias? RISK: Unclear
B. Applicability
Is there concern that the target condition as defined by the index test does not match the
review question?
CONCERN: LOW
DOMAIN 3: REFERENCE STANDARD
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: OFC was described
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: LOW
B. Applicability
Is there concern that the target condition as defined by the reference standard does not
match the review question?
CONCERN: LOW
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DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded
from the 2 × 2 table(s): All patients appear to have been included in the analysis. Patients reporting anaphylaxis after
accidental ingestion and controls with no history of CMPA who ingested cow’s milk daily did not receive OFC testing
Describe the time interval and any interventions between index, comparator(s) and reference standard: No time intervals
were reported.
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive a reference standard? No
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: UNCLEAR
CMPA, cow’s milk protein allergy.
Study ID: Wohrl 200645
DOMAIN 1: PATIENT SELECTION
A. Risk of bias
Describe methods of patient selection: Not reported. Adults at the end of the pollen season from two allergy clinics.
Patients with total serum IgE of > 1000 kU/l were excluded to minimise non-specific binding in the ImmunoCAP system.
The system should be able to cope with the full range of patients
Was a consecutive or random sample of patients enrolled?
Was a case–control design avoided?
Unclear
No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? RISK: HIGH
B. Applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Patients were allergic to one
or more aeroallergens (house mite, cat, birch pollen, grass pollen or mugwort pollen). Patients were given a SPT and a
history was taken. ISAC and single IgE test were used to distinguish between those who were allergic (positive SPT and
history) vs. non-allergic (negative SPT and atopic/negative history). Did not specify patients with ‘difficult to manage’ allergic
disease or similar classification and only five allergy sources were being investigated. The study was not conducted in the
UK
Do the included patients match the review question? CONCERN: HIGH
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DOMAIN 2: INDEX TEST
Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted: The method for ImmunoCAP ISAC
(cut-off points: NR) was provided but not for ImmunoCAP (cut-off points: NR). Cut-off points were calculated from ROC
curves but were not described for individual components
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it prespecified?
Unclear
No
Could the conduct or interpretation of the index test have introduced bias? RISK: HIGH
B. Applicability
Is there concern that the target condition as defined by the index test does not match the
review question?
CONCERN: LOW
DOMAIN 3: REFERENCE STANDARD
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: SPT method was reported (positive result:
mean weal diameter of ≥ 3mm) and details of clinical history were partially reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: LOW
B. Applicability
Is there concern that the target condition as defined by the reference standard does not
match the review question?
CONCERN: LOW
DOMAIN 4: FLOW AND TIMING
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded
from the 2 × 2 table(s): All patients appear to have been included in the analysis
Describe the time interval and any interventions between index, comparator(s) and reference standard: No time intervals
were reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: UNCLEAR
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Appendix 5 Between-system concordance data
provided by Microtest Matrices Ltd
Confidential information has been removed.
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Appendix 6 Survey to inform the number of
patients receiving each test
1. Do you have experience with ImmunoCAP ISAC testing? Yes/No
Although some of the questions below are related to ImmunoCAP ISAC testing, it would still be greatly
appreciated if you could answer as many of the questions as possible.
For questions 2 and 3, consider patients where the primary presentation is inhalation allergy for whom
you would consider testing with ImmunoCAP ISAC.
2. With current standard care:
– What is the number of IgE tests that you would order? (average, range)
– What is the proportion of patients that would get a food challenge test? (average, range)
– What is the proportion of patients that would get a skin prick test? (average, range)
– In those patients, what is the number of allergens tested (using skin prick testing)? (average, range).
3. With ISAC:
– For what proportion of patients would you order further IgE tests? (average, range)
– In those patients, what is the number of IgE tests that you would order? (average, range)
– What is the proportion of patients that would get a food challenge test? (average, range)
– What is the proportion of patients that would get a skin prick test? (average, range)
– In those patients, what is the number of allergens tested (using skin prick testing)? (average, range).
For questions 4 and 5, consider patients where the primary presentation is food allergy for whom you
would consider testing with ImmunoCAP ISAC.
4. With current standard care:
– What is the number of IgE tests that you would order? (average, range)
– What is the proportion of patients that would get a food challenge test? (average, range)
– What is the proportion of patients that would get a skin prick test? (average, range)
– In those patients, what is the number of allergens tested (using skin prick testing)? (average, range).
5. With ISAC:
– For what proportion of patients would you order further IgE tests? (average, range)
– In those patients, what is the number of IgE tests that you would order? (average, range)
– What is the proportion of patients that would get a food challenge test? (average, range)
– What is the proportion of patients that would get a skin prick test? (average, range)
– In those patients, what is the number of allergens tested (using skin prick testing)? (average, range).
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Appendix 7 Cost calculation for individual tests
SPT costs Total Cost per test Costs per patient tested Source
Vial costs (includes 80 drops, so can
be used for 80 tests)
£17.00 £0.21 £1.70 NICE 201186
Control costs (includes 2 × 80 drops,
so can be used for 160 tests)
£12.00 £0.08 £0.60 NICE 201186
Lancet costs (200 pack) £12.00 £0.06 £0.48 NICE 201186
Capital costs
None
Other costs (service, maintenance)
None
Personnel costs to perform and interpret test
Personnel time to interpret test
results (hours per test): GP
0.02 NICE 201186
Personnel costs for interpreting test
results (per hour): GP
£234.00 £4.88 £39.00 Curtis 201488
Personnel time to perform tests
(hours per tests): nurse
0.06 NICE 201186
Personnel costs to perform one
batch of 4 tests (per hour): nurse
£41.00 £2.56 £20.50 Curtis 201488
No. of tests
No. of allergens tested per person 8 NICE 201186
Total costs £62.28
GP, general practitioner.
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IgE test costs Total Cost per test Costs per patient tested Source
Test costs per allergy £12.00 £12.00 £96.00 NICE 201186
Capital costs
None
Other costs (service, maintenance)
None
Personnel costs to perform and interpret test
Personnel time to interpret test
results (hours per test): GP
0.02 NICE 201186
Personnel costs for interpreting test
results (per hour): GP
£234.00 £4.88 £39.00 Curtis 201488
Personnel time to perform tests
(hours per patient): nurse
0.03 NICE 201186
Personnel costs to perform one
batch of four tests (per hour): nurse
£41.00 £1.37 Curtis 201488
No. of tests
No. of allergens tested per person 8 NICE 201186
Total costs £136.37
GP, general practitioner.
OFC test costs Total Cost per test Costs per patient tested Source
Hospital appointment to implement
the food elimination diet
£314.00 £314.00 Department of Health
2013–1489
Hospital appointment to carry out
OFC for diagnosis
£256.00 £256.00 Department of Health
2013–1489
Total costs £570.00
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ImmunoCAP ISAC –
minimum Total
Per year
(annuitised)
Costs per test
(annuitised)
Costs per
patient tested
(annuitised) Source
Test costs
Costs per ImmunoCAP ISAC
112 IgE kit
£2500.00 £125.00 £125.00 Information submitted
to NICE by Thermo
Fisher Scientific
Wash solution costs £18.50 £0.34 £0.34
Capital costs
Costs of the LuxScan 10k
reader
£28,999.00 £2411.73 £6.25 £6.25 Information submitted
to NICE by Thermo
Fisher Scientific
Resale value £0.00
Life time of LuxScan 10k
reader (years)
10
Cost of ImmunoCAP starter
kit
£500.00 £41.58 £0.11 £0.11
Resale value £0.00 Assumption
Life time of ImmunoCAP
starter kit (years)
10 Assumption
Other costs (service, maintenance)
Single flat fee to cover all
eventualities (0–4 kits per
month)
£2000.00 £0.00 £0.00 Information submitted
to NICE by Thermo
Fisher Scientific
Single flat fee to cover all
eventualities (4–6 kits per
month)
£4000.00 £10.36 £10.36
Personnel costs to perform/process and interpret test
Personnel time to interpret
test results (hours per test)
0.08 Information submitted
to NICE by Thermo
Fisher Scientific
Personnel costs for
interpreting test results
(per hour): immunologista
£140.00 £11.67 £11.67 Curtis 201488
Personnel time to perform
one batch of 4 tests (hours
per kit)
0.05 Information submitted
to NICE by Thermo
Fisher Scientific
Personnel costs to perform
one batch of 4 tests (per
hour): biomedical scientistb
£55.16 £0.69 £0.69 Curtis 201488
No. of tests
No. of kits per year 97 Information submitted
to NICE by Thermo
Fisher ScientificNo. of tests per kit 4
Total costs £154.41
a Costs of a medical consultant was used to reflect the costs of an immunologist.
b Costs of a health-care scientist was used to reflect the costs of a biomedical scientist.
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ImmunoCAP ISAC –
minimum Total
Per year
(annuitised)
Costs per test
(annuitised)
Costs per
patient tested
(annuitised) Source
Test costs
Costs per ImmunoCAP ISAC
112 IgE kit
£2500.00 £125.00 £125.00 Information submitted
to NICE by Thermo
Fisher Scientific
Wash solution costs £18.50 £0.34 £0.34
Capital costs
Costs of the LuxScan 10k
reader
£28,999.00 £3114.65 £8.07 £8.07 Information submitted
to NICE by Thermo
Fisher Scientific
Resale value £0.00
Life time of LuxScan 10k
reader (years)
8
Cost of ImmunoCAP starter
kit
£500.00 £53.70 £0.14 £0.14
Resale value £0.00 Assumption
Life time of ImmunoCAP
starter kit (years)
8 Assumption
Other costs (service, maintenance)
Single flat fee to cover all
eventualities (0–4 kits per
month)
£2000.00 £0.00 £0.00 Information submitted
to NICE by Thermo
Fisher Scientific
Single flat fee to cover all
eventualities (4–6 kits per
month)
£4000.00 £10.36 £10.36
Personnel costs to perform/process and interpret test
Personnel time to interpret
test results (hours per test)
1.00 Information submitted
to NICE by Thermo
Fisher Scientific
Personnel costs for
interpreting test results (per
hour): immunologista
£140.00 £140.00 £140.00 Curtis 201488
Personnel time to perform
one batch of 4 tests (hours
per kit)
0.05 Information submitted
to NICE by Thermo
Fisher Scientific
Personnel costs to perform
one batch of 4 tests (per
hour): biomedical scientistb
£55.16 £0.69 £0.69 Curtis 201488
No. of tests
No. of kits per year 97 Information submitted
to NICE by Thermo
Fisher ScientificNo. of test per kit 4
Total costs £284.60
a Costs of a medical consultant was used to reflect the costs of an immunologist.
b Costs of a health-care scientist was used to reflect the costs of a biomedical scientist.
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Microtesta – minimum Total
Costs per
test
Costs per patient
tested Source
Test costs
Cost of allergy reagents (can be used for
1–5 tests)
£1.00 £1.00 Information submitted
to NICE by Microtest DX
Shipping costs £7.70 £7.70
Sample handling fee £20.00 £20.00
Costs of allergy biochip £100.00 £100.00
Capital costs
None £0.00 £0.00
Other costs (service, maintenance)
None £0.00 £0.00 Information submitted
to NICE by Microtest DX
Personnel costs to perform and interpret
test
Personnel time to interpret test results
(hours per test)
0.08 Information submitted
to NICE by Microtest DX
Personnel costs for interpreting test
results (per hour): immunologistb
£140.00 £11.67 £11.67 Curtis 201488
Total costs £140.37
a This calculation assumed that test samples would be send to Microtest DX, where the test would be performed.
b Costs of a medical consultant was used to reflect the costs of an Immunologist.
Microtesta – maximum Total
Costs per
test
Costs per patient
tested Source
Test costs
Cost of allergy reagents (can be used for
1–5 tests)
£5.00 £5.00 Information submitted
to NICE by Microtest DX
Shipping costs £15.00 £15.00
Sample handling fee £30.00 £30.00
Costs of allergy biochip £100.00 £100.00
Capital costs
None £0.00 £0.00
Other costs (service, maintenance)
None £0.00 £0.00 Information submitted
to NICE by Microtest DX
Personnel costs to perform and interpret test
Personnel time to interpret test results
(hours per test)
0.17 Information submitted
to NICE by Microtest DX
Personnel costs for interpreting test
results (per hour): immunologistb
£140.00 £23.33 £23.33 Curtis 201488
Total costs £173.33
a This calculation assumed that test samples would be send to Microtest DX, where the test would be performed.
b Costs of a medical consultant was used to reflect the costs of an immunologist.
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Appendix 8 Cost calculation for Microtest
(performed at service provider laboratory)
Microtesta – minimum Total
Per year
(annuitised)
Costs per test
(annuitised)
Costs per
patient tested
(annuitised) Source
Test costs
Cost of allergy reagents
(can be used for
1–5 tests)
£1.00 £1.00 Information submitted
to NICE by Microtest DX
Costs of allergy biochip £100.00 £100.00
Capital costs
Microtest instrument Confidential
information
has been
removed
£6321.07 £16.38 £16.38 Information submitted
to NICE by Microtest DX
Resale value £0.00
Life time of Microtest
instrument (years)
5
Other costs (service, maintenance)
Personnel time for quality
control
7.00 Information submitted
to NICE by Microtest DX
Personnel costs for
quality control
£55.16 £1.00 £1.00 Curtis 201488
Personnel costs to perform and interpret test
Personnel time to
interpret test results
(hours per test)
0.08 Information submitted
to NICE by Microtest DX
Personnel costs for
interpreting test results
(per hour): immunologistb
£140.00 £11.67 £11.67 Curtis 201488
Personnel time to
perform one test
(hours per test)
0.17 Information submitted
to NICE by Microtest DX
Personnel costs to
perform one batch of
4 tests (per hour):
biomedical scientistc
£55.16 £9.19 £9.19 Curtis 201488
No. of tests
No. of tests per year 386 Assumption
Total costs £139.24
a This calculation assumed that test would be performed at the service provider laboratories.
b Costs of a medical consultant was used to reflect the costs of an immunologist.
c Costs of a health-care scientist was used to reflect the costs of a biomedical scientist.
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Microtesta – minimum Total
Per year
(annuitised)
Costs per test
(annuitised)
Costs per
patient tested
(annuitised) Source
Test costs
Cost of allergy reagents
(can be used for
1–5 tests)
£5.00 £5.00 Information submitted
to NICE by Microtest DX
Costs of allergy biochip £100.00 £100.00
Capital costs
Microtest instrument £35,000.00 £6,321.07 £16.38 £16.38 Information submitted
to NICE by Microtest DX
Resale value £0.00
Life time of Microtest
instrument (years)
5
Other costs (service, maintenance)
Personnel time for quality
control
7.00 Information submitted
to NICE by Microtest DX
Personnel costs for
quality control
£55.16 £1.00 £1.00 Curtis 201488
Personnel costs to perform and interpret test
Personnel time to
interpret test results
(hours per test)
0.17 Information submitted
to NICE by Microtest DX
Personnel costs for
interpreting test results
(per hour): immunologistb
£140.00 £23.33 £23.33 Curtis 201488
Personnel time to
perform one test
(hours per test)
0.25 Information submitted
to NICE by Microtest DX
Personnel costs to
perform one batch of
4 tests (per hour):
biomedical scientistc
£55.16 £13.79 £13.79 Curtis 201488
No. of tests
No. of tests per year 386 Assumption
Total costs £159.50
a This calculation assumed that test would be performed at the service provider laboratories.
b Costs of a medical consultant was used to reflect the costs of an immunologist.
c Costs of a health-care scientist was used to reflect the costs of a biomedical scientist.
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Appendix 9 Guidance relevant to difficult to
manage allergic disease
National Institute for Health and Care Excellence guidance
Atopic Eczema in Children. NICE Quality Standards, QS44, September 2014.
Omalizumab for Treating Severe Persistent Allergic Asthma (review of technology appraisal guidance 133
and 201). NICE technology appraisals, TA278, April 2013.
Atopic Eczema in Children. NICE Pathway, August 2012.
Pharmalgen for the Treatment of Bee and Wasp Venom Allergy. NICE technology appraisals, TA246,
February 2012.
Anaphylaxis. NICE Pathway, December 2011.
Anaphylaxis: Assessment to Confirm an Anaphylactic Episode and the Decision to Refer after Emergency
Treatment for a Suspected Anaphylactic Episode. NICE Clinical Guidelines, CG134, December 2011.
Food Allergy in Children and Young People. NICE Pathway, December 2011.
Food Allergy in Children and Young People: Diagnosis and Assessment of Food Allergy in Children and
Young People in Primary Care and Community Settings. NICE Clinical Guidelines, CG116, February 2011.
Alitretinoin for the Treatment of Severe Chronic Hand Eczema. NICE technology appraisals, TA177,
August 2009.
Inhaled Corticosteroids for the Treatment Of Chronic Asthma in Adults and in Children aged 12 years and
over. NICE technology appraisals, TA131, November 2007.
Atopic Eczema in Children: Management of Atopic Eczema in Children from Birth up to the age of
12 years. NICE Clinical Guidelines, CG57, December 2007.
Inhaled Corticosteroids for the Treatment of Chronic Asthma in Children under the age of 12 years.
NICE technology appraisals, TA131, November 2007.
Tacrolimus and Pimecrolimus for Atopic Eczema. NICE technology appraisals, TA82, August 2004.
Frequency of Application of Topical Corticosteroids for Atopic Eczema. NICE technology appraisals, TA81,
August 2004.
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Guidance from other agencies
Patient UK (June 2014) Skin Prick Allergy Test.
BUPA (May 2014) Managing Your Allergies.
NHS Choices (April 2014) Allergies.
NHS Choices (April 2014) Food allergy.
Map of Medicine (April 2014) Anaphylaxis – Suspected.
British Society for Allergy & Clinical Immunology (April 2014) Guideline for the Diagnosis and Management
of Cow’s Milk Allergy.
Anaphylaxis Campaign (February 2014) Latex Allergy: The Facts.
Anaphylaxis Campaign (February 2014) Food Allergens in Non-food Items.
World Allergy Organization (October 2013) A WAO – ARIA – GA2LEN Consensus Document on
Molecular-based Allergy Diagnostics.
Children’s Acute Transport Service (June 2013) Anaphylaxis/Latex Allergy.
Anaphylaxis Campaign (April 2013) Celery Allergy: The Facts.
Patient UK (December 2012) Anaphylaxis.
Patient UK (May 2012) Food Allergy and Intolerance.
British Society for Allergy & Clinical Immunology (March 2012) Standards for Paediatric Allergy Services in
Secondary Care.
Patient UK (March 2012) Allergy – General Overview.
Patient UK (March 2012) Nut Allergy.
Patient UK (March 2012) House Dust Mite and Pet Allergy.
Patient UK professional reference (February 2012) Anaphylaxis and its Treatment.
Royal College of Paediatrics and Child Health (November 2011) Care Pathway for Food Allergy in Children:
an Evidence and Consensus Based National Approach.
Patient UK professional reference (November 2011) Food Allergy and Food Intolerance.
World Allergy Organization (February 2011) Guidelines for the Assessment and Management
of Anaphylaxis.
Quality, Innovation, Productivity and Prevention (QIPP) (October 2011) Pharmacological Interventions to
Prevent Allergic and Febrile Non-haemolytic Transfusion Reactions.
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British Society for Allergy & Clinical Immunology (August 2011) Diagnosis and Management of
Hymenoptera Venom Allergy.
British Society for Allergy & Clinical Immunology (July 2011) Immunotherapy for Allergic Rhinitis.
Scottish Intercollegiate Guidelines Network (SIGN) (March 2011) Management of Atopic Eczema in
Primary Care.
Royal College of Paediatrics and Child Health (2011) Care Pathway for Latex Allergy.
Royal College of Paediatrics and Child Health (2011) Care Pathway for Venom Allergy.
Royal College of Paediatrics and Child Health (2011) Care Pathway for Drug Allergy.
Royal College of Paediatrics and Child Health (2011) Care Pathway for Urticaria, Angio-odema
or Mastocytosis.
Royal College of Paediatrics and Child Health (2011) Care Pathway for Eczema.
Royal College of Paediatrics and Child Health (2011) Care Pathway for Asthma and/or Rhinitis.
Royal College of Paediatrics and Child Health (2011) Care Pathway for Food Allergy.
Royal College of Paediatrics and Child Health (2011) Care Pathway for Anaphylaxis.
British Society for Allergy & Clinical Immunology (June 2010) Guidelines for the Management of
Egg Allergy.
British Society for Allergy & Clinical Immunology (December 2008) Guidelines for the Management of
Drug Allergy.
Scottish Intercollegiate Guidelines Netwrok (SIGN) (July 2008 updated April 2014) Antibiotic Prophylaxis
in Surgery.
Royal College of Physicians of London (May 2008) Latex Allergy: Occupational Aspects of Management.
Royal College of Physicians of London (March 2008) Latex Allergy Guideline.
Joint Royal Colleges Ambulance Liaison Committee (2007) Anaphylaxis and Allergic Reactions in Children.
Joint Royal Colleges Ambulance Liaison Committee (2007) Anaphylaxis and Allergic Reactions in Adults.
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